var title_f9_42_9888="Heart anatomy PI";
var content_f9_42_9888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 337px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a drawing of a normal heart. The heart has 4 chambers: right atrium, left atrium, right ventricle, and left ventricle. Blood flows from the right atrium to the right ventricle through the tricuspid valve. Blood flows from the left atrium to the left ventricle through the mitral valve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9888=[""].join("\n");
var outline_f9_42_9888=null;
var title_f9_42_9889="Contents: Bones, joints, and muscles";
var content_f9_42_9889=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Bones, joints, and muscles",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Bones, joints, and muscles",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Achilles problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/14/17634\">",
"           Patient information: Achilles tendinopathy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ankle sprain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/46/34529\">",
"           Patient information: Ankle sprain (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ankylosing spondylitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/7/8307\">",
"           Patient information: Ankylosing spondylitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/38/19045\">",
"           Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Arm pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/36/25153\">",
"           Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/32/2563\">",
"           Patient information: Biceps tendinopathy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Back pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/16/11522\">",
"           Patient information: Cauda equina syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/57/25490\">",
"           Patient information: Diffuse idiopathic skeletal hyperostosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/16/33026\">",
"           Patient information: Do I need imaging for low back pain? (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/62/41954\">",
"           Patient information: Herniated disc (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/47/8950\">",
"           Patient information: Low back pain in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/7/36978\">",
"           Patient information: Low back pain in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/8/32898\">",
"           Patient information: Radiculopathy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/44/40642\">",
"           Patient information: Spinal stenosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bursitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/27/44467\">",
"           Patient information: Bursitis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/23/3443\">",
"           Patient information: Bursitis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Carpal tunnel",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/49/18194\">",
"           Patient information: Carpal tunnel syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/11/7347\">",
"           Patient information: Hand pain (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cast care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/21/25937\">",
"           Patient information: Cast and splint care (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/51/11058\">",
"           Patient information: Cast and splint care (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chest pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/34/21027\">",
"           Patient information: Chest pain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/27/34225\">",
"           Patient information: Costochondritis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/45/4819\">",
"           Patient information: Pleuritic chest pain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/53/41810\">",
"           Patient information: Rib fractures in adults (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic fatigue syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/11/42161\">",
"           Patient information: Chronic fatigue syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/47/4850\">",
"           Patient information: Chronic fatigue syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/12/23746\">",
"           Patient information: Chronic pain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/6/11363\">",
"           Patient information: Narcotic pain medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/42/8867\">",
"           Patient information: Neuropathic pain (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Compartment syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/9/32913\">",
"           Patient information: Acute compartment syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/24/25985\">",
"           Patient information: Chronic compartment syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complex regional pain syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/17/9490\">",
"           Patient information: Complex regional pain syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Connective tissue disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/60/15298\">",
"           Patient information: Ehlers-Danlos syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/11/25778\">",
"           Patient information: Marfan syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diffuse idiopathic skeletal hyperostosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/57/25490\">",
"           Patient information: Diffuse idiopathic skeletal hyperostosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Elbow pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/18/44321\">",
"           Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/47/38642\">",
"           Patient information: Elbow tendinopathy (tennis and golf elbow) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fibromyalgia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24854\">",
"           Patient information: Fibromyalgia (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/20/43329\">",
"           Patient information: Fibromyalgia (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Foot pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/50/29473\">",
"           Patient information: Bunion (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/42/38561\">",
"           Patient information: Heel pain (caused by plantar fasciitis) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/5/40018\">",
"           Patient information: Heel pain (caused by plantar fasciitis) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/37/8786\">",
"           Patient information: Metatarsalgia (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fractures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/25/40338\">",
"           Patient information: Ankle fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/6/5219\">",
"           Patient information: Boxer���������s fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39330\">",
"           Patient information: Clavicle fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/35/20018\">",
"           Patient information: Elbow fracture in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/34/30243\">",
"           Patient information: Fractures (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/33/14867\">",
"           Patient information: Hip fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/0/15363\">",
"           Patient information: Neck fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/4/41026\">",
"           Patient information: Nose fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/21/5459\">",
"           Patient information: Pelvic fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/53/41810\">",
"           Patient information: Rib fractures in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12819\">",
"           Patient information: Shinbone fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/24/34178\">",
"           Patient information: Skull and facial fractures (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/22/355\">",
"           Patient information: Toe fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/63/27635\">",
"           Patient information: Vertebral compression fracture (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ganglion cysts",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/21/338\">",
"           Patient information: Ganglion cyst (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hand and finger problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/49/18194\">",
"           Patient information: Carpal tunnel syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/17/2323\">",
"           Patient information: Common finger injuries (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/58/36769\">",
"           Patient information: De Quervain���������s tenosynovitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/41/31377\">",
"           Patient information: Dupuytren���������s contracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/5/33874\">",
"           Patient information: Finger dislocation (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/5/3155\">",
"           Patient information: Finger fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/11/7347\">",
"           Patient information: Hand pain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/15/10482\">",
"           Patient information: Tenosynovitis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hip pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/46/23266\">",
"           Patient information: Aseptic necrosis of the hip (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/27/44467\">",
"           Patient information: Bursitis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/23/3443\">",
"           Patient information: Bursitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24289\">",
"           Patient information: Hip pain (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/25/43409\">",
"           Patient information: Hip pain in older people (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/34/23075\">",
"           Patient information: Hip replacement (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/30/21987\">",
"           Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Jaw pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/35/36401\">",
"           Patient information: Temporomandibular joint (TMJ) disorders (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Joint infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/6/36962\">",
"           Patient information: Fungal meningitis and septic arthritis outbreak (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18769\">",
"           Patient information: Joint infection (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/63/17393\">",
"           Patient information: Septic arthritis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Joint replacement",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/34/23075\">",
"           Patient information: Hip replacement (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/50/29474\">",
"           Patient information: Knee replacement (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/30/21987\">",
"           Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/13/21717\">",
"           Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Knee pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/48/1797\">",
"           Patient information: Anterior cruciate ligament injury (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/12/7362\">",
"           Patient information: Anterior cruciate ligament tear (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/6/35937\">",
"           Patient information: Baker���������s (popliteal) cyst (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/37/11858\">",
"           Patient information: Chondromalacia patella (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/27/5554\">",
"           Patient information: Iliotibial band syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/4/24642\">",
"           Patient information: Knee pain (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/36/7747\">",
"           Patient information: Knee pain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/29/3539\">",
"           Patient information: Meniscal tear (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/10/18594\">",
"           Patient information: Patellofemoral pain syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Muscle disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/63/5106\">",
"           Patient information: Dermatomyositis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/2/34849\">",
"           Patient information: Dystonia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/11/26804\">",
"           Patient information: Myositis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/33/32276\">",
"           Patient information: Overview of muscular dystrophies (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/47/30450\">",
"           Patient information: Polymyositis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Muscle pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/56/4994\">",
"           Patient information: Groin strain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/3/1074\">",
"           Patient information: Hamstring injury (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39938\">",
"           Patient information: Muscle strain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/9/15506\">",
"           Patient information: Nocturnal (nighttime) leg cramps (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/59/22450\">",
"           Patient information: Rhabdomyolysis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/30/36321\">",
"           Patient information: Shin splints (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neck pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/35/27188\">",
"           Patient information: Neck pain (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/31/23026\">",
"           Patient information: Neck pain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/45/17106\">",
"           Patient information: Whiplash (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteoarthritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/10/30881\">",
"           Patient information: Arthritis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28645\">",
"           Patient information: Arthritis and exercise (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/22/9571\">",
"           Patient information: Arthritis and exercise (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/13/2262\">",
"           Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/15/40178\">",
"           Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43058\">",
"           Patient information: Osteoarthritis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/46/16098\">",
"           Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/29/21975\">",
"           Patient information: Osteoarthritis treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/17/3345\">",
"           Patient information: Shoulder osteoarthritis treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/57/37778\">",
"           Patient information: Steroid medicines (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteoporosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/29/1491\">",
"           Patient information: Bone density testing (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/6/23650\">",
"           Patient information: Bone density testing (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/60/23491\">",
"           Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/12/36034\">",
"           Patient information: Calcium and vitamin D for bone health (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/33/14867\">",
"           Patient information: Hip fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/62/29665\">",
"           Patient information: Kyphosis in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/41/6803\">",
"           Patient information: Medicines for osteoporosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/58/35746\">",
"           Patient information: Osteoporosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/49/25366\">",
"           Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/4/42050\">",
"           Patient information: Preventing falls (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/63/27635\">",
"           Patient information: Vertebral compression fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/62/15331\">",
"           Patient information: Vitamin D deficiency (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/45/10962\">",
"           Patient information: Vitamin D deficiency (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Paget's disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/59/12211\">",
"           Patient information: Paget disease of bone (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/59/14258\">",
"           Patient information: Paget disease of bone (osteitis deformans) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rheumatoid arthritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28645\">",
"           Patient information: Arthritis and exercise (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/22/9571\">",
"           Patient information: Arthritis and exercise (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/29/39378\">",
"           Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/21/26962\">",
"           Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/40/27266\">",
"           Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/61/12242\">",
"           Patient information: Juvenile rheumatoid arthritis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16883\">",
"           Patient information: Rheumatoid arthritis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/52/12098\">",
"           Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/14/39138\">",
"           Patient information: Rheumatoid arthritis and pregnancy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/61/21463\">",
"           Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/44/24264\">",
"           Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/57/37778\">",
"           Patient information: Steroid medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17586\">",
"           Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Shoulder pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/21/20818\">",
"           Patient information: Acromioclavicular joint injury (shoulder separation) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/21/37201\">",
"           Patient information: Frozen shoulder (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/26/22946\">",
"           Patient information: Frozen shoulder (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/53/29522\">",
"           Patient information: Rotator cuff injury (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/49/24341\">",
"           Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/47/7923\">",
"           Patient information: Separated shoulder (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/35/26162\">",
"           Patient information: Shoulder impingement (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/49/8977\">",
"           Patient information: Shoulder impingement syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/17/3345\">",
"           Patient information: Shoulder osteoarthritis treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Wrist problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/49/18194\">",
"           Patient information: Carpal tunnel syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/20/7491\">",
"           Patient information: Common wrist injuries (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/58/36769\">",
"           Patient information: De Quervain���������s tenosynovitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/21/338\">",
"           Patient information: Ganglion cyst (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/15/10482\">",
"           Patient information: Tenosynovitis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-DBB276316F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f9_42_9889=[""].join("\n");
var outline_f9_42_9889=null;
var title_f9_42_9890="Calculator: Stool osmolal gap";
var content_f9_42_9890=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"StoolsOsmolality_form\" name=\"StoolsOsmolality_form\" onkeydown=\"clrResults();\" onkeyup=\"StoolsOsmolality_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Stool osmolal gap",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         SOG = StoolOsm - (2 * (StoolNa + StoolK))",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Stool Osm",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Stool_Osm_param\" onblur=\"StoolsOsmolality_fx(); minMaxCheck();\" onchange=\"StoolsOsmolality_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Stool_Osm_unit\" onchange=\"StoolsOsmolality_fx();\" style=\"width:105px;\">",
"             <option value=\"10|0|mOsm/dL\">",
"              mOsm/dL",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mOsm/kg\">",
"              mOsm/kg",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Stool Na",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Stool_Na_param\" onblur=\"StoolsOsmolality_fx(); minMaxCheck();\" onchange=\"StoolsOsmolality_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Stool_Na_unit\" onchange=\"StoolsOsmolality_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|mEq/L\">",
"              mEq/L",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Stool K",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Stool_K_param\" onblur=\"StoolsOsmolality_fx(); minMaxCheck();\" onchange=\"StoolsOsmolality_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Stool_K_unit\" onchange=\"StoolsOsmolality_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|mEq/L\">",
"              mEq/L",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Result:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             SOG",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"SOG_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"SOG_unit\" onchange=\"StoolsOsmolality_fx();\" style=\"width:105px;\">",
"              <option value=\"10|0|mOsm/dL\">",
"               mOsm/dL",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mOsm/kg\">",
"               mOsm/kg",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"StoolsOsmolality_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Stool Osmolal Gap (",
"        <b>",
"         SOG",
"        </b>",
"        ) Interpretation",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"      <tr id=\"rr1_1\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         SOG &lt; 50:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Compatible with secretory diarrhea",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_2\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         SOG &gt;= 50 and &lt;= 125:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Indeterminate",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_3\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         SOG &gt; 125:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Compatible with osmotic diarrhea",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      Please see appropriate UpToDate topic reviews for further information.",
"     </li>",
"    </ul>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9890=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function StoolsOsmolality_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.StoolsOsmolality_form){",
"",
"",
"doCalc = true;",
"if (Stool_Osm_param.value.indexOf(',') >= 0){ Stool_Osm_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Stool_Osm_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Stool_Osm_unit.options[Stool_Osm_unit.selectedIndex].value.split('|');",
"Stool_Osm = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Stool_Na_param.value.indexOf(',') >= 0){ Stool_Na_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Stool_Na_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Stool_Na_unit.options[Stool_Na_unit.selectedIndex].value.split('|');",
"Stool_Na = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Stool_K_param.value.indexOf(',') >= 0){ Stool_K_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Stool_K_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Stool_K_unit.options[Stool_K_unit.selectedIndex].value.split('|');",
"Stool_K = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"SOG =  Stool_Osm - (2 * (Stool_Na + Stool_K));",
"",
"unit_parts = SOG_unit.options[SOG_unit.selectedIndex].value.split('|');",
"if (doCalc) SOG_param.value = fixDP((SOG - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"if (doCalc){",
"",
"rrclr();",
"if (SOG < 50){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((SOG >= 50) && (SOG <= 125)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if (SOG > 125){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.StoolsOsmolality_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.StoolsOsmolality_form){",
"",
"SOG_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"}",
"",
"",
"/* ]]> */"].join("\n");
var outline_f9_42_9890=null;
var title_f9_42_9891="Squamous cell carcinoma eyelid";
var content_f9_42_9891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9891=[""].join("\n");
var outline_f9_42_9891=null;
var title_f9_42_9892="Herpetic whitlow";
var content_f9_42_9892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75510%7EID%2F52029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75510%7EID%2F52029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpetic whitlow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In addition to erythema, swelling, and pain, herpetic whitlow is characterized by the presence of vesicular or pustular lesions. Patients may also experience fever, lymphadenitis, and epitrochlear or axillary lymphadenopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nikkels AF, Peirard GE. Treatment of mucocutaneous presentations of herpes simplex virus infections. Am J Clin Dermatol 2002; 3:479. Copyright &copy; 2002 Adis International.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpetic whitlow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9892=[""].join("\n");
var outline_f9_42_9892=null;
var title_f9_42_9893="Dimercaprol: Drug information";
var content_f9_42_9893=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dimercaprol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"    see \"Dimercaprol: Pediatric drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/51/35635?source=see_link\">",
"    see \"Dimercaprol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BAL in Oil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F160839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F160826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedication with a histamine H",
"     <sub>",
"      1",
"     </sub>",
"     antagonist (eg, diphenhydramine) is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Arsenic or gold poisoning (acute, mild):",
"     </b>",
"     Deep I.M.: 2.5 mg/kg every 6 hours for 2 days, then every 12 hours for 1 day, followed by once daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Arsenic or gold poisoning (acute, severe):",
"     </b>",
"     Deep I.M.: 3 mg/kg every 4 hours for 2 days, then every 6 hours for 1 day, followed every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mercury poisoning (acute):",
"     </b>",
"     Deep I.M.: 5 mg/kg initially, followed by 2.5 mg/kg 1-2 times/day for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lead poisoning:",
"     </b>",
"     Deep I.M.:",
"     <b>",
"      Note:",
"     </b>",
"     For the treatment of high blood lead levels in children, the CDC recommends chelation treatment when blood lead levels are &gt;45 mcg/dL (CDC, 2002); however, dimercaprol is only recommended for use (in combination with edetate CALCIUM disodium) in children whose blood lead levels are &gt;70 mcg/dL or in children with lead encephalopathy (AAP, 2005; Chandran, 2010). In adults, available guidelines recommend chelation therapy with blood lead levels &gt;50 mcg/dL and significant symptoms; chelation therapy may also be indicated with blood lead levels &ge;100 mcg/dL and/or symptoms (Kosnett, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Blood lead levels &ge;70 mcg/dL, symptomatic lead poisoning, or lead encephalopathy (in conjunction with edetate CALCIUM disodium): 4 mg/kg every 4 hours for 2-7 days; duration of therapy of at least 3 days is recommended by some experts (Chandran, 2010).",
"     <b>",
"      Note:",
"     </b>",
"     Begin treatment with edetate CALCIUM disodium with the second dimercaprol dose.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F160833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"      see \"Dimercaprol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedication with a histamine H",
"     <sub>",
"      1",
"     </sub>",
"     antagonist (eg, diphenhydramine) is recommended. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F160827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15796178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment provided in manufacturer&rsquo;s labeling. Use with extreme caution or discontinue if acute renal insufficiency develops during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in hepatic insufficiency (except in cases of postarsenical jaundice).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, oil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BAL in Oil&reg;: 100 mg/mL (3 mL) [contains benzyl benzoate, peanut oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F160813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer all injections by deep I.M. injection.  Rotate injection sites. Keep urine alkaline to protect renal function. When used in the treatment of lead poisoning, administer in a separate site from edetate CALCIUM disodium.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F160811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antidote to gold, arsenic (except arsine), or acute mercury poisoning (except nonalkyl mercury); adjunct to edetate CALCIUM disodium in acute lead poisoning",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F160837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypertension (dose related), tachycardia (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, fever (children ~30%), headache, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Abscess",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, burning sensation (lips, mouth, throat), nausea, salivation, throat irritation/pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Burning sensation (penis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia (polymorphonuclear)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesias (hand), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blepharospasm, conjunctivitis, lacrimation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Rhinorrhea, throat constriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F160816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic insufficiency (unless due to arsenic poisoning)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F160800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxicity: Potentially a nephrotoxic drug; use with caution in patients with oliguria. Keep urine alkaline to protect the kidneys (prevents dimercaprol-metal complex breakdown). Discontinue or use with extreme caution if renal insufficiency develops during treatment. Hemodialysis may be used to remove dimercaprol-metal chelate in patients with renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose 6-phosphate dehydrogenase deficiency: Use with caution in patients with glucose 6-phosphate dehydrogenase deficiency; may increase the risk of hemolytic anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Fevers may occur in ~30% of children and may persist for the duration of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lead poisoning: Investigate, identify, and remove sources of lead exposure prior to treatment; do not permit patients to re-enter the contaminated environment until lead abatement has been completed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heavy metal poisoning: Primary care providers should consult experts in the chemotherapy of heavy metal toxicity before using chelation drug therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peanut oil: Product contains peanut oil; use with caution in patients with peanut allergy; medication for the treatment of hypersensitivity reactions should be available for immediate use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Administer all injections deep I.M. at different sites;",
"     <b>",
"      not",
"     </b>",
"     for I.V. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not indicated for the treatment of iron, cadmium, or selenium poisoning; use in these patients may result in toxic dimercaprol-metal complexes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F160804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Dimercaprol may enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Dimercaprol may enhance the adverse/toxic effect of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, Dimercaprol may enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F160807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5026033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Lead poisoning: Lead is known to cross the placenta in amounts related to maternal plasma levels.  Prenatal lead exposure may be associated with adverse events such as spontaneous abortion, preterm delivery, decreased birth weight, and impaired neurodevelopment.  Some adverse outcomes may occur with maternal blood lead levels &lt;10 mcg/dL.  In addition, pregnant women exposed to lead may have an increased risk of gestational hypertension.  Consider chelation therapy in pregnant women with confirmed blood lead levels &ge;45 mcg/dL (pregnant women with blood lead levels &ge;70 mcg/dL should be considered for chelation regardless of trimester); consultation with experts in lead poisoning and high-risk pregnancy is recommended.  Encephalopathic pregnant women should be chelated regardless of trimester (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5026034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6151604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if dimercaprol is excreted in breast milk; however, it is not absorbed orally, which would limit the exposure to a nursing infant. When used for the treatment of lead poisoning, the amount of lead in breast milk may range from 0.6% to 3% of the maternal serum concentration. Women with confirmed blood lead levels &ge;40 mcg/dL should not initiated breast-feeding; pumping and discarding breast milk is recommended until blood lead levels are &lt;40 mcg/dL, at which point breast-feeding may resume (CDC, 2010).  Calcium supplementation may reduce the amount of lead in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5026037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function, urine pH, infusion-related reactions",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For lead poisoning: Blood lead levels (baseline and 7-21 days after completing chelation therapy); hemoglobin or hematocrit, iron status, free erythrocyte protoporphyrin or zinc protoporphyrin; neurodevelopmental changes",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For arsenic poisoning: Urine arsenic concentration",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      B.A.L. (DE, FR, IN, IT);",
"     </li>",
"     <li>",
"      BAL (IE);",
"     </li>",
"     <li>",
"      BAL In Oil (GR, MY);",
"     </li>",
"     <li>",
"      Dicaptol (HU);",
"     </li>",
"     <li>",
"      DMPS-Heyl (NO);",
"     </li>",
"     <li>",
"      Sulfactin (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F160799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfhydryl group combines with ions of various heavy metals to form relatively stable, nontoxic, soluble chelates which are excreted in urine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F160815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Rapid; Oral: Not absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: To all tissues including the brain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; rapid to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cantilena LR Jr and Klaassen CD, &ldquo;The Effect of Chelating Agents on the Excretion of Endogenous Metals,&rdquo;",
"      <i>",
"       Toxicol Appl Pharmacol",
"      </i>",
"      , 1982, 63(3):344-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/42/9893/abstract-text/6285552/pubmed\" id=\"6285552\" target=\"_blank\">",
"        6285552",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevetion (CDC),",
"      <i>",
"       Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women",
"      </i>",
"      , Atlanta: CDC; 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC),",
"      <i>",
"       Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention",
"      </i>",
"      , Atlanta: CDC; 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Interpreting and Managing Blood Lead Levels &lt;10 microg/dL in Children and Reducing Childhood Exposures to Lead: Recommendations of CDC's Advisory Committee on Childhood Lead Poisoning Prevention,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2007, 56(RR-8):1-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/42/9893/abstract-text/17975528/pubmed\" id=\"17975528\" target=\"_blank\">",
"        17975528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chandran L and Cataldo R, &ldquo;Lead Poisoning: Basics and New Developments,&rdquo;",
"      <i>",
"       Pediatr Rev",
"      </i>",
"      , 2010, 31(10):399-406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/42/9893/abstract-text/20889734/pubmed\" id=\"20889734\" target=\"_blank\">",
"        20889734",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardella C, &ldquo;Lead Exposure in Pregnancy: A Review of the Literature and Argument for Routine Prenatal Screening,&rdquo;",
"      <i>",
"       Obstet Gynecol Surv",
"      </i>",
"      , 2001, 56(4):231-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/42/9893/abstract-text/11285436/pubmed\" id=\"11285436\" target=\"_blank\">",
"        11285436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kosnett MJ, &ldquo;Chelation for Heavy Metals (Arsenic, Lead, and Mercury): Protective or Perilous?&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2010, 88(3):412-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/42/9893/abstract-text/20664538/pubmed\" id=\"20664538\" target=\"_blank\">",
"        20664538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kosnett MJ, &ldquo;Unanswered Questions in Metal Chelation,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1992, 30(4):529-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/42/9893/abstract-text/1331492/pubmed\" id=\"1331492\" target=\"_blank\">",
"        1331492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kosnett MJ, Wedeen RP, Rothenberg SJ, et al, &ldquo;Recommendations for Medical Management of Adult Lead Exposure,&rdquo;",
"      <i>",
"       Environ Health Perspect",
"      </i>",
"      , 2007, 115(3):463-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/42/9893/abstract-text/17431500/pubmed\" id=\"17431500\" target=\"_blank\">",
"        17431500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Lead Exposure in Children: Prevention, Detection, and Management. American Academy of Pediatrics Committee on Environmental Health,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 116(4):1036-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/42/9893/abstract-text/16199720/pubmed\" id=\"16199720\" target=\"_blank\">",
"        16199720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shannon M, &ldquo;Severe Lead Poisoning in Pregnancy,&rdquo;",
"      <i>",
"       Ambul Pediatr",
"      </i>",
"      , 2003, 3(1):37-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/42/9893/abstract-text/12540252/pubmed\" id=\"12540252\" target=\"_blank\">",
"        12540252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9367 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-77.94.48.4-BBE44F2A81-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9893=[""].join("\n");
var outline_f9_42_9893=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160824\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160839\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160826\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160833\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160827\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796178\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796179\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160810\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160796\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160813\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160811\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160837\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160816\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160800\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299205\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160804\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160807\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5026033\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5026034\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6151604\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5026037\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038601\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160799\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160815\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9367\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9367|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/51/35635?source=related_link\">",
"      Dimercaprol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=related_link\">",
"      Dimercaprol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_42_9894="Duloxetine: Patient drug information";
var content_f9_42_9894=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Duloxetine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     see \"Duloxetine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cymbalta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5687669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cymbalta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691614",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help painful nerve diseases and diabetic nerve problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691590",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease long-term pain problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691845",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat fibromyalgia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat an overactive bladder.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701994",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to duloxetine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2996279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on applesauce or in apple juice. Do not chew.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11358 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-9318902EC1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9894=[""].join("\n");
var outline_f9_42_9894=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163737\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5687669\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026987\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026989\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026988\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026993\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026994\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026996\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026991\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026992\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026997\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026998\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=related_link\">",
"      Duloxetine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_42_9895="Clinical features and management of sepsis in the asplenic patient";
var content_f9_42_9895=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and management of sepsis in the asplenic patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/42/9895/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9895/contributors\">",
"     Mark S Pasternack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/42/9895/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9895/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/42/9895/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9895/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/42/9895/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic function is lost when the spleen has been surgically removed, is congenitally absent, has atrophied following repeated infarction (eg, sickle cell disease), or has infarcted following splenic artery thrombosis. In addition, splenic function is reduced in the neonate and may be abnormally reduced (ie, hyposplenism or functional asplenia) when the spleen is engorged with blood (eg, splenic sequestration crisis associated with sickle cell disease, malaria, splenic vein thrombosis), or infiltrated (eg, sarcoidosis, amyloidosis, tumors, or cysts). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asplenic patients and those with impaired splenic function are at risk for a fulminant sepsis syndrome, usually due to Streptococcus pneumoniae. The importance of the spleen for clearance of bacteria and humoral immune response, conditions leading to asplenia, clinical manifestations of infection in the asplenic patient, and the management of postsplenectomy sepsis will be reviewed here.",
"   </p>",
"   <p>",
"    The prevention of sepsis in the asplenic patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ROLE OF THE SPLEEN IN HOST DEFENSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sinusoids of the spleen serve as a \"fine tooth comb\" to filter blood through a series of capillaries as small as 1 micron in diameter to sequester senescent, rigid erythrocytes from the circulation. The mononuclear phagocytes located within this capillary network also ingest circulating bacteria, particularly unopsonized organisms, thus cleansing the roughly 6 percent of cardiac output that perfuses the spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/1\">",
"     1",
"    </a>",
"    ]. The spleen also serves as the largest lymphoid organ within the body and contains nearly half of the body's total immunoglobulin-producing B lymphocytes. Thus, the spleen not only clears bacteria from the circulation but also processes this foreign material to stimulate the production of opsonizing antibody. This function is particularly important in the clearance of encapsulated organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CAUSES OF IMPAIRED SPLENIC FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired splenic function can result from splenic disease (hyposplenism) or, more commonly, splenectomy. The causes of splenic disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobinopathy (eg, sickle cell disease)",
"     </li>",
"     <li>",
"      Other hemolytic processes",
"     </li>",
"     <li>",
"      Congenital asplenia (rare)",
"     </li>",
"     <li>",
"      Collagen vascular diseases (rare)",
"     </li>",
"     <li>",
"      Allogeneic bone marrow transplantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major indications for splenectomy are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemolytic anemia",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Malignancy (eg, hairy cell leukemia or other hematopoietic cancers)",
"     </li>",
"     <li>",
"      Hypersplenism",
"     </li>",
"     <li>",
"      Splenic trauma",
"     </li>",
"     <li>",
"      Splenic injury complicating intraabdominal surgical procedures",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asplenic individuals are at increased risk of postsplenectomy sepsis (PSS), a fulminant and rapidly fatal illness that complicates bacteremic infections due to encapsulated pathogens, which are normally cleared from the circulation by the spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The incidence of this syndrome is highest in children who undergo splenectomy in infancy and in splenectomized lymphoma patients who have received combined modality therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of PSS has been estimated to be approximately 1 per 175 patient-years in children, and 1 per 400 to 500 patient-years among adults [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, a later study found a rate of 1 per 14 patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/7\">",
"     7",
"    </a>",
"    ]. Such aggregate data do not stratify risk as a function of underlying disorder and associated immunodeficiency. PSS can occur in otherwise healthy asplenic adults, and the risk of infection persists indefinitely [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The highest risk of PSS occurs during the first few years following splenectomy but has been documented as late as 20 years after splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/5,7,9-13\">",
"     5,7,9-13",
"    </a>",
"    ]. In a population-based cohort study, the risk of infection requiring hospital contact was highest during the 90 days following splenectomy, occurring in 10 percent of individuals who had undergone splenectomy compared with 0.6 percent in the general population (adjusted odds ratio 18.1, 95% CI 14.8 to 22.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/13\">",
"     13",
"    </a>",
"    ]. In comparison, hazard of infection was 4.6-fold higher from 91 to 365 days following splenectomy and 2.5-fold higher &gt;365 days following splenectomy compared with the general population. The fraction of bacteremic episodes due to pneumococci in splenectomized patients was surprisingly low (&lt;5 percent); the frequency of PSS complicating bacteremia due to non-encapsulated pathogens was not reported.",
"   </p>",
"   <p>",
"    Similar risks of postsplenectomy infection were noted in a review of 288 patients who had undergone splenectomy: one-third of first infections occurred within the first year of surgery and just over half within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/12\">",
"     12",
"    </a>",
"    ]. One-third of all pneumococcal infections occurred at least five years after splenectomy. Among survivors of an initial episode of severe PSS in another series, the risk of subsequent severe infection was increased more than sixfold, and the risk of a third episode among survivors of two severe infections was further increased more than twofold [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who undergo posttraumatic splenectomy are thought to retain variable degrees of splenic function postoperatively, and may have a reduced risk of subsequent postsplenectomy sepsis. However, experimental studies suggest that regenerated splenic tissue is histologically and functionally abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/14\">",
"     14",
"    </a>",
"    ], thus offering limited protection against PSS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BACTERIAL PATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postsplenectomy sepsis (PSS) is classically caused by encapsulated organisms, including Streptococcus pneumoniae, Haemophilus influenza, and Neisseria meningitidis.",
"   </p>",
"   <p>",
"    The single most important pathogen is Streptococcus pneumoniae. In a review of 349 episodes of sepsis in patients with anatomic or functional asplenia, S. pneumoniae accounted for 57 percent of infections and 59 percent of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/12\">",
"     12",
"    </a>",
"    ]. There is no suggestion that any particular serotype of S. pneumoniae is more common in PSS cases when compared with other forms of invasive S. pneumoniae infections.",
"   </p>",
"   <p>",
"    Haemophilus influenzae and Neisseria meningitidis made up a much smaller proportion of the infections seen in PSS. In the same series of 349 patients, only 22 episodes of sepsis were caused by H. influenzae, with a mortality rate of 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/12\">",
"     12",
"    </a>",
"    ]. Furthermore, most of these cases occurred in children prior to the availability of the H. influenzae vaccine. N. meningitidis infections occurred in only 13 patients. The small number of cases of Neisseria meningitidis may reflect the low incidence of this infection in the general population. Others have questioned whether splenectomy truly increases the risk of acquiring this pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anatomic or functional asplenia has also been identified as a risk factor for infection related to other uncommon gram-negative pathogens. Fulminant postsplenectomy sepsis has been caused by Capnocytophaga canimorsus (formerly known as CDC group DF-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/16\">",
"     16",
"    </a>",
"    ], which is almost exclusively observed after dog bites or dog scratches. Bordetella holmesii is associated with bacteremia, endocarditis, and respiratory illness, mainly in immunocompromised hosts. Of the 30 cases described by the Centers for Disease Control and Prevention (CDC), 85 percent of those with available clinical histories were asplenic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK OF OTHER INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to bacterial infection, anatomic or functional asplenia is also a risk factor for severe infection with other pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Parasitic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In malaria and babesiosis, the spleen sequesters infected erythrocytes from the circulation through a combination of both nonimmune (loss of erythrocyte deformability) and immune (antibody-coated erythrocytes) mechanisms.",
"   </p>",
"   <p>",
"    Splenectomy is an important risk factor for severe babesiosis and should lead to prompt initiation of therapy when babesiosis is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, it may be a risk factor for persistent and relapsing babesiosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42248?source=see_link\">",
"     \"Epidemiology and pathogenesis of babesiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39321?source=see_link\">",
"     \"Clinical manifestations, diagnosis, treatment, and prevention of babesiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether splenectomy alters the course of malaria is unclear. Nonimmune asplenic individuals infected with Plasmodium falciparum may have a delayed response to appropriate therapy, with persistent fever and parasitemia, due to the loss of splenic filtration. In contrast, immune individuals who are reinfected following splenectomy appear to have a typical mild course of infection, suggesting that the spleen is not required for the immune sequestration of infected erythrocytes. However, severe cases of falciparum malaria with high levels of parasitemia were reported in two splenectomized patients from French Guiana, leading to death in one subject [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ehrlichiosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent and prolonged fever has been described in two asplenic patients with human granulocytic ehrlichiosis in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cytomegalovirus infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe systemic CMV infections have been reported in two asplenic individuals with prolonged febrile illnesses, lymphocytosis, and mild anicteric hepatitis. The diagnosis of CMV was made through PCR detection of viremia; CMV IgM responses were absent. The reported individuals recovered without antiviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of known splenectomy or a dysfunctional asplenic state, fever must be interpreted as a sign of possible PSS since clinical deterioration without appropriate treatment can occur over hours.",
"   </p>",
"   <p>",
"    PSS may follow minor upper or lower respiratory tract symptoms, but also can develop precipitously without antecedent complaints. The illness provokes acute distress, intractable rigors, high fever, and rapidly manifests complications of high grade bacteremia that can include petechiae, purpura, meningitis, and hypotension.",
"   </p>",
"   <p>",
"    Meningitis is more common in children after splenectomy. In one series, 83 percent of cases of pure meningitis occurred in children under 15 years, with a mortality rate of 17 percent (9 of 54 cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Headache and gastrointestinal complaints can be present. In one case report, a patient with postsplenectomy sepsis due to C. canimorsus actually presented with symptoms suggestive of an acute abdomen 11 years after undergoing a splenectomy for trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical evaluation reveals a toxic and acutely ill individual, who has marked tachycardia and hypotension; an altered sensorium may also be present due to hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meningitis. An obvious primary focus of infection such as otitis media, sinusitis, pharyngitis, or pneumonia may be present in some individuals. High grade bacteremia, hypotension, endovascular injury, and coagulopathy may contribute to the development of purpura fulminans, extremity gangrene, and even autoamputation. Metastatic infection (eg, septic arthritis, meningitis, or pericarditis) may also be evident.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation demonstrates an abnormal granulocyte count, which can be elevated or markedly depressed in the early stages of illness. Review of the peripheral smear usually demonstrates a marked left shift with bands and earlier myeloid forms. These cells often contain toxic granulations and Dohle bodies. Blood smears will also demonstrate Howell-Jolly bodies, commonly seen in the erythrocytes of asplenic individuals.",
"   </p>",
"   <p>",
"    Intracellular or extracellular bacteria can occasionally be visualized directly on the peripheral blood smear or via Gram or Wright stain on the white cell buffy coat, reflecting high-grade bacteremia (",
"    <a class=\"graphic graphic_picture graphicRef50416 \" href=\"UTD.htm?2/60/3009\">",
"     picture 1",
"    </a>",
"    ). Cutaneous lesions can be aspirated for Gram stain and culture.",
"   </p>",
"   <p>",
"    Other findings include thrombocytopenia, disseminated intravascular coagulation (DIC), and elevated creatinine and aminotransferases, consistent with multiorgan dysfunction. Arterial blood gas analysis reveals hypoxemia, marked hypocarbia, and a mixed metabolic acidosis and respiratory alkalosis.",
"   </p>",
"   <p>",
"    A lumbar puncture (LP) is often deferred acutely because of DIC. For patients who have an LP, a normal or only slightly abnormal LP does not necessarily rule out meningitis. Patients may become ill so quickly that characteristic changes in the cerebrospinal fluid (CSF) will not be present at the time of initial lumbar puncture, although CSF culture may be positive.",
"   </p>",
"   <p>",
"    Chest radiography may reveal cardiomegaly and a primary pneumonitis; emergency transthoracic cardiac ultrasound can distinguish between acute tamponade and impaired myocardial contractility as contributors to septic shock. Blood cultures often turn positive within hours of inoculation; negative cultures may be seen if prior antibiotic therapy has been administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate broad-spectrum antibiotic therapy and life support measures must be rapidly instituted in the patient with postsplenectomy sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9895/abstract/2,24,25\">",
"     2,24,25",
"    </a>",
"    ]. Administration of antibiotics should NOT be delayed in order to perform diagnostic studies, including LP. These patients often have a minimal or only transient response to fluid resuscitation and frequently require support with multiple inotropic agents. Intubation and mechanical ventilation are generally necessary because of marked respiratory distress",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obtundation.",
"   </p>",
"   <p>",
"    The following addresses issues related specifically to the management of postsplenectomy sepsis. A broader discussion about the management of septic shock in general is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Empiric antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled trials of treatment regimens in this patient population have not been performed. Thus antibiotic recommendations are based on expert opinion and assessment of the epidemiology and antimicrobial sensitivity patterns of the pathogens most likely to cause infection in this group.",
"   </p>",
"   <p>",
"    Initial empiric therapy for adults should include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (1 g IV every 12 hours) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV daily) due to concerns regarding possible penicillin-resistant pneumococcal infection and beta-lactamase producing H. influenzae.",
"   </p>",
"   <p>",
"    If meningitis is suspected, the dosage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    should be increased to 2 g IV twice daily and the dosage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be increased to 30 to 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV per day in two or three divided doses. Following initial vancomycin therapy, the dose of vancomycin should be optimized according to trough levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=see_link&amp;anchor=H13#H13\">",
"     \"Vancomycin dosing and serum concentration monitoring in adults\", section on 'Serum concentration monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adult patients with a history of immediate hypersensitivity to beta-lactam antibiotics should be given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    750 mg in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Once loading doses are administered, subsequent dosing of antibiotics may need revision if the patient has developed acute renal failure or \"shock liver.\" The course of illness is often quite stormy, with a high immediate mortality rate, and a long and complex intensive care unit stay among survivors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Adjuvant dexamethasone for meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    may be warranted in some patients with suspected meningitis. The recommended criteria and regimen are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=see_link&amp;anchor=H3#H3\">",
"     \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\", section on 'Dexamethasone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/24/18818?source=see_link\">",
"       \"Patient information: Preventing severe infection after splenectomy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asplenic patients and those with impaired splenic function are at risk for severe sepsis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spleen clears bacteria from the circulation and processes this foreign material to stimulate the production of opsonizing antibody. This function is particularly important in the clearance of encapsulated organisms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Role of the spleen in host defense'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postsplenectomy sepsis is typically caused by encapsulated organisms, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Bacterial pathogens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the setting of asplenia, fever must be interpreted as possible postsplenectomy sepsis since clinical deterioration can occur over hours in the absence of effective therapy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever or rigors should be considered the first warning signs of possible postsplenectomy sepsis. Broad-spectrum antibiotics must be initiated promptly since clinical deterioration can occur over hours. Antibiotic administration should not be delayed by a diagnostic work-up. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Empiric antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to concerns regarding possible penicillin-resistant pneumococcal infection as well as beta-lactamase producing H. influenzae, we recommend that initial empiric therapy include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (1 g IV every 12 hours) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (2 g daily). In cases of suspected meningitis, we recommend higher doses of ceftriaxone (2 g IV every 12 hours) and vancomycin (30 to 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV per day in two or three divided doses). Vancomycin levels should be adjusted using trough levels for CNS infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"       \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=see_link&amp;anchor=H13#H13\">",
"       \"Vancomycin dosing and serum concentration monitoring in adults\", section on 'Serum concentration monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a history of immediate hypersensitivity to beta-lactam antibiotics can be given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      750 mg in addition to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Empiric antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations regarding the use of adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      for children or adults with suspected meningitis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"       \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=see_link&amp;anchor=H3#H3\">",
"       \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\", section on 'Dexamethasone'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/1\">",
"      Hosea SW, Brown EJ, Hamburger MI, Frank MM. Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med 1981; 304:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/2\">",
"      Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet 2011; 378:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/3\">",
"      KING H, SHUMACKER HB Jr. Splenic studies. I. Susceptibility to infection after splenectomy performed in infancy. Ann Surg 1952; 136:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/4\">",
"      Weitzman S, Aisenberg AC. Fulminant sepsis after the successful treatment of Hodgkin's disease. Am J Med 1977; 62:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/5\">",
"      Styrt B. Infection associated with asplenia: risks, mechanisms, and prevention. Am J Med 1990; 88:33N.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/6\">",
"      Schwartz PE, Sterioff S, Mucha P, et al. Postsplenectomy sepsis and mortality in adults. JAMA 1982; 248:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/7\">",
"      Kyaw MH, Holmes EM, Toolis F, et al. Evaluation of severe infection and survival after splenectomy. Am J Med 2006; 119:276.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/8\">",
"      Gopal V, Bisno AL. Fulminant pneumococcal infections in 'normal' asplenic hosts. Arch Intern Med 1977; 137:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/9\">",
"      Zarrabi MH, Rosner F. Serious infections in adults following splenectomy for trauma. Arch Intern Med 1984; 144:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/10\">",
"      Cullingford GL, Watkins DN, Watts AD, Mallon DF. Severe late postsplenectomy infection. Br J Surg 1991; 78:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/11\">",
"      Eber SW, Langend&ouml;rfer CM, Ditzig M, et al. Frequency of very late fatal sepsis after splenectomy for hereditary spherocytosis: impact of insufficient antibody response to pneumococcal infection. Ann Hematol 1999; 78:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/12\">",
"      Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. Br J Surg 1991; 78:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/13\">",
"      Thomsen RW, Schoonen WM, Farkas DK, et al. Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Ann Intern Med 2009; 151:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/14\">",
"      Clayer MT, Drew PA, Leong AS, Jamieson GG. IgG-mediated phagocytosis in regenerated splenic tissue. Clin Exp Immunol 1994; 97:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/15\">",
"      Loggie BW, Hinchey EJ. Does splenectomy predispose to meningococcal sepsis? An experimental study and clinical review. J Pediatr Surg 1986; 21:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/16\">",
"      Martone WJ, Zuehl RW, Minson GE, Scheld WM. Postsplenectomy sepsis with DF-2: report of a case with isolation of the organism from the patient's dog. Ann Intern Med 1980; 93:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/17\">",
"      Shepard CW, Daneshvar MI, Kaiser RM, et al. Bordetella holmesii bacteremia: a newly recognized clinical entity among asplenic patients. Clin Infect Dis 2004; 38:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/18\">",
"      Rosner F, Zarrabi MH, Benach JL, Habicht GS. Babesiosis in splenectomized adults. Review of 22 reported cases. Am J Med 1984; 76:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/19\">",
"      Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008; 46:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/20\">",
"      Demar M, Legrand E, Hommel D, et al. Plasmodium falciparum malaria in splenectomized patients: two case reports in French Guiana and a literature review. Am J Trop Med Hyg 2004; 71:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/21\">",
"      Rabinstein A, Tikhomirov V, Kaluta A, et al. Recurrent and prolonged fever in asplenic patients with human granulocytic ehrlichiosis. QJM 2000; 93:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/22\">",
"      Han XY, Lin P, Amin HM, Ferrajoli A. Postsplenectomy cytomegaloviral mononucleosis: marked lymphocytosis, TCRgamma gene rearrangements, and impaired IgM response. Am J Clin Pathol 2005; 123:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/23\">",
"      Sawmiller CJ, Dudrick SJ, Hamzi M. Postsplenectomy Capnocytophaga canimorsus sepsis presenting as an acute abdomen. Arch Surg 1998; 133:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/24\">",
"      Brigden ML, Pattullo AL. Prevention and management of overwhelming postsplenectomy infection--an update. Crit Care Med 1999; 27:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9895/abstract/25\">",
"      Lynch AM, Kapila R. Overwhelming postsplenectomy infection. Infect Dis Clin North Am 1996; 10:693.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1404 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9895=[""].join("\n");
var outline_f9_42_9895=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ROLE OF THE SPLEEN IN HOST DEFENSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CAUSES OF IMPAIRED SPLENIC FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BACTERIAL PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK OF OTHER INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Parasitic infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ehrlichiosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cytomegalovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Empiric antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Adjuvant dexamethasone for meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1404\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1404|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/60/3009\" title=\"picture 1\">",
"      Capnocytophaga peripheral smear",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39321?source=related_link\">",
"      Clinical manifestations, diagnosis, treatment, and prevention of babesiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=related_link\">",
"      Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=related_link\">",
"      Dexamethasone to prevent neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42248?source=related_link\">",
"      Epidemiology and pathogenesis of babesiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/24/18818?source=related_link\">",
"      Patient information: Preventing severe infection after splenectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=related_link\">",
"      Vancomycin dosing and serum concentration monitoring in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_42_9896="Pathogenesis of autoimmune adrenal insufficiency";
var content_f9_42_9896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of autoimmune adrenal insufficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/42/9896/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9896/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/42/9896/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9896/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/42/9896/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9896/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/42/9896/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of primary adrenal insufficiency is autoimmune adrenalitis. This topic will review the pathogenesis of autoimmune adrenal insufficiency, including the roles of humoral and cellular immunity and genetics. The clinical manifestations of this disorder and its association with polyglandular autoimmune syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H240131434\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune adrenalitis is characterized by the presence of serum antibodies against the steroidogenic enzymes P450scc (CYP11A1, side-chain cleavage enzyme), P450c17 (CYP17, 17-alpha-hydroxylase), and P450c21 (CYP21A2, 21-hydroxylase) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These enzymes are involved in the side-chain cleavage and subsequent hydroxylation of steroids (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 1",
"    </a>",
"    ). The autoantibodies to CYP21A2 are of the IgG1 or IgG2a subclass [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], suggesting that T helper (Th) cells are involved in destruction of the adrenal cortex in patients with autoimmune Addison&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/6\">",
"     6",
"    </a>",
"    ]. Ample evidence demonstrates an important influence of genetic background on the development of adrenal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HUMORAL IMMUNITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anti-adrenal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies evaluated the ability of serum antibodies to react with primate adrenal cortex using an indirect immunofluorescence technique. Because the test detects any IgG antibodies that are bound, it is not specific for a given antigen. Thus, the results are commonly referred to as \"anti-adrenal\" antibodies, reflecting the non-specific nature of the test. Subsequent studies showed that the antiadrenal autoantibodies detected by immunofluorescence on tissue sections were mainly directed against CYP17 and CYP21A2 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies to all three zones of the adrenal cortex are present in the serum of 60 to 75 percent of patients with primary adrenal insufficiency caused by autoimmune adrenalitis; in contrast, they are rarely found in patients with other causes of adrenal insufficiency, in first-degree relatives of patients with autoimmune primary adrenal insufficiency, or in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/1,8-13\">",
"     1,8-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiadrenal antibodies are more common in women, particularly those with the polyglandular autoimmune syndrome (type 2). Patients with antibodies develop adrenal insufficiency at a rate of up to 19 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In autoimmune polyendocrinopathy syndrome type 1, or autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome, the presence of adrenal autoantibodies has a 92 percent predictive value for the development of adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/14,16\">",
"     14,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antigen targets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific tests for antibodies against the steroidogenic enzymes P450scc (CYP11A1, side-chain cleavage enzyme), P450c17 (CYP17, 17-alpha-hydroxylase), and p450c21 (CYP21A2, 21-hydroxylase) have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. A comparison of results from four laboratories showed that CYP21A2 autoantibodies are those most commonly detected in patients with APECED (13 or 14 of 15 patients) and sporadic disease (82 to 84 percent of 205 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/17\">",
"     17",
"    </a>",
"    ], while autoantibodies against CYP11A1 or CYP17 were detected in up to 50 percent of patients with polyglandular autoimmune disorders but less than 10 percent of those with sporadic disease.",
"   </p>",
"   <p>",
"    In one study of 94 Norwegian patients, 38 of the 40 patients (95 percent) who had adrenal insufficiency for less than five years and six of the 10 patients (60 percent) who had adrenal insufficiency for more than 35 years had the autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of adrenal autoantibodies may be a stronger predictor of adrenal insufficiency in children than adults. One study evaluated 10 children with autoimmune hypoparathyroidism or diabetes mellitus who had antiadrenocortical autoantibodies and antibodies to CYP21A2; nine developed adrenal insufficiency during 3 to 121 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/19\">",
"     19",
"    </a>",
"    ]. In contrast, another report evaluated 48 adults with an autoimmune disorder and antiadrenocortical autoantibodies (44 of whom had antibodies to CYP21A2); only 21 percent developed overt adrenal insufficiency and 29 percent subclinical adrenal insufficiency in four years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/20\">",
"     20",
"    </a>",
"    ]. The same investigators reported that of 100 patients with antiadrenocortical autoantibodies, the estimated cumulative risk (using a life-table analysis) of developing overt adrenal insufficiency during a mean follow-up period of six years was 100 percent in children and 32 percent in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 90 patients from Sweden, Norway, and Germany with type I polyglandular autoimmune syndrome, testing of CYP21A2 alone was sufficient for the prediction of adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/22\">",
"     22",
"    </a>",
"    ]. However, it has been reported that anti-interferon autoantibodies, particularly to interferon-omega, are more common than the standard autoantibodies and correlate extremely well with mutated AIRE, so they may be the diagnostic markers of choice, especially for early or atypical patients who have not developed the full APS I picture [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a second study of 222 patients from Italy with primary adrenal insufficiency, simultaneous presence of both antiadrenocortical antibodies and anti-CYP21A2 antibodies permitted a definitive diagnosis of autoimmune adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of adrenal insufficiency follows four stages: stage 1, high plasma renin activity and normal or low serum aldosterone; stage 2, impaired serum cortisol response to cosyntropin stimulation; stage 3, increased morning plasma ACTH with normal serum cortisol; and stage 4, low morning serum cortisol [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/15,26,27\">",
"     15,26,27",
"    </a>",
"    ]. The serum concentration of autoantibodies, specifically against CYP21A2, correlates strongly with the degree of adrenal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antibodies against other endocrine glands",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies against other endocrine glands are common in patients with autoimmune adrenal insufficiency, but rare in normal subjects (",
"    <a class=\"graphic graphic_table graphicRef79074 \" href=\"UTD.htm?23/45/24283\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/8,10,11,29,30\">",
"     8,10,11,29,30",
"    </a>",
"    ]. Polyglandular autoimmune syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 60 percent of patients have high serum antithyroid peroxidase (microsomal) antibody concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/31\">",
"       31",
"      </a>",
"      ], and almost one-half of these patients have overt hypothyroidism. Many other patients have subclinical hypothyroidism (ie, high serum thyrotropin (TSH) and normal serum thyroxine concentrations) and are at risk for developing overt hypothyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/8,10,30\">",
"       8,10,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of gastric parietal cell, intrinsic factor, and gonadal antibodies correlates with the presence of atrophic gastritis, pernicious anemia, and premature ovarian failure, respectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23976?source=see_link\">",
"       \"Pathogenesis, diagnosis, and treatment of autoimmune ovarian failure\"",
"      </a>",
"      .) Antigonadal antibodies are much less common in men, as is testicular failure. In a study of 68 Finnish patients with APECED, the presence of autoantibodies against the IA-2 tyrosine phosphatase-like protein or insulin had a 67 percent predictive value for type 1 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with polyglandular autoimmune syndrome type I, acquired hypoparathyroidism sometimes occurs in association with antiparathyroid gland antibodies that are directed against the calcium-sensing receptor in the parathyroid gland [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24984?source=see_link\">",
"       \"Etiology of hypocalcemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a study of 90 patients with polyglandular autoimmune syndrome type I, the best predictors for disease manifestations were autoantibodies against CYP11A1 and tyrosine phosphatase-like protein IA-2 for gonadal failure and type 1 diabetes, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/22\">",
"       22",
"      </a>",
"      ]. Anti-tryptophan hydroxylase antibodies were associated with both intestinal dysfunction and autoimmune hepatitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of antiadrenal antibodies in serum from patients with normal adrenal function who have other autoimmune endocrine diseases is low (2 percent), with the exception of those with hypoparathyroidism (16 percent) (",
"    <a class=\"graphic graphic_table graphicRef70711 \" href=\"UTD.htm?7/62/8171\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/11,15,29,33,34\">",
"     11,15,29,33,34",
"    </a>",
"    ]. In three reports comprising more than 2000 children and adults, 1 to 2 percent of patients with type 1 diabetes had antibodies against 21-hydroxylase (CYP21A2) (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Given the low prevalence, routine screening of patients with type 1 diabetes for 21-hydroxylase antibodies is not indicated.",
"   </p>",
"   <p>",
"    Antibodies to CYP21A2 block the hydroxylase activity of recombinant CYP21A2 in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/38\">",
"     38",
"    </a>",
"    ], but the antibodies may not gain access to CYP21A2 in vivo. Furthermore, although the antibodies from most patients block the stimulatory effect of corticotropin (ACTH) on adrenal cortisol production and DNA synthesis in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/39\">",
"     39",
"    </a>",
"    ], this effect may be in part an artifact of the ion-exchange chromatography method of preparing the immunoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/40\">",
"     40",
"    </a>",
"    ]. Analysis of the 17-hydroxyprogesterone to cortisol ratio at various stages in the development of clinical adrenal insufficiency did not provide evidence that antibodies block CYP21A2 in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CELLULAR IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The autoantibodies to CYP21A2 in patients with isolated autoimmune adrenal insufficiency or autoimmune polyglandular syndromes type 1 or 2 are of the IgG1 or IgG2a subclass, implicating a Th1 response [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The Th1 response is characterized by the production of Interferon-gamma, an antigen-specific T helper cell-driven process with cytotoxic T lymphocytes and activated macrophages mediating the destruction of the adrenal cortex. The presence of lymphocytic infiltration of the adrenal glands further supports a possible role for cellular immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/42\">",
"     42",
"    </a>",
"    ]. Decreased suppressor T-cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/43\">",
"     43",
"    </a>",
"    ] and increased numbers of circulating Ia-positive T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/44\">",
"     44",
"    </a>",
"    ] have been described in these patients. In addition, human adrenal homogenate inhibited the in vitro migration of leukocytes from 14 of 30 patients with idiopathic adrenal insufficiency, but only one of seven patients with tuberculous adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/45\">",
"     45",
"    </a>",
"    ]. The substrate-binding domain of 21-hydroxylase is an immunodominant T cell epitope. PBMCs proliferate and secrete interferon gamma in the presence of CYP21A2 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/46\">",
"     46",
"    </a>",
"    ] and PBMCs from patients with autoimmune adrenal insufficiency proliferate and increase gamma interferon secretion in the presence of CYP21A2 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune adrenal insufficiency may be familial or nonfamilial. It is somewhat less likely to be familial when it occurs alone. Approximately one-third of such patients have affected family members, as compared with about one-half of patients who have adrenal insufficiency as part of polyglandular autoimmune syndrome type I or II [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Polyglandular autoimmune syndrome type I'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H4#H4\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Polyglandular autoimmune syndrome type II'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HLA associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic susceptibility to autoimmune adrenal insufficiency is strongly associated with HLA B8, DR3, and DR4 alleles, except when it occurs as part of polyglandular autoimmune syndrome type I, in which no HLA association has been found [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/50,52,53\">",
"     50,52,53",
"    </a>",
"    ]. Several specific HLA antigens, including DQA1*0301, DQA1*0501, DQB1*0201, DQB1*0302, DRB1*0404, and DRB1*0301, are associated with sporadic autoimmune adrenal insufficiency and polyglandular autoimmune syndrome type II [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/36,54-56\">",
"     36,54-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alterations in the major histocompatibility complex class I chain-related microsatellite also confer susceptibility. In a study of 28 patients and 75 normal subjects in Italy, the combination of the HLA DRB1*03-DQA1*0501-DQB1*0201",
"    <span class=\"nowrap\">",
"     (DR3/DQ2)",
"    </span>",
"    haplotype and the major histocompatibility complex class I chain-related microsatellite polymorphism MIC-A5.1, both of which are located in the same region of chromosome 6, was necessary to confer increased genetic risk for Addison's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/57\">",
"     57",
"    </a>",
"    ]. Compared with subjects homozygous for MIC-A6, MIC-A5.1 homozygotes had a 60-fold greater risk of developing Addison's disease. The normal function of the MIC-A gene product, which is expressed mostly in epithelial cells, and the role of the MIC-A5.1 allele in the pathogenesis of Addison's disease are unknown.",
"   </p>",
"   <p>",
"    DQA1*0501 is associated with adrenal insufficiency, diabetes mellitus, and Graves' disease, and an Arg52 substitution in either DQA1*0501 or DQA1*0301 is also linked strongly with adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/55\">",
"     55",
"    </a>",
"    ]. Type 1 diabetic patients with a",
"    <span class=\"nowrap\">",
"     DRB1*0404/DQ8",
"    </span>",
"    genotype or the heterozygous",
"    <span class=\"nowrap\">",
"     DR3-DQ2/DR4B1*0404-DQ8",
"    </span>",
"    genotype and circulating anti-CYP21A2 autoantibodies are at high risk for Addison's disease, while those with",
"    <span class=\"nowrap\">",
"     DRB1*0401/DQ8",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     DRB1*0402/DQ8",
"    </span>",
"    have much less risk, even though they have anti-CYP21A2 autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/18,36\">",
"     18,36",
"    </a>",
"    ]. Presence of the DQB1*0602 allele appears to protect patients with APECED from developing type 1 diabetes, as it does in the general population, but not patients with polyglandular autoimmune syndrome type 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These associations result from the location of the CYP21A1P (P450c21A) and CYP21A2 (P450c21B) genes, along with the tumor necrosis factor TNFB*1 gene and complement C4A and C4B genes, in the class III region between the class I and class II MHC loci on the short arm of chromosome 6 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/58\">",
"     58",
"    </a>",
"    ]. However, there is no HLA linkage in some families with polyglandular autoimmune syndrome type II [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/52,59\">",
"     52,59",
"    </a>",
"    ]. Furthermore, chronic autoimmune thyroiditis, pernicious anemia, and premature ovarian failure, all components of polyglandular autoimmune syndrome type II, are not closely linked to any HLA haplotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. These observations suggest that a gene or genes linked to certain HLA haplotypes convey susceptibility to autoimmune adrenal insufficiency and diabetes mellitus and that different non-HLA-associated genes are linked to chronic autoimmune thyroiditis and gastric autoimmune disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Non-HLA genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene responsible for polyglandular autoimmune syndrome type I is located on chromosome 21q22.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/60\">",
"     60",
"    </a>",
"    ]. It is termed AIRE (autoimmune regulator) and encodes a protein that is probably a transcription factor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. An Arg257 stop mutation was found in 10 of 12 Finnish APECED patients, and a Lys83Glu mutation was found in Swiss and the remaining two Finnish patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/61\">",
"     61",
"    </a>",
"    ]. Eleven mutations were described in a nationwide study that identified 36 Norwegian patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the genes for CYP11A1 and CYP17, the targets for the antiadrenal antibodies in most patients with autoimmune adrenal insufficiency, lie on chromosomes 15q23-q24 and 10q24-q25, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/63\">",
"     63",
"    </a>",
"    ]. These genes are therefore not linked to HLA haplotypes or implicated in the genetic susceptibility to autoimmune adrenalitis.",
"   </p>",
"   <p>",
"    Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene (on chromosome 2q33), which have been reported to be associated with autoimmune thyroid disease, may also confer susceptibility to autoimmune adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=see_link\">",
"     \"Pathogenesis of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A polymorphism in the class II transactivator (CIITA) gene, MHC2TA, is positively associated with genetic risk for AAD, independently from HLA class II gene polymorphism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/56\">",
"     56",
"    </a>",
"    ]. This gene regulates HLA-D gene expression.",
"   </p>",
"   <p>",
"    Normal adrenocortical cells express MHC class II molecules. Thus, inappropriate expression of these molecules is probably not involved in the pathogenesis of autoimmune adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic changes in autoimmune adrenal insufficiency vary with the stage of the disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the initial stage, the adrenal glands may be enlarged, with extensive lymphocytic infiltration [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/9,42,66\">",
"       9,42,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In long-standing disease, the glands are small and sometimes difficult to locate. The capsule is thickened and fibrotic, and the cortex is completely destroyed, although there may be a few small clusters of adrenocortical cells surrounded by lymphocytes. The medulla is relatively spared.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adrenal insufficiency becomes clinically manifest only after",
"    <strong>",
"     at least 90 percent",
"    </strong>",
"    of the cortex has been destroyed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9896/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801912073\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <strong>",
"     Humoral immunity",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune adrenalitis is characterized by the presence of serum antibodies against the steroidogenic enzymes, mostly P450c21 (CYP21A2, 21-hydroxylase) and less frequently P450scc (CYP11A1, side-chain cleavage enzyme) and P450c17 (CYP17, 17-alpha-hydroxylase). Ample evidence demonstrates an important influence of genetic background on the development of adrenal insufficiency. (See",
"      <a class=\"local\" href=\"#H240131434\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiadrenal antibodies are more common in women, particularly those with the polyglandular autoimmune syndrome (type II). Patients with antibodies develop adrenal insufficiency at a rate of up to 19 percent per year. In autoimmune polyendocrinopathy syndrome type I, or autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome, the presence of adrenal autoantibodies has a 92 percent predictive value for the development of adrenal insufficiency. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anti-adrenal antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of adrenal insufficiency follows four stages: stage 1, high plasma renin activity and normal or low serum aldosterone; stage 2, impaired serum cortisol response to cosyntropin stimulation; stage 3, increased morning plasma ACTH with normal serum cortisol; and stage 4, low morning serum cortisol. The serum concentration of autoantibodies, specifically against CYP21A2, correlates strongly with the degree of adrenal dysfunction. Adrenal insufficiency becomes clinically manifest only after",
"      <strong>",
"       at least 90 percent",
"      </strong>",
"      of the cortex has been destroyed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antigen targets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibodies against other endocrine glands are common in patients with autoimmune adrenal insufficiency, but rare in normal subjects. Polyglandular autoimmune syndromes are discussed separately. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antibodies against other endocrine glands'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link\">",
"       \"Causes of primary adrenal insufficiency (Addison's disease)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Genetic susceptibility",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune adrenal insufficiency may be familial or nonfamilial. It is somewhat less likely to be familial when it occurs alone. Approximately one-third of such patients have affected family members, as compared with about one-half of patients who have adrenal insufficiency as part of polyglandular autoimmune syndrome type I or II. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Genetics'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H3#H3\">",
"       \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Polyglandular autoimmune syndrome type I'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H4#H4\">",
"       \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Polyglandular autoimmune syndrome type II'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic susceptibility to autoimmune adrenal insufficiency is strongly associated with HLA B8, DR3, and DR4 alleles, except when it occurs as part of polyglandular autoimmune syndrome type I, in which no HLA association has been found. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'HLA associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The gene responsible for polyglandular autoimmune syndrome type I is located on chromosome 21q22.3. It is termed AIRE (autoimmune regulator) and encodes a protein that is probably a transcription factor. However, the genes for CYP11A1 and CYP17, the other two targets for the antiadrenal antibodies in patients with autoimmune adrenal insufficiency, lie on chromosomes 15q23-q24 and 10q24-q25, respectively. These genes are therefore",
"      <strong>",
"       not",
"      </strong>",
"      linked to HLA haplotypes or implicated in the genetic susceptibility to autoimmune adrenalitis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Non-HLA genes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/1\">",
"      Nerup J. Addison's disease--serological studies. Acta Endocrinol (Copenh) 1974; 76:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/2\">",
"      Boscaro M, Betterle C, Sonino N, et al. Early adrenal hypofunction in patients with organ-specific autoantibodies and no clinical adrenal insufficiency. J Clin Endocrinol Metab 1994; 79:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/3\">",
"      Song YH, Connor EL, Muir A, et al. Autoantibody epitope mapping of the 21-hydroxylase antigen in autoimmune Addison's disease. J Clin Endocrinol Metab 1994; 78:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/4\">",
"      Chen S, Sawicka J, Prentice L, et al. Analysis of autoantibody epitopes on steroid 21-hydroxylase using a panel of monoclonal antibodies. J Clin Endocrinol Metab 1998; 83:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/5\">",
"      Brozzetti A, Marzotti S, La Torre D, et al. Autoantibody responses in autoimmune ovarian insufficiency and in Addison's disease are IgG1 dominated and suggest a predominant, but not exclusive, Th1 type of response. Eur J Endocrinol 2010; 163:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/6\">",
"      B&oslash;e AS, Bredholt G, Knappskog PM, et al. Autoantibodies against 21-hydroxylase and side-chain cleavage enzyme in autoimmune Addison's disease are mainly immunoglobulin G1. Eur J Endocrinol 2004; 150:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/7\">",
"      Chen S, Sawicka J, Betterle C, et al. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. J Clin Endocrinol Metab 1996; 81:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/8\">",
"      Blizzard RM, Chee D, Davis W. The incidence of adrenal and other antibodies in the sera of patients with idiopathic adrenal insufficiency (Addison's disease). Clin Exp Immunol 1967; 2:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/9\">",
"      Irvine, WJ, Barnes, EW. Addison's disease, ovarian failure and hypoparathyroidism. Clin Endocrinol Metab 1975; 4:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/10\">",
"      Irvine WJ, Stewart AG, Scarth L. A clinical and immunological study of adrenocortical insufficiency (Addison's disease). Clin Exp Immunol 1967; 2:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/11\">",
"      Irvine, WJ, Barnes, EW. Adrenocortical insufficiency. Clin Endocrinol Metab 1972; 1:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/12\">",
"      Colls J, Betterle C, Volpato M, et al. Immunoprecipitation assay for autoantibodies to steroid 21-hydroxylase in autoimmune adrenal diseases. Clin Chem 1995; 41:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/13\">",
"      Falorni A, Nikoshkov A, Laureti S, et al. High diagnostic accuracy for idiopathic Addison's disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. J Clin Endocrinol Metab 1995; 80:2752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/14\">",
"      Ahonen P, Miettinen A, Perheentupa J. Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. J Clin Endocrinol Metab 1987; 64:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/15\">",
"      Betterle C, Scalici C, Presotto F, et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol 1988; 117:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/16\">",
"      Gylling M, Tuomi T, Bj&ouml;rses P, et al. ss-cell autoantibodies, human leukocyte antigen II alleles, and type 1 diabetes in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2000; 85:4434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/17\">",
"      Falorni A, Chen S, Zanchetta R, et al. Measuring adrenal autoantibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. Clin Immunol 2011; 140:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/18\">",
"      Myhre AG, Undlien DE, L&oslash;v&aring;s K, et al. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J Clin Endocrinol Metab 2002; 87:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/19\">",
"      Betterle C, Volpato M, Rees Smith B, et al. II. Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison's disease. J Clin Endocrinol Metab 1997; 82:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/20\">",
"      Betterle C, Volpato M, Rees Smith B, et al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison's disease. J Clin Endocrinol Metab 1997; 82:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/21\">",
"      Coco G, Dal Pra C, Presotto F, et al. Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab 2006; 91:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/22\">",
"      S&ouml;derbergh A, Myhre AG, Ekwall O, et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2004; 89:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/23\">",
"      Wolff AS, Erichsen MM, Meager A, et al. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab 2007; 92:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/24\">",
"      Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 2006; 3:e289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/25\">",
"      Falorni A, Laureti S, De Bellis A, et al. Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J Clin Endocrinol Metab 2004; 89:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/26\">",
"      Saenger P, Levine LS, Irvine WJ, et al. Progressive adrenal failure in polyglandular autoimmune disease. J Clin Endocrinol Metab 1982; 54:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/27\">",
"      De Bellis A, Bizzarro A, Rossi R, et al. Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. J Clin Endocrinol Metab 1993; 76:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/28\">",
"      Laureti S, De Bellis A, Muccitelli VI, et al. Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison's disease. J Clin Endocrinol Metab 1998; 83:3507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/29\">",
"      Blizzard RM, Chee D, Davis W. The incidence of parathyroid and other antibodies in the sera of patients with idiopathic hypoparathyroidism. Clin Exp Immunol 1966; 1:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/30\">",
"      McHardy-Young S, Lessof MH, Maisey MN. Serum TSH and thyroid antibody studies in Addison's disease. Clin Endocrinol (Oxf) 1972; 1:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/31\">",
"      Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison's disease. J Autoimmun 1995; 8:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/32\">",
"      Li Y, Song YH, Rais N, et al. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J Clin Invest 1996; 97:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/33\">",
"      Ketchum CH, Riley WJ, Maclaren NK. Adrenal dysfunction in asymptomatic patients with adrenocortical autoantibodies. J Clin Endocrinol Metab 1984; 58:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/34\">",
"      Scherbaum WA, Berg PA. Development of adrenocortical failure in non-Addisonian patients with antibodies to adrenal cortex. A clinical follow-up study. Clin Endocrinol (Oxf) 1982; 16:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/35\">",
"      Brewer, KW, Parziale, VS, Eisenbarth, GS. Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency (letter). New Engl J Med 1997; 337:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/36\">",
"      Yu L, Brewer KW, Gates S, et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J Clin Endocrinol Metab 1999; 84:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/37\">",
"      Triolo TM, Armstrong TK, McFann K, et al. Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. Diabetes Care 2011; 34:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/38\">",
"      Furmaniak J, Kominami S, Asawa T, et al. Autoimmune Addison's disease--evidence for a role of steroid 21-hydroxylase autoantibodies in adrenal insufficiency. J Clin Endocrinol Metab 1994; 79:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/39\">",
"      Wulffraat NM, Drexhage HA, Bottazzo GF, et al. Immunoglobulins of patients with idiopathic Addison's disease block the in vitro action of adrenocorticotropin. J Clin Endocrinol Metab 1989; 69:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/40\">",
"      Wardle CA, Weetman AP, Mitchell R, et al. Adrenocorticotropic hormone receptor-blocking immunoglobulins in serum from patients with Addison's disease: a reexamination. J Clin Endocrinol Metab 1993; 77:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/41\">",
"      Boscaro M, Betterle C, Volpato M, et al. Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo. J Clin Endocrinol Metab 1996; 81:2801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/42\">",
"      Neville, AM, Mackay, AM. The structure of the human adrenal cortex in health and disease. Clin Endocrinol Metab 1972; 1:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/43\">",
"      Fairchild RS, Schimke RN, Abdou NI. Immunoregulation abnormalities in familial Addison's disease. J Clin Endocrinol Metab 1980; 51:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/44\">",
"      Rabinowe SL, Jackson RA, Dluhy RG, Williams GH. Ia-positive T lymphocytes in recently diagnosed idiopathic Addison's disease. Am J Med 1984; 77:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/45\">",
"      Nerup J, Bendixen G. Anti-adrenal cellular hypersensitivity in Addison's disease. II. Correlation with clinical and serological findings. Clin Exp Immunol 1969; 5:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/46\">",
"      Husebye ES, Bratland E, Bredholt G, et al. The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitope. Endocrinology 2006; 147:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/47\">",
"      Bratland E, Skinningsrud B, Undlien DE, et al. T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency. J Clin Endocrinol Metab 2009; 94:5117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/48\">",
"      Leshin M. Polyglandular autoimmune syndromes. Am J Med Sci 1985; 290:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/49\">",
"      Nerup J. Addison's disease--clinical studies. A report fo 108 cases. Acta Endocrinol (Copenh) 1974; 76:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/50\">",
"      Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 1981; 60:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/51\">",
"      Spinner MW, Blizzard RM, Childs B. Clinical and genetic heterogeneity in idiopathic Addison's disease and hypoparathyroidism. J Clin Endocrinol Metab 1968; 28:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/52\">",
"      Farid NR, Bear JC. The human major histocompatibility complex and endocrine disease. Endocr Rev 1981; 2:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/53\">",
"      Maclaren NK, Riley WJ. Thyroid, gastric, and adrenal autoimmunities associated with insulin-dependent diabetes mellitus. Diabetes Care 1985; 8 Suppl 1:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/54\">",
"      Partanen J, Peterson P, Westman P, et al. Major histocompatibility complex class II and III in Addison's disease. MHC alleles do not predict autoantibody specificity and 21-hydroxylase gene polymorphism has no independent role in disease susceptibility. Hum Immunol 1994; 41:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/55\">",
"      Badenhoop K, Walfish PG, Rau H, et al. Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease. J Clin Endocrinol Metab 1995; 80:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/56\">",
"      Ghaderi M, Gambelunghe G, Tortoioli C, et al. MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. J Clin Endocrinol Metab 2006; 91:4107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/57\">",
"      Gambelunghe G, Falorni A, Ghaderi M, et al. Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease. J Clin Endocrinol Metab 1999; 84:3701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/58\">",
"      Miller WL. Molecular biology of steroid hormone synthesis. Endocr Rev 1988; 9:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/59\">",
"      Butler MG, Hodes ME, Conneally PM, et al. Linkage analysis in a large kindred with autosomal dominant transmission of polyglandular autoimmune disease type II (Schmidt syndrome). Am J Med Genet 1984; 18:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/60\">",
"      Aaltonen J, Bj&ouml;rses P, Sandkuijl L, et al. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type I assigned to chromosome 21. Nat Genet 1994; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/61\">",
"      Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet 1997; 17:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/62\">",
"      Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997; 17:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/63\">",
"      Sparkes RS, Klisak I, Miller WL. Regional mapping of genes encoding human steroidogenic enzymes: P450scc to 15q23-q24, adrenodoxin to 11q22; adrenodoxin reductase to 17q24-q25; and P450c17 to 10q24-q25. DNA Cell Biol 1991; 10:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/64\">",
"      Blomhoff A, Lie BA, Myhre AG, et al. Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease. J Clin Endocrinol Metab 2004; 89:3474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/65\">",
"      Jackson R, McNicol AM, Farquharson M, Foulis AK. Class II MHC expression in normal adrenal cortex and cortical cells in autoimmune Addison's disease. J Pathol 1988; 155:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/66\">",
"      Guttman, PH. Addison's disease. A statistical analysis of five hundred and sixty-six cases and a study of the pathology. Arch Pathol 1930; 10:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/67\">",
"      Barker, NW. The pathologic anatomy in twenty-eight cases of Addison's disease. Arch Pathol 1929; 8:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9896/abstract/68\">",
"      Cedermark BJ, Sj&ouml;berg HE. The clinical significance of metastases to the adrenal glands. Surg Gynecol Obstet 1981; 152:607.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 169 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9896=[""].join("\n");
var outline_f9_42_9896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H801912073\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H240131434\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HUMORAL IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anti-adrenal antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antigen targets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antibodies against other endocrine glands",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CELLULAR IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HLA associations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Non-HLA genes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801912073\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/169\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/169|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/7/123\" title=\"figure 1\">",
"      Adrenal steroid synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/169|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/45/24283\" title=\"table 1\">",
"      Autoantibodies in Addisons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/62/8171\" title=\"table 2\">",
"      Antiadrenal antibodies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24984?source=related_link\">",
"      Etiology of hypocalcemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=related_link\">",
"      Pathogenesis of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23976?source=related_link\">",
"      Pathogenesis, diagnosis, and treatment of autoimmune ovarian failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_42_9897="Overview of stem cells";
var content_f9_42_9897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of stem cells",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/42/9897/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9897/contributors\">",
"     David T Scadden, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9897/contributors\">",
"     Marc HGP Raaijmakers, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/42/9897/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9897/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/42/9897/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9897/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/42/9897/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H541321347\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stem cells are those cells that have the capability of self-renewal and differentiation. First identified in the hematopoietic system, they are likely to be present in many other tissues. Stem cells have altered the care of individuals with hematologic, oncologic, dermatologic, ophthalmologic, and orthopedic conditions. The range of possible applications of stem cells to medicine extends beyond the conception of stem cells as replacement parts (",
"    <a class=\"graphic graphic_table graphicRef69800 \" href=\"UTD.htm?0/4/68\">",
"     table 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    The evolving role of stem cells in clinical medicine is developing along at least three lines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stem cells as therapy (either to replace cell lines that have been lost or destroyed, or to modify the behavior of other cells)",
"     </li>",
"     <li>",
"      Stem cells as targets of drug therapy",
"     </li>",
"     <li>",
"      Stem cells to generate differentiated tissue for in vitro study of disease models for drug development.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the biology of stem cells and present an overview of their use in clinical and research settings, as well as ethical considerations that have generated much controversy.",
"   </p>",
"   <p>",
"    Hematopoietic stem cells are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .) Hematopoietic stem cell transplantation for specific clinical conditions is discussed in multiple related topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982123\">",
"    <span class=\"h1\">",
"     TYPES OF STEM CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All stem cells share two cardinal features: they are capable of self-renewal and they can differentiate. Self-renewal is the ability of cells to proliferate without the loss of differentiation potential and without undergoing senescence (biologic aging). Self-renewal does not imply that each cell division results in two exact replicas of the stem cell; daughter cells may be either stem cells or more differentiated cells. Indeed, stem cells are hypothesized to be able to divide symmetrically (in which both daughter cells are either stem cells or differentiated cells) or asymmetrically (yielding both a stem cell and a more differentiated cell) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef54474 \" href=\"UTD.htm?2/44/2766\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The potency of a stem cell is defined by the types of more differentiated cells that the stem cell can make (",
"    <a class=\"graphic graphic_table graphicRef78504 \" href=\"UTD.htm?7/1/7195\">",
"     table 2",
"    </a>",
"    ). Stem cells can be either totipotent, pluripotent, multipotent, or unipotent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Totipotent cells have the capability to produce all cell types of the developing organism, including both embryonic and extraembryonic (eg, placenta) tissues.",
"     </li>",
"     <li>",
"      Pluripotent cells can only make cells of the embryo proper, but make all cells of the embryo including germ cells and cells from any of the germ layers. Therefore, they can make any cell of the body.",
"     </li>",
"     <li>",
"      Multipotent cells can only make cells within a given germ layer. For example, multipotent stem cells from a mesodermal tissue like the blood can make all the cells of the blood, but cannot make cells of a different germ layer such as neural cells (ectoderm) or liver cells (endoderm).",
"     </li>",
"     <li>",
"      Unipotent cells make cells of a single cell type. An example is a germ cell stem cell that makes the cells that mature to become egg or sperm, but not other cell types.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982130\">",
"    <span class=\"h1\">",
"     SOURCES OF STEM CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classically, the potency of cells has been thought to be tied to the time of embryonic development of the organism. That is, cells that arise from the first few cell divisions following fertilization of the egg are generally the only cells that have totipotency. Pluripotent cells were thought to be limited to cells derived from either the inner cell mass of the blastocyst (a pre-implantation stage of development occurring approximately 7 to 10 days after fertilization in the human) or nascent germ cells in the embryo. Cells cultured and cell lines established from these structures are called embryonic stem (ES) cells and embryonic germ cells respectively. It is now known that pluripotent cells can arise from other cells types as well. (See",
"    <a class=\"local\" href=\"#H3982137\">",
"     'Induced pluripotent stem cells (iPS)'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Once the primitive streak forms in embryonic development (day 10 to 14 post fertilization in the human), it is thought that most stem cells are restricted to be either multipotent or unipotent. These have often been called 'adult' stem cells. If they are derived from tissue other than the germ cells, they may be called 'somatic' stem cells. Such cells would include cells derived from the cord blood, sometimes mistakenly considered equivalent to ES cells in the popular press.",
"   </p>",
"   <p>",
"    Adult stem cells are thought to be present in most, but not all, tissues and to persist throughout life (",
"    <a class=\"graphic graphic_figure graphicRef67256 \" href=\"UTD.htm?1/8/1155\">",
"     figure 2",
"    </a>",
"    ). They are thought to provide the basis for tissue maintenance and response to injury. This is particularly true for tissues where there is high cell turnover, such as the blood, skin, and intestine, where stem cells have been clearly defined experimentally [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. There is also clear evidence for a resident stem cell population for some tissues where the rate of cell turnover is lower (such as muscle, brain, lung, and kidney) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, for other tissues, including the islet cells of the pancreas, it is not clear whether adult stem cells exist and it is possible that stem cells are a durable source of replacement cells in some tissues but not in others. Division of mature cells may be the basis for replacement after loss of some cells in other tissues. The implications of this are that mature cells are thought to only have a limited number of cell divisions, as opposed to stem cells. Therefore in settings of extensive injury, a tissue that depends upon residual mature cells to replace the injured cells may be more limited in its regenerative capacity than tissues that can rely on resident stem cells. This is one hypothesis for the failure of repair of pancreatic islet damage in type I diabetes mellitus, whereas extensive cell damage to the blood with cancer chemotherapy can result in complete restoration of tissue function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982137\">",
"    <span class=\"h2\">",
"     Induced pluripotent stem cells (iPS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of the close relationship between stem cell potential and stage of development dramatically changed in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/10\">",
"     10",
"    </a>",
"    ]. In a remarkable set of experiments, Shinya Yamanaka and his colleagues took genes that were expressed in pluripotent ES cells, but not generally in mature cells, and introduced them into mature cells. They did so in a manner such that the genes would now be &ldquo;ectopically&rdquo; expressed, ie, expressed in a cell type where the gene is normally not expressed. A small number of the mature cells reverted back to a highly immature cell state that resembled an ES cell. This process, now called reprogramming, induced a pluripotent state in a previously differentiated cell type (",
"    <a class=\"graphic graphic_figure graphicRef81456 \" href=\"UTD.htm?35/5/35924\">",
"     figure 3",
"    </a>",
"    ). These cells are therefore called induced pluripotent stem cells (iPS).",
"   </p>",
"   <p>",
"    The ability to induce pluripotency has changed the landscape of stem cell biology along several lines.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, it indicates that the state of a given cell (ie, its level of differentiation) can be manipulated, resulting in drastic shifts in cell function. Cells have a plasticity that is far greater than previously recognized and can be programmed by specific manipulations to achieve a different cell state. A keratinocyte derived from the skin can be induced to become a pluripotent stem cell, essentially rewinding the cell&rsquo;s history to revert to an embryonic-like state.",
"     </li>",
"     <li>",
"      Second, a cell taken from an individual can be induced to become a cell type capable of forming any other cell type in that individual's body. This means, for example, that a skin or blood sample obtained from a patient with a degenerative brain disorder can be converted into a pluripotent cell. The iPS cell can then become a source for generating the neural cells affected by the disease. Thus, disease models can be generated using human cells for disorders where obtaining primary tissue, or developing reliable animal models, has been difficult.",
"     </li>",
"     <li>",
"      Third, iPS from a given individual represents a highly personalized source of cells. While technologies to generate iPS currently involve genetic manipulation, it is anticipated that other methods will be developed to generate iPS that are genetically identical to the individual. Such cells could be used to assess 'personalized' drug therapies and may represent a source of immunologically identical cells for transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While under active development, such approaches remain far from clinical application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982144\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS: CELL REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The paradigm for stem cells as a means of replacing injured or diseased tissue was first explored in response to the threat of nuclear warfare after World War II. Research on overcoming the effects of radiation injury led to the first demonstration of stem cells, whose existence had been hypothesized since the early twentieth century. In 1963, researchers in Toronto demonstrated that a bone marrow-derived cell could replace all the blood elements and rescue an otherwise lethally-irradiated animal by simple infusion of donor cells into the blood [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This demonstration quickly led to clinical testing and application. Over the ensuing twenty years, hematopoietic stem cell transplantation has become a standard means of treating individuals with hematologic malignancies as well as clinical and acquired bone marrow failure states, including radiation injury. In 1975, it was reported that cultured cells from the skin could result in the generation of large numbers of cells sufficient to provide an autologous cutaneous barrier in patients with severe burns [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus both unmanipulated stem cells from bone marrow and manipulated stem cells from skin have tremendous clinical utility in otherwise fatal settings.",
"   </p>",
"   <p>",
"    In addition to treatment for hematologic disease and burns, stem cells are now used for bone grafting in orthopedics and for corneal generation from limbal stem cells in ophthalmology. The presence of stem cells in other tissue types has led to the preclinical testing of stem cell therapies for other disorders, including those involving muscle and nerve tissue. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982151\">",
"    <span class=\"h2\">",
"     Preclinical examples using human ES cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human embryonic stem cells have been successfully differentiated in vitro into multiple cell types for therapeutic uses, including oligodendrocytes, pancreatic cells, cardiomyocytes, motor and dopaminergic neurons, and hematopoietic precursor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/13\">",
"     13",
"    </a>",
"    ]. The therapeutic potential for ES cell-derived somatic cells has been demonstrated in animal models of retinal blindness, Parkinson's disease, spinal cord injury, myocardial infarction, and type I diabetes mellitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982158\">",
"    <span class=\"h3\">",
"     Retinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human ES cell-derived retinal photoreceptors have been used to improve visual function in blind mice [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/14\">",
"     14",
"    </a>",
"    ]. Following intraocular injection, retinal cells derived from human ES migrated into the appropriate retinal layers and expressed markers of differentiated rod and cone photoreceptor cells. Subretinal transplantation of the cells into the subretinal space of mice modeling Leber's congenital amaurosis restored light responses to the animals. (See",
"    <a class=\"local\" href=\"#H11274542\">",
"     'Clinical use of human ES cells'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17239?source=see_link&amp;anchor=H8#H8\">",
"     \"Retinitis pigmentosa: Treatment\", section on 'Retinal cell transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982165\">",
"    <span class=\"h3\">",
"     Parkinson disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A highly enriched population of midbrain neural stem cells was derived from mouse ES cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/15\">",
"     15",
"    </a>",
"    ]. The dopamine neurons generated by these stem cells showed electrophysiologic and behavioral properties expected of neurons from the midbrain. These ES-derived neurons survived after being transplanted into rats with symptoms of Parkinson disease, showed appropriate electrophysiological properties, and ameliorated pathologic movements in the animals. Subsequently, functional improvement was seen with use of human ES cell-derived dopaminergic neurons after transplantation in a rat model of Parkinsonism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982172\">",
"    <span class=\"h3\">",
"     Spinal cord injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplantation of human ES-derived oligodendrocyte progenitor cells into adult rats, seven days after the induction of a spinal cord injury, was shown to enhance remyelination and promote improved motor function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/17\">",
"     17",
"    </a>",
"    ]. Transplanted cells survived, redistributed over short distances, and differentiated into oligodendrocytes, demonstrating their therapeutic potential after recent spinal cord injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982179\">",
"    <span class=\"h3\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated that transplantation of human ES-derived cardiomyocytes improves contractile function of the infarcted mouse heart. Using a combination of pro-survival factors that limited cardiomyocyte death after transplantation, one group demonstrated decreased rates of heart failure and partial remuscularization (as evidenced by systolic thickening of the infarction wall) in animals treated with human ES-derived cardiomyocytes when compared to control animals treated with non-cardiac human ES derivatives [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/18\">",
"     18",
"    </a>",
"    ]. Similar results in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/19\">",
"     19",
"    </a>",
"    ] highlight the potential of human ES for myocardial cell therapy strategies. Another report, however, found that the beneficial effects were transient, stressing the importance of long-term follow-up in the assessment of therapeutic benefit in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18617?source=see_link&amp;anchor=H11#H11\">",
"     \"Genetic and cellular therapy in heart failure and myocardial infarction\", section on 'Hematopoietic stem cell therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39513?source=see_link&amp;anchor=H19#H19\">",
"     \"New therapies for angina pectoris\", section on 'Stem cell therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982186\">",
"    <span class=\"h3\">",
"     Diabetes mellitus type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently no reproducible methods for the efficient direct differentiation of human ES cells to insulin-producing beta cells, although the generation of beta cells",
"    <strong>",
"    </strong>",
"    in vitro by selecting for the expression of beta cell genes or varying growth conditions has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the physiologic ability of human ES-derived pancreatic endoderm to differentiate in vivo into glucose-responsive insulin-secreting cells in immunodeficient mice with streptozotocin-induced diabetes, ameliorating hyperglycemia in these mice, has been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11274542\">",
"    <span class=\"h2\">",
"     Clinical use of human ES cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human embryonic stem (ES) cells, initially discovered in 1998, have been successfully differentiated in vitro into multiple cell types for therapeutic uses that have been extensively studied in animal models. As research into this potential treatment modality continues, and the potential challenges limiting their use are addressed, initial efforts are expected to use ES cells to treat a variety of human pathologies. (See",
"    <a class=\"local\" href=\"#H3982151\">",
"     'Preclinical examples using human ES cells'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3982200\">",
"     'Challenges in the clinical use of stem cells as replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In 2012, the first report of the safety and tolerability of human ES cell use for the treatment of two patients with retinal disease appeared (one patient with dry age-related macular degeneration, one patient with Stargardt&rsquo;s macular dystrophy) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/24\">",
"     24",
"    </a>",
"    ]. Human ES cell differentiation resulted in greater than 99 percent pure retinal pigment epithelium (RPE), of which 50,000 RPE cells were injected into the subretinal space. The human ES cell-derived RPE proliferation was confined to the subretinal space. Both patients were treated with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil for immunosuppression beginning one week before the procedure and continuing for six weeks, followed by six additional weeks of mycophenolate mofetil only, with no signs of rejection noted during the follow-up. Improvement in visual acuity was noted in both patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In the patient with macular degeneration, visual acuity improved from",
"      <span class=\"nowrap\">",
"       20/500",
"      </span>",
"      at baseline to",
"      <span class=\"nowrap\">",
"       20/200",
"      </span>",
"      at two weeks post-procedure before settling at",
"      <span class=\"nowrap\">",
"       20/320",
"      </span>",
"      at long-term follow-up.",
"     </li>",
"     <li>",
"      In the patient with Stargardt&rsquo;s macular dystrophy, visual acuity improved from seeing hand motions at baseline to counting fingers at two weeks post-procedure with improvement to",
"      <span class=\"nowrap\">",
"       20/800",
"      </span>",
"      at one, two, and three months follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This initial report of human ES cell transplantation into the retinae of two patients shows the apparent short-term safety and tolerability of this treatment in humans, with apparent efficacy as well. Additional studies assessing the dosage, efficacy, and longer-term safety are required prior to widespread clinical application of human ES cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982193\">",
"    <span class=\"h2\">",
"     Preclinical studies using iPS cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recognition that a cell taken from an individual can be induced to become pluripotent (a cell type capable of forming any other cell type in that individual's body) provides unprecedented opportunities for regenerative medicine. Easily accessible patient cell types, such as skin fibroblasts or blood cells, can be reprogrammed to induced pluripotent stem cells (iPS). These pluripotent cells are envisioned to then be differentiated into mature cells that may be deficient in diseases such as islet cells for type I diabetes, or into tissue-specific adult (stem) cells. The cells can theoretically be used for tissue regeneration in the same patient (",
"    <a class=\"graphic graphic_figure graphicRef51751 \" href=\"UTD.htm?0/48/782\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In such a way, iPS cell technology could overcome two important obstacles associated with human ES cells: immune rejection after transplantation and ethical concerns regarding the use of human embryos. The approach would be particularly powerful in monogenic diseases, where &lsquo;patient-specific&rsquo; iPS can be generated, the diseased gene in those cells potentially corrected, and the gene-corrected cells transplanted to restore organ function. This field is rapidly evolving, although there remains a great deal of research needed to make such a schema viable in the clinical setting.",
"   </p>",
"   <p>",
"    Many of the studies to evaluate iPS cells as a source of cell replacement are being conducted in rodents. These studies permit testing of basic principles in a physiologic setting and are therefore useful, particularly where murine models of human diseases have been generated. For two such models, Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/18\">",
"     18",
"    </a>",
"    ] and hemophilia A [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/25\">",
"     25",
"    </a>",
"    ], iPS cells have been generated and used to differentiate cells that could then be transplanted for therapy.",
"   </p>",
"   <p>",
"    Other technologies developed for gene therapy have also been used to test whether iPS cells can be used to create gene corrected cells for transplantation. One proof-of-principle study used a mouse model of sickle cell disease in which the mouse hemoglobin genes contained the mutations known to cause sickling in human sickle cell anemia. Investigators generated iPS cells from skin cells of the mouse and introduced a normal hemoglobin gene allele to replace the sickle hemoglobin gene (using the gene targeting technology used to engineer mouse strains for research) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/26\">",
"     26",
"    </a>",
"    ]. They then generated blood stem cells from the gene corrected iPS cells. Transplantation of these cells into sickle cell anemic mice improved the disease phenotype. This represents a model for the use of iPS cells as cell therapy in the setting of genetic disorders.",
"   </p>",
"   <p>",
"    This approach was extended to humans, using fibroblasts from Fanconi anemia patients that were corrected for the diseased Fanconi gene [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/27\">",
"     27",
"    </a>",
"    ]. The normal (non-diseased) Fanconi gene was transferred into the fibroblast cells using a virus specifically engineered for transferring genes into cells. The gene-corrected cells were reprogrammed to pluripotency to generate patient-specific iPS cells. The iPS cells now carrying a normal Fanconi gene were tested for their ability to become blood cells in tissue culture outside the body. The cells with the normal Fanconi gene were able to generate blood cell types in a manner similar to cells from normal volunteers. This study indicated that skin cells from patients with an abnormal gene (as in the setting of Fanconi anemia) can be used to generate gene-corrected iPS cells that might serve as a source of cells for transplantation. Therefore, we are edging closer to demonstrating the feasibility of using iPS cells as therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982200\">",
"    <span class=\"h2\">",
"     Challenges in the clinical use of stem cells as replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of stem cells to replace abnormal or missing cells is conceptually compelling. The successful use of stems cells for bone marrow and skin therapies, and the identification of stem or progenitor populations in a number of tissue types, offers great promise for expanded clinical applications. There is the additional potential that human pluripotent cells may be a source of virtually any cell type. However, several complexities must be addressed before widespread application becomes feasible, including the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95681659\">",
"    <span class=\"h3\">",
"     Tissue integration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first issue is how transplanted cells will integrate into surrounding tissue to achieve a physiologically beneficial effect. This is of particular relevance where coordination of complex networks of cells is essential, such as in the heart and brain where aberrant circuits can result in serious adverse events. Although extensive testing is needed, one encouraging observation is that some cells appear to have an inherent capacity to incorporate into existing structures. An example is that, in an animal model, human endothelial cells derived from ES cells were able to organize into tubular structures and integrate into the host vasculature when inserted as dispersed cells into a host tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95681666\">",
"    <span class=\"h3\">",
"     Oncogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second concern is the potential for transplanted cells to form tumors. This is of particular importance when using pluripotent cells, since these are characterized by the ability to form teratomas (neoplastic tumors containing cells corresponding to all three embryonic layers) in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/10,29\">",
"     10,29",
"    </a>",
"    ]. Thus, the differentiation state of transplanted cells will need to be defined with high precision to avoid delivery of residual pluripotent cells that may differentiate aberrantly in vivo. Evidence also suggests that oncogenesis is not restricted to pluripotent cells. In one case, a child was given cultured fetal brain cells intrathecally and subsequently developed multiple CNS tumors of donor origin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/30\">",
"     30",
"    </a>",
"    ]. The culture process may enable the outgrowth of genetically abnormal cell types that could be of potential danger. The specifics of what types of testing will be required for pluripotent or other cells to assure genetic integrity of transplanted cells is an active area of consideration.",
"   </p>",
"   <p>",
"    The issue of malignant potential of cells is of greatest concern in induced pluripotent stem cells (iPS) cells. The methods of greatest efficiency for reprogramming cells are currently retrovirus or lentivirus-based, and therefore run the risk of mutagenesis by virtue of viral integration into the host genome. In addition, some of the genes used to induce reprogramming have known oncogenic potential (eg, c-Myc) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/31\">",
"     31",
"    </a>",
"    ]. Progress in reducing the number of gene products needed for reprogramming, and in the use of either non-integrating viruses or small molecules to supplant retrovirus-based reprogramming, is ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. These developments may mitigate the concerns about insertional mutagenesis, but will not entirely assuage concern for altered growth control of modified cells, particularly those with pluripotency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95681673\">",
"    <span class=\"h3\">",
"     Directed differentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A third concern is the ability to direct the differentiation state of the cells to be used. Generating the proper cell type from pluripotent cells remains a significant challenge for some cell types. Protocols have now been devised to create some neural cell types of clear clinical importance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/37\">",
"     37",
"    </a>",
"    ]. However, for other tissues, such as the blood, the cell types created most closely resemble embryonic blood cells and are not capable of engrafting the bone marrow without further and undesirable genetic manipulation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Achieving the right stage of differentiation is another consideration in development of the stem cell derived cell therapies. It may be most desirable to generate progenitors, rather than fully mature terminally differentiated cells in some tissues so that the replaced cells do not quickly senesce and die.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95681680\">",
"    <span class=\"h3\">",
"     Uniformity and consistency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Finally, the uniformity and consistency of the cell product may be difficult to achieve across different donor sources of cells.",
"   </p>",
"   <p>",
"    These hurdles are not likely to be prohibitive, but each will require considerable effort and attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982207\">",
"    <span class=\"h1\">",
"     OTHER CLINICAL APPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281036\">",
"    <span class=\"h2\">",
"     Disease modifiers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond use of stem cells for cell replacement, the ability of certain stem cells to alter disease without engrafting has been explored as a means of modifying cellular response to injury or aberrant immune activity. Such non-engrafting stem cells are hypothesized to provide complex signals, affecting disease outcome without directly replacing injured cells.",
"   </p>",
"   <p>",
"    The identification of a population of cells in the bone marrow that could form a number of mesenchymal cell populations ex vivo led to the concept of a mesenchymal stem cell [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. This population of cells is defined primarily by its ability to form colonies in tissue culture, and by the ability of single cells derived from the colonies to differentiate into osteoblasts, adipocytes or chondrocytes in vitro. Identification of these cells in the body, and understanding of how they function in vivo, remains controversial.",
"   </p>",
"   <p>",
"    The potential for these mesenchymal stem cells to form muscle led to exploration of their use in the setting of ischemic injury of the heart. While initial indications suggested that the cells may directly contribute to generating cells in the area of injury, it has subsequently been shown that the cells do not engraft [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/41\">",
"     41",
"    </a>",
"    ]. Rather, it is proposed that they provide complex signals, in a paracrine manner, that may alter the ability of the heart (and other tissues) to respond to ischemic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. This concept remains highly contested, in part because the mechanisms by which stem cells may function in this capacity are not clear. The mesenchymal stem cell populations studied are highly variable and have been variably reported to secrete a number of factors including indoleamine 2, 3-dioxygenase, prostaglandins, interleukin-6, hepatocyte growth factor, inducible nitric oxide synthase, and tumor growth factor (TGF)-&szlig;1 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been proposed that the mesenchymal stem cell population is capable of altering immune function and may therefore modulate injury responses as in ischemia, or mitigate the effects of immune mediated diseases. Mesenchymal stem cells have been tested in clinical trials in humans in settings of graft versus host disease following allogeneic hematopoietic stem cell transplantation, and in inflammatory bowel disease. For each, there has been controversy regarding the impact of the cells and the mechanism by which the cells may be acting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6666?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of acute graft-versus-host disease: Clinical trials\", section on 'Mesenchymal stem cells'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17962?source=see_link&amp;anchor=H4393312#H4393312\">",
"     \"Investigational therapies in the medical management of Crohn's disease\", section on 'Stem cell therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While this use of stem cell populations as disease modifying cell platforms is an area of active investigation, the concept should not be considered proven at this time. The prospect that mesenchymal cell populations may have the ability to arrive at sites of injury and provide paracrine signals is an exciting and potentially important application of stem cell biology, but it is not yet a defined therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982214\">",
"    <span class=\"h2\">",
"     Drugs targeting endogenous stem cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is emerging recognition that stem cells resident in adult tissues may be targets for pharmacologic interventions with the goal of altering the function of endogenous stem cells. This approach may avoid concerns related to tissue integration of exogenous cells.",
"   </p>",
"   <p>",
"    Growing understanding of the signaling processes that induce activation of stem cells, or modify their differentiation, makes this approach one of growing interest. Analogous to the use of erythropoietin to modify the activity of red cell progenitors, agents with similar effects on stem cells might generate reconstitution of other types of blood cells in the case of hematopoietic stem cells, or other mature cell types for other tissue stem cells.",
"   </p>",
"   <p>",
"    Some studies have identified agents capable of altering stem cell activity in settings of injury to the bone marrow or the bone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. One study has identified an agent (a derivative of prostaglandin E2) that is being tested for the ability to improve stem cell regeneration of hematopoiesis in the treatment of hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982221\">",
"    <span class=\"h2\">",
"     Disease models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stem cells offer the possibility of creating in vitro disease models that may improve molecular understanding of disease and accelerate the development of new therapies. Human cells from affected individuals with diseases affecting the nervous system, for example, have been extremely difficult to obtain for in vitro analysis. With stem cell approaches, it is possible to generate sufficiently large numbers of cells to study the molecular basis of functional deficits associated with the disease or to be used in the development and testing of new drugs.",
"   </p>",
"   <p>",
"    The development of induced pluripotent stem cells (iPS) cells has led to a number of efforts to create in vitro disease models amenable to genetic and small molecule study. A major goal of such efforts is to identify compounds capable of altering the progression of cell events corresponding to disease progression. These efforts depend upon robust cell culture systems that resemble the in vivo context closely enough to be useful for drug evaluation. Fulfillment of this requirement still needs validation.",
"   </p>",
"   <p>",
"    Two early examples depict use of iPS cells to create a disease model for further study of human disease pathogenesis and treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      iPS cell lines were created from patients with familial dysautonomia (FD), a rare fatal sensory autonomic neuropathy caused by a point mutation in the IKBKAP gene involved in transcriptional elongation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/48\">",
"       48",
"      </a>",
"      ]. The investigators demonstrated tissue-specific missplicing of IKBKAP in purified FD-iPSC-derived lineages, suggesting a mechanism for disease specificity. Functional studies revealed marked defects in neurogenic differentiation and migration behavior, recapitulating disease characteristics. FD-iPSCs were subsequently used for validating the potency of candidate drugs to reverse aberrant splicing and ameliorate neuronal differentiation and migration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link&amp;anchor=H7#H7\">",
"       \"Hereditary sensory and autonomic neuropathies\", section on 'HSAN3 (Familial dysautonomia)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In another study, iPS cells were generated from skin fibroblasts from a child with spinal muscular atrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/49\">",
"       49",
"      </a>",
"      ]. These cells expanded robustly in culture, maintained the disease genotype, and generated motor neurons that showed selective deficits compared to those derived from the child's unaffected mother.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    iPS cells have also been used to generate disease models for a wide variety of (genetic) diseases, including neurological, hematological, metabolic, and cardiovascular disorders. These studies have generated novel insights into the molecular mechanisms driving these disorders and platforms for drug screening [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional application of stem cell biology to disease modeling is in the setting of cancer. The model hypothesizes that there is a definable population of malignant cells that can be demonstrated to have the two cardinal features of stem cells (self-renewal and differentiation capacity). These cells, like stem cells in normal tissues, would replace more mature cells whose lifespan is limited. They are therefore hypothesized to be the cells that enable persistence and perhaps metastasis of tumors.",
"   </p>",
"   <p>",
"    The hypothesis has gained experimental support through the use of immunodeficient mice in whom human cancer cells can be engrafted [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. A subset of tumor cells can be defined in these animals that is capable of engrafting the tumor, while other subsets cannot. Further, the tumor-initiating subset can be sequentially transplanted to initiate new tumors and can yield the full diversity of cells observed in the original malignancy, thereby fulfilling the experimental definition of stem cells. Human acute myelogenous leukemia, breast, colon, ovarian, pancreatic, head and neck cancer, and malignant glioma have been shown to have such a subpopulation of cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9897/abstract/51-57\">",
"     51-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether all tumors have a stem-like cell is controversial, and much of the definition depends upon engraftment in a mouse model, which is not necessarily a surrogate for function in humans. However, the model is beginning to impact the way cancer is viewed and how oncologic drugs are developed. Studies are now investigating whether drugs affect the stem-like cells and not just tumor bulk, and whether agents can target distinctive features of the stem-like cells of cancer rather than the mixture of cells comprising a malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982228\">",
"    <span class=\"h1\">",
"     ETHICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first derivation of human embryonic stem and embryonic germ cells in 1998 sparked enormous interest and controversy regarding pluripotent stem cells. The initial, and still most frequent, techniques used to derive ES cells disrupt the blastocyst from which the cells are derived, raising concern that an early human life form was being destroyed. The source of the blastocyst was generally discarded material from in vitro fertilization clinics. Nonetheless, the issue of using the material for research, even if that research was intended to assuage human suffering, was morally unacceptable for many. These controversies led to policy decisions among some nations that precluded ES cell research or, as in the case of the United States, federal funding to support such research.",
"   </p>",
"   <p>",
"    The advent of reprogramming to generate induced pluripotent stem cells (iPS) has provided an alternative source of pluripotent cells. It should be recognized that iPS have not yet been shown to be fully equivalent to ES cells, and ES cells still represent the best defined pluripotent cell population. However, iPS cells are increasingly the focus of research and appear to engender less ethical concern since they do not involve the use of blastocysts or embryonic tissue. The cells from animals do have the ability to contribute to a developing organism though, so other ethical concerns are not entirely mitigated.",
"   </p>",
"   <p>",
"    An issue that is relevant for both pluripotent and other stem cells is how to define safety when proceeding to clinical trial. The area of cell therapies has been well explored in hematology, transfusion medicine, and hematopoietic stem cell transplant. Infusion of other cultured cell products has a well-defined safety profile for keratinocyte skin grafts and mesenchymal stem cell transplants. Several features are unique to the use of pluripotent cells, however:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concern regarding the placement of cells in tissues highly intolerant of aberrant growth control such as the central nervous system and heart.",
"     </li>",
"     <li>",
"      Defining the genetic integrity of manipulated cells can be extremely difficult, though may be resolvable through emerging genomic technologies.",
"     </li>",
"     <li>",
"      Whether the cells have tumorigenic potential is hard to define since even established cancers can be difficult to grow with functional in vitro or in vivo assays.",
"     </li>",
"     <li>",
"      Defining the potential to integrate as functional tissue requires in vivo settings, and animal models have only limited ability to predict events in humans.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, clinical experience will be necessary to define some of the risks in stem cell-based therapeutics, and careful design of clinical trials with a range of parameters specific to the field are in process.",
"   </p>",
"   <p>",
"    Stem cells have enormous potential that is well recognized by the public, and are a source of hope for those dealing with otherwise untreatable medical problems. However, the field is in its infancy and progress is painstaking; for those desperate to get help, unproven therapies even outside of reputable centers or clinical trial are a highly tempting option. The potential for patient exploitation raises another extremely challenging area. There has been a profusion of centers in many parts of the world, often offering treatment without clear definition of what cells would be used, what the source of cells is, and what the full experience has been. Services are often offered for cash payment and with unclear provisions to monitor safety or respond to adverse events. Patients and providers should ask a range of specific questions about such therapies. The International Society for Stem Cell Research (ISSCR) has provided suggested questions and other information that may be of use (",
"    <a class=\"external\" href=\"file://www.isscr.org/\">",
"     www.isscr.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1280948\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stem cells are those cells that have the capability of self-renewal and differentiation. Stem cells are classified based on the type of differentiated cell they can reproduce. Pluripotent stem cells can make all cells of the embryo, including germ cells and cells derived from ectodermal, mesodermal, and endodermal germ cell lines. (See",
"      <a class=\"local\" href=\"#H3982123\">",
"       'Types of stem cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Embryonic stem cells are typically derived from the preimplantation blastocyst (7 to 10 days post fertilization). Adult stem cells typically derive from tissue formed beyond 10 to 14 days post fertilization and are called &ldquo;somatic&rdquo; stem cells when derived from non-germ cell tissue. It is unclear whether adult stem cells are present in all tissues, such as pancreatic islet cells. (See",
"      <a class=\"local\" href=\"#H3982130\">",
"       'Sources of stem cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since 2006, it has been possible to create induced pluripotent stem cells by &ldquo;reprogramming,&rdquo; a process that involves gene transplantation into mature cells, with reversion to a pluripotent state. Induced pluripotent stem (iPS) cells provide the potential to create a specific tissue in tissue culture derived from an entirely other somatic cell. The potential for therapeutic use is great, although the need for genetic manipulation in the process limits the transference clinical application at the present time. (See",
"      <a class=\"local\" href=\"#H3982137\">",
"       'Induced pluripotent stem cells (iPS)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stem cells present current and future opportunities for several different clinical applications. Hematopoietic stem cell replacement is currently a robust intervention for a number of hematologic conditions. Burn therapy, bone grafting, and corneal transplant tissues are examples of other current uses of stem cell&ndash;generated tissue. Tissue replacement treatment for other conditions (retinal disease, Parkinson disease, myocardial infarction) is in development. Concerns about the technology include integrating the transplanted cells into complex cell networks, oncogenesis of the transplant material, and the ability to generate the correct target cell types in the right stage of differentiation. (See",
"      <a class=\"local\" href=\"#H3982144\">",
"       'Clinical applications: Cell replacement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stem cell transplantation may have the ability to modify diseased tissue in a paracrine fashion, without actual engraftment. Drugs directed at endogenous tissue stem cells may modify tissue response to injury. Finally, stem cells may generate tissue to be used as laboratory models for the study of diseases where obtaining live tissue is otherwise difficult or not possible. (See",
"      <a class=\"local\" href=\"#H3982207\">",
"       'Other clinical applications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ethical concerns have been raised regarding stem cell research. The use of induced pluripotent cells may mitigate concerns about disruption of embryos, but several other concerns remain to be addressed. (See",
"      <a class=\"local\" href=\"#H3982228\">",
"       'Ethical considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/1\">",
"      Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006; 441:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/2\">",
"      Tajbakhsh S, Rocheteau P, Le Roux I. Asymmetric cell divisions and asymmetric cell fates. Annu Rev Cell Dev Biol 2009; 25:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/3\">",
"      Gong JK. Endosteal marrow: a rich source of hematopoietic stem cells. Science 1978; 199:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/4\">",
"      Tumbar T, Guasch G, Greco V, et al. Defining the epithelial stem cell niche in skin. Science 2004; 303:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/5\">",
"      Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/6\">",
"      Montarras D, Morgan J, Collins C, et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science 2005; 309:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/7\">",
"      Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992; 255:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/8\">",
"      Kajstura J, Rota M, Hall SR, et al. Evidence for human lung stem cells. N Engl J Med 2011; 364:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/9\">",
"      Song B, Niclis JC, Alikhan MA, et al. Generation of induced pluripotent stem cells from human kidney mesangial cells. J Am Soc Nephrol 2011; 22:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/10\">",
"      Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/11\">",
"      BECKER AJ, McCULLOCH EA, TILL JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963; 197:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/12\">",
"      Rheinwald JG, Green H. Formation of a keratinizing epithelium in culture by a cloned cell line derived from a teratoma. Cell 1975; 6:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/13\">",
"      Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 2008; 132:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/14\">",
"      Lamba DA, Gust J, Reh TA. Transplantation of human embryonic stem cell-derived photoreceptors restores some visual function in Crx-deficient mice. Cell Stem Cell 2009; 4:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/15\">",
"      Kim JH, Auerbach JM, Rodr&iacute;guez-G&oacute;mez JA, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002; 418:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/16\">",
"      Yang D, Zhang ZJ, Oldenburg M, et al. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells 2008; 26:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/17\">",
"      Keirstead HS, Nistor G, Bernal G, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 2005; 25:4694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/18\">",
"      Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007; 25:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/19\">",
"      Caspi O, Huber I, Kehat I, et al. Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. J Am Coll Cardiol 2007; 50:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/20\">",
"      van Laake LW, Passier R, Monshouwer-Kloots J, et al. Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res 2007; 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/21\">",
"      Borowiak M, Melton DA. How to make beta cells? Curr Opin Cell Biol 2009; 21:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/22\">",
"      Shim JH, Kim SE, Woo DH, et al. Directed differentiation of human embryonic stem cells towards a pancreatic cell fate. Diabetologia 2007; 50:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/23\">",
"      Jiang J, Au M, Lu K, et al. Generation of insulin-producing islet-like clusters from human embryonic stem cells. Stem Cells 2007; 25:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/24\">",
"      Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012; 379:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/25\">",
"      Xu D, Alipio Z, Fink LM, et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci U S A 2009; 106:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/26\">",
"      Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/27\">",
"      Raya A, Rodr&iacute;guez-Piz&agrave; I, Guenechea G, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009; 460:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/28\">",
"      Wang ZZ, Au P, Chen T, et al. Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol 2007; 25:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/29\">",
"      Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/30\">",
"      Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009; 6:e1000029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/31\">",
"      Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007; 448:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/32\">",
"      Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration. Science 2008; 322:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/33\">",
"      Okita K, Nakagawa M, Hyenjong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/34\">",
"      Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009; 4:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/35\">",
"      Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009; 324:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/36\">",
"      Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008; 26:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/37\">",
"      Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008; 321:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/38\">",
"      Kyba M, Perlingeiro RC, Daley GQ. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 2002; 109:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/39\">",
"      Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/40\">",
"      Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/41\">",
"      Iso Y, Spees JL, Serrano C, et al. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun 2007; 354:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/42\">",
"      Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/43\">",
"      Burt RK, Loh Y, Pearce W, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008; 299:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/44\">",
"      Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. Stem Cells 2007; 25:2896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/45\">",
"      Adams GB, Martin RP, Alley IR, et al. Therapeutic targeting of a stem cell niche. Nat Biotechnol 2007; 25:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/46\">",
"      Mukherjee S, Raje N, Schoonmaker JA, et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008; 118:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/47\">",
"      North TE, Goessling W, Walkley CR, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007; 447:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/48\">",
"      Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009; 461:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/49\">",
"      Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009; 457:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/50\">",
"      Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 2012; 481:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/51\">",
"      Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/52\">",
"      Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/53\">",
"      O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/54\">",
"      Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68:4311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/55\">",
"      Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/56\">",
"      Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9897/abstract/57\">",
"      Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432:396.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14598 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-211.167.112.15-CF2E8830EA-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9897=[""].join("\n");
var outline_f9_42_9897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1280948\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541321347\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3982123\">",
"      TYPES OF STEM CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3982130\">",
"      SOURCES OF STEM CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3982137\">",
"      Induced pluripotent stem cells (iPS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3982144\">",
"      CLINICAL APPLICATIONS: CELL REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3982151\">",
"      Preclinical examples using human ES cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3982158\">",
"      - Retinal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3982165\">",
"      - Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3982172\">",
"      - Spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3982179\">",
"      - Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3982186\">",
"      - Diabetes mellitus type I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11274542\">",
"      Clinical use of human ES cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3982193\">",
"      Preclinical studies using iPS cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3982200\">",
"      Challenges in the clinical use of stem cells as replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95681659\">",
"      - Tissue integration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95681666\">",
"      - Oncogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95681673\">",
"      - Directed differentiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95681680\">",
"      - Uniformity and consistency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3982207\">",
"      OTHER CLINICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1281036\">",
"      Disease modifiers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3982214\">",
"      Drugs targeting endogenous stem cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3982221\">",
"      Disease models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3982228\">",
"      ETHICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1280948\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/14598\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14598|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/44/2766\" title=\"figure 1\">",
"      Signature characteristics of stem cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/8/1155\" title=\"figure 2\">",
"      Relationship of development to stem cell type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/5/35924\" title=\"figure 3\">",
"      Reprogramming adult cells to become pluripotent cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/48/782\" title=\"figure 4\">",
"      Induced pluripotent stem cells in therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14598|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/4/68\" title=\"table 1\">",
"      Stem cells in medicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/1/7195\" title=\"table 2\">",
"      Classification of stem cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18617?source=related_link\">",
"      Genetic and cellular therapy in heart failure and myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=related_link\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17962?source=related_link\">",
"      Investigational therapies in the medical management of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39513?source=related_link\">",
"      New therapies for angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17239?source=related_link\">",
"      Retinitis pigmentosa: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6666?source=related_link\">",
"      Treatment of acute graft-versus-host disease: Clinical trials",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_42_9898="Fertility sparing surgery for invasive cervical cancer";
var content_f9_42_9898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fertility sparing surgery for invasive cervical cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/42/9898/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9898/contributors\">",
"     Marie Plante, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/42/9898/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9898/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9898/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/42/9898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/42/9898/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/42/9898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Cancer Society encourages physicians to discuss fertility issues in reproductive age cancer patients prior to initiating cancer treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/1\">",
"     1",
"    </a>",
"    ]. Most young cancer survivors desire to eventually become parents; thus, the psychosocial impact of cancer-related infertility is significant, with a high proportion of these patients experiencing feelings of depression, grief, stress, and sexual dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns about fertility preservation are particularly common among women with gynecological malignancies: 42 percent of cases of cervical cancer are diagnosed in women prior to age 45 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/4\">",
"     4",
"    </a>",
"    ]. These young women may be candidates for fertility preservation options, such as radical trachelectomy, since most of their cancers are diagnosed at an early stage (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 1",
"    </a>",
"    ) when survival is over 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/4\">",
"     4",
"    </a>",
"    ]. Observational studies published in the past decade have reported good oncologic and obstetric outcomes after this procedure.",
"   </p>",
"   <p>",
"    Radical trachelectomy will be discussed here. Additional issues related to fertility and cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=see_link\">",
"     \"Overview of fertility and pregnancy in cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with stage IA1 disease (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 1",
"    </a>",
"    ) without lymphovascular space involvement (LVSI) are candidates for treatment with cervical cold knife conization alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/5\">",
"     5",
"    </a>",
"    ]. A United States national cancer database study (n=1409) of women age &le;40 years with stage IA1 cervical cancer found no significant difference in five-year survival between those who underwent conization versus hysterectomy (98 versus 99 percent); data regarding LVSI were not available [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VAGINAL RADICAL TRACHELECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vaginal radical trachelectomy (VRT) procedure was developed by the late Professor Daniel Dargent from Lyon, France at the end of the 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria for appropriate candidates for VRT have remained essentially unchanged since first proposed in 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Desire to preserve fertility",
"     </li>",
"     <li>",
"      Age less than 40 years (45 could be acceptable in some cases)",
"     </li>",
"     <li>",
"      Stage IA1 with vascular space invasion, IA2, or IB1 (stage IA1 without vascular space invasion can be treated with conization alone)",
"     </li>",
"     <li>",
"      Lesion size &le;2 cm, with limited endocervical extension as assessed by colposcopy and magnetic resonance imaging &nbsp;",
"     </li>",
"     <li>",
"      Squamous carcinoma or adenocarcinoma histology",
"     </li>",
"     <li>",
"      No evidence of lymph node metastasis",
"     </li>",
"     <li>",
"      Lymphovascular space invasion within the tumor is a risk factor for lymph node recurrence, but as a sole finding it is not a contraindication for the trachelectomy",
"     </li>",
"     <li>",
"      Absence of high-risk histologies (eg, neuroendocrine tumors)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using these criteria, one group estimated that 40 percent of patients who underwent a radical hysterectomy at their institution would have been candidates for a VRT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/9\">",
"     9",
"    </a>",
"    ]. However, even with these selection criteria, approximately 10 to 12 percent of patients are found to have more extensive endocervical disease at the time of surgery or positive nodes on frozen section, which require abandoning the procedure in favor of adjuvant radiation therapy or completion of surgery by radical hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/10-13\">",
"     10-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preoperative assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to surgery, magnetic resonance (MR) imaging of the pelvis is a mandatory examination on all patients who have a macroscopic tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/14\">",
"     14",
"    </a>",
"    ]. The sagittal T2-weighted images allow a clear assessment of the tumor size and location, degree of extension into the endocervical canal, length of the endocervical canal, and the distance between the upper margin of the lesion and the isthmus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/15\">",
"     15",
"    </a>",
"    ]. The latter measurement is particularly important because, in cases where this distance is less than 1 cm, it is our preference to offer neoadjuvant chemotherapy (NACT) initially and then proceed with the VRT in patients with good clinical response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete laparoscopic lymph node dissection is performed initially to exclude the presence of lymph node metastasis, which would be a contraindication to fertility sparing surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/16\">",
"     16",
"    </a>",
"    ]. Although sentinel node mapping may eventually replace this procedure, its reliability for clinical use in the treatment of early stage cervical cancer has not been firmly established.",
"   </p>",
"   <p>",
"    A detailed, illustrated description of VRT is beyond the scope of this topic, but is available elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/17\">",
"     17",
"    </a>",
"    ]. A brief synopsis is provided below. The trachelectomy procedure can be divided into the following six phases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preparatory phase &mdash; A 1 to 2 cm cuff of vaginal mucosa around the cervix is delineated and excised. The anterior and posterior edges of the vaginal mucosa are approximated in the midline to cover the cervix.",
"     </li>",
"     <li>",
"      Anterior phase &mdash; The vesicovaginal space is defined anteriorly to safely mobilize the bladder. The paravesical spaces are then defined laterally; this allows the bladder pillars to be defined. The ureters are palpated and identified within the bladder pillars, which can then be safely excised.",
"     </li>",
"     <li>",
"      Posterior phase &mdash; The posterior cul-de-sac (pouch of Douglas) is opened posteriorly, the pararectal space is identified, and the proximal uterosacral ligaments are excised.",
"     </li>",
"     <li>",
"      Lateral phase &mdash; After relocating the ureters, the proximal parametrial tissues are excised at the level of the isthmus. Care is taken to preserve the main uterine artery branches to optimize uterine vascularization in the event of a pregnancy. Although ureteral stents can be used to facilitate identification of the ureters, renal failure secondary to edema of the ureteral orifices has been reported with this procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Excision &mdash; The trachelectomy specimen is excised approximately 1 cm below the isthmus, followed by an endocervical curettage.",
"     </li>",
"     <li>",
"      Closure &mdash; The posterior cul-de-sac is closed with a purse string suture and a permanent cerclage is placed at the level of the isthmus. The vaginal mucosa is reapproximated to the new exocervix with interrupted sutures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best method of cerclage is controversial. We use a permanent nonresorbable monofilament 0-polypropylene suture [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/13\">",
"     13",
"    </a>",
"    ]. Polypropylene has good tensile strength; the use of a monofilament may reduce the risk of infection. It is important to not place the suture too deep within the cervical stroma to avoid erosion into the endocervical canal.",
"   </p>",
"   <p>",
"    Some surgeons prefer Mersilene tape [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/19\">",
"     19",
"    </a>",
"    ], but we feel it increases the chance of erosion and infection and does not stretch as much. Dargent used the Saling procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/20\">",
"     20",
"    </a>",
"    ], which results in total cervical occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/21\">",
"     21",
"    </a>",
"    ]. It does not appear to improve outcome over conventional cerclage and has been associated with additional complications [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/19,22,23\">",
"     19,22,23",
"    </a>",
"    ]. We consider it only in patients who failed conventional cerclage procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective study of 140 women who were candidates for VRT found that approximately 10 percent of planned VRT procedures were be abandoned intraoperatively, mainly because of the detection of lymph node metastasis (60 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Use of frozen section",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a visible lesion is present on clinical evaluation, we send the specimen for frozen section [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The pathologist is asked to perform the frozen section longitudinally (from the exocervix to the endocervix) at the level of the lesion in order to determine the distance between the upper endocervical tumor margin and the specimen excision margin. Ideally, 8 to 10 mm of normal tissue should be present, otherwise an additional section of the cervix may need to be removed. If the tumor extends higher into the endocervical canal and the margins remain positive or too close (&lt;5 mm), it may be necessary to perform a complete radical hysterectomy.",
"   </p>",
"   <p>",
"    If no visible lesion is present on clinical evaluation, (eg, after a diagnostic cone), we prefer to keep the trachelectomy specimen intact for final pathological analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Morbidity compared to hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative morbidity of radical trachelectomy is the same or less than that for radical hysterectomy. In one of the largest series from a single institution, the perioperative morbidity of laparoscopic-assisted vaginal radical trachelectomy (LAVRT, n = 118) was compared to that of laparoscopic-assisted vaginal radical hysterectomy (LAVRH, n = 139) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/10\">",
"     10",
"    </a>",
"    ]. The rates of intraoperative and postoperative complications were similar for both groups (intraoperative complications 2.5 and 5.8 percent, respectively; postoperative complications 21.2 and 19.4 percent, respectively). Similar results have been reported in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/11,12,27,28\">",
"     11,12,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study compared VRT to abdominal radical hysterectomy (ARH) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/29\">",
"     29",
"    </a>",
"    ]. VRT had less operative and short-term morbidity than ARH, but specific long-term morbidity due to the retained uterus and presence of the cerclage was reported (eg, vaginal discharge, irregular bleeding, deep dysmenorrhea, cerclage erosion). In addition, some women who underwent VRT became amenorrheic.",
"   </p>",
"   <p>",
"    Ten to 15 percent of patients develop cervical stenosis following VRT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Most patients are asymptomatic, but some experience dysmenorrhea, hematometra, hematosalpinx, or endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/31\">",
"     31",
"    </a>",
"    ]. Cervical stenosis can be problematic in women who require assisted reproduction, which may involve intrauterine insemination or embryo transfer following in vitro fertilization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Approaches to managing cervical stenosis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=see_link&amp;anchor=H23#H23\">",
"     \"Congenital cervical anomalies and benign cervical lesions\", section on 'Cervical stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Oncologic issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;A total of 550 cases of cervical cancer managed by VRT have been described in the literature. The overall rate of cervical cancer recurrence was less than 5 percent and mortality was 2 to 3 percent (",
"    <a class=\"graphic graphic_table graphicRef76213 \" href=\"UTD.htm?24/49/25372\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. These results are comparable to those following radical hysterectomy for lesions of similar size [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/10\">",
"     10",
"    </a>",
"    ]. These results are consistent with other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/24,35\">",
"     24,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 40 percent of recurrences occurred in the parametrium or pelvic sidewall, possibly due to insufficient parametrial excision or to the presence of microscopic LVSI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/36\">",
"     36",
"    </a>",
"    ]. Twenty-five percent of recurrences were in the pelvic, paraaortic, and supraclavicular lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/12\">",
"     12",
"    </a>",
"    ]. In the future, use of sentinel node mapping may help identify potentially missed nodal micrometastasis and aberrant lymph node draining sites, which may explain some of these nodal recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. Five centropelvic recurrences have been reported, four of these were in patients with adenocarcinomas and may have been due to the multifocal nature of this type of lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no high quality data comparing VRT with radical hysterectomy for treatment of cervical cancer. In a case-control study, 137 women who underwent VRT were matched with radical hysterectomy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/38\">",
"     38",
"    </a>",
"    ]. Five-year recurrence-free survival rates were similar between groups (95 and 100 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Risk factors for recurrence",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large lesion size &mdash; Lesions &gt;2 cm are associated with a higher risk of recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/10,12,13,39\">",
"       10,12,13,39",
"      </a>",
"      ]. In one of the large series described above, six of the seven recurrences (86 percent) were associated with tumor &ge;2 cm; 6 of 21 patients with lesions &ge;2 cm had a recurrence versus only 1 of 62 patients with lesions &lt;2 cm (29 versus 1.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/10\">",
"       10",
"      </a>",
"      ]. However, patients with lesions &gt;2 cm may still be candidates for VRT if their lesion is very exophytic and has minimal stromal invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LVSI &mdash; The presence of LVSI is associated with a higher risk of recurrence (12 versus 2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/12\">",
"       12",
"      </a>",
"      ]. Although LVSI has been implicated as an independent prognostic factor for recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/10\">",
"       10",
"      </a>",
"      ], in our experience and that of others, the presence of LVSI alone as a risk factor is not considered an absolute contraindication for VRT [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/12,13,41\">",
"       12,13,41",
"      </a>",
"      ]. This issue is controversial and patients with LVSI should be informed of the higher risk of recurrence, particularly when LVSI is extensive [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nonsquamous histology &mdash; Adenocarcinomas have not been proven to be associated with a higher risk of recurrence, although one series reported three of the four recurrences were in patients with adenocarcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/37,41\">",
"       37,41",
"      </a>",
"      ]. Similarly, adenosquamous histology does not appear to significantly increase the recurrence rate [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/12\">",
"       12",
"      </a>",
"      ]. However, neuroendocrine tumors are clearly a very aggressive variant of cervical cancer associated with rapid and widespread metastasis despite negative local resection margins and negative nodes [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/10,12,13\">",
"       10,12,13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5498?source=see_link\">",
"       \"Small cell neuroendocrine carcinoma of the cervix\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prospective study of 125 patients showed that high tumor grade, presence of LVSI, and tumor size &gt;2 cm were associated with a higher risk of abandoning the trachelectomy procedure. In addition, tumor size &gt;2 cm was statistically significantly associated with a higher risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Need for adjuvant treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant therapy is typically recommended for cervical cancer patients at high risk of recurrence, but carries a risk of premature ovarian failure and permanent loss of fertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H546745501#H546745501\">",
"     \"Management of early stage cervical cancer\", section on 'Adjuvant therapy indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review including seven series noted that approximately 10 percent of patients who underwent VRT had either positive nodes, positive margins, or parametrial involvement on final pathology, and thus would be candidates for adjuvant treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/12\">",
"     12",
"    </a>",
"    ]. Occasionally, margins appear adequate on frozen section, but are close (less than 5 mm) on final pathology, possibly because of tissue retraction after fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/25\">",
"     25",
"    </a>",
"    ]. Whether adjuvant therapy can be safely avoided in some of these patients has not been determined. A conservative approach with close follow-up may be risky. These cases require careful individualized discussion, weighing the potential higher risk of local recurrence against the permanent loss of fertility with adjuvant treatment. Data are sparse:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one of the large series described above, three of five women with nodal micrometastasis chose not to have adjuvant radiation therapy and did not experience a recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/10\">",
"       10",
"      </a>",
"      ]. Two patients with margins less than 5 mm refused to receive adjuvant treatment and neither had a recurrence.",
"     </li>",
"     <li>",
"      In another series, one patient with &lt;5 mm margins recurred in the corpus uteri three months after VRT, and one patient who developed adenocarcinoma in situ two years post VRT refused definitive treatment and developed an invasive cancer 10 months later [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In that same series, four patients had positive nodes on final pathology, despite a negative frozen section. All four refused adjuvant radiation therapy, but accepted chemotherapy",
"    <span class=\"nowrap\">",
"     (",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"      carboplatin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"      ifosfamide",
"     </a>",
"     )",
"    </span>",
"    in order to preserve fertility, and all are alive without recurrence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three of our patients had close margins (5, 4, and 1 mm) and none have recurred at this time (at least two years follow-up) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no definitive guidelines for follow-up of patients after VRT. In general, a colposcopic examination with a cervical cytology (with or without endocervical curettage) is recommended every three to four months for the first three years, every six months for the next two years, and yearly thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/44\">",
"     44",
"    </a>",
"    ]. Some experts advocate follow-up pelvic MR imaging at 6, 12, and 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/44\">",
"     44",
"    </a>",
"    ]. These should be read by radiologists familiar with patients who have undergone VRT, as some of the anatomical changes secondary to the procedure may be misinterpreted as cancer recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follow-up cytology after VRT frequently shows abnormal results. A good colposcopic evaluation of patients with abnormal cervical cytology and good communication with an experienced cytopathologist are critical to avoid unnecessary evaluation of benign smears [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/11\">",
"     11",
"    </a>",
"    ]. A review of 197 Pap tests post VRT reported false positive results in 2 percent, most often due to the presence of atypical endometrial cells, and up to 41 percent of smears contained only squamous cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/46\">",
"     46",
"    </a>",
"    ]. It has been proposed that such smears be reported as \"unsatisfactory\" in the first two years and \"negative for intraepithelial neoplasia or cancer\" thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/44\">",
"     44",
"    </a>",
"    ]. However, in a few cases, cytology identified recurrences long before the recurrences became clinically apparent; therefore, an abnormal result should be carefully monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/46\">",
"     46",
"    </a>",
"    ]. A follow-up with high-risk HPV testing may be useful for patients post trachelectomy. Patients who remain high-risk HPV positive should be followed-up carefully as their risk of local recurrence is probably higher. HPV vaccination should be offered to these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hysterectomy when childbearing is completed",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to perform hysterectomy after childbearing has been completed is a matter of debate, as no data are available comparing long-term outcome with, versus without, the procedure. We and others do not recommend routine hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/11,13\">",
"     11,13",
"    </a>",
"    ], but this issue should be discussed with patients to offer individualized recommendations. We do not advocate cesarean hysterectomy unless there are special circumstances, but others offer this procedure at the time of the last delivery for women who have completed childbearing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Reproductive issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thorough preoperative counseling is mandatory to ensure that women have realistic expectations with respect to fertility issues following VRT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/47\">",
"     47",
"    </a>",
"    ]. Women of advanced maternal age or with known or suspected subfertility should be encouraged to seek preoperative consultation with an infertility specialist [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/27\">",
"     27",
"    </a>",
"    ]. However, risk factors for infertility are not a contraindication for VRT, as assisted reproductive technologies may allow some of these women to become pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/24,27,30,48\">",
"     24,27,30,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported incidence of infertility following VRT ranges widely from 14 to 41 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/24,30\">",
"     24,30",
"    </a>",
"    ]. In one prospective study, 12 of 15 women who initially had a fertility problem ultimately conceived [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/24\">",
"     24",
"    </a>",
"    ]. Post-VRT, cervical factors (eg, cervical stenosis) account for 40 to 75 percent of fertility issues and the remainder are due to causes unrelated to the surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/19,24,32,49\">",
"     19,24,32,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who encounter infertility should be evaluated for cervical issues and other etiologies (including evaluation of a male partner), as appropriate. Managing the tight and scarred cervical opening may be challenging post trachelectomy, and a variety of approaches have been proposed to help manage the problem [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"     \"Evaluation of female infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link\">",
"     \"Evaluation of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pregnancy outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A literature review including 200 pregnancies reported that 66 percent of pregnancies following radical trachelectomy ended in a live birth [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/22\">",
"     22",
"    </a>",
"    ]. Overall, 42 percent of the pregnancies culminated with the birth of a healthy newborn at term; preterm delivery before 37 weeks of gestation occurred in 25 percent, but only about one-half of these deliveries ended with significant prematurity (before 32 weeks).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First trimester miscarriage &mdash; The rate of first trimester miscarriage following radical trachelectomy is comparable to the rate in the general population (16 to 20 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/22,23,30\">",
"       22,23,30",
"      </a>",
"      ]. The cerclage does not usually prevent expulsion of the products of conception. If spontaneous expulsion does not occur with expectant management,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      can be given to stimulate contractions [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/23,51\">",
"       23,51",
"      </a>",
"      ]. If medical management is unsuccessful, dilation and curettage (D&amp;C) is another option. In these cases, the cervix should be dilated minimally to avoid breaking the cerclage. Some clinicians use laminaria to facilitate dilation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2841?source=see_link\">",
"       \"Spontaneous abortion: Management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Second trimester miscarriage &mdash; The rate of second trimester miscarriage following VRT is higher than in the general population (9.5 versus 4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/22,30\">",
"       22,30",
"      </a>",
"      ]. It is hypothesized that chorioamnionitis develops and activates the cytokine cascade leading to preterm premature rupture of membranes (PPROM).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients will spontaneously pass the products of conception without the need for cerclage removal. If a dilation and evacuation (D&amp;E) is required, the cervix should be dilated just enough to allow passage of the suction cannula. Others prefer removal of the cerclage, followed by labor induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/19\">",
"     19",
"    </a>",
"    ]. Hysterotomy is rarely required to effect pregnancy termination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preterm delivery &mdash; A major concern following VRT is the higher rate of preterm labor and delivery. The etiology may involve one or both of the following: mechanical factors (the uterus puts too much pressure on the short cervix causing it to open prematurely), or infectious factors (impaired endocervical mucus plug does not provide adequate barrier against ascending infection) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rate of preterm birth varies substantially among the different surgical teams performing VRT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/22\">",
"     22",
"    </a>",
"    ]. In our practice, the second trimester pregnancy loss rate is 3 percent and preterm delivery rate is 4 percent for 24 to &lt;32 weeks of gestation and 14 percent for 32 to &lt;37 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/24\">",
"     24",
"    </a>",
"    ]. We believe that our very low rate is probably due to our technique of preserving at least 1 cm of endocervix at the time of the trachelectomy procedure; this allows some support of the lower uterine segment. Another institution, also with a VRT technique of transecting the cervix approximately 1 cm from the internal os, reported a second trimester pregnancy loss rate of 5 percent and preterm delivery rate of 5 percent for &lt;28 weeks of gestation and 25 percent for 28 to 36 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/37,52\">",
"     37,52",
"    </a>",
"    ]. By comparison, other groups excise the specimen directly at the isthmus leaving essentially no cervical tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/23,49\">",
"     23,49",
"    </a>",
"    ]. Our oncological data do not support the assumption that leaving some cervix increases the risk of local cancer recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective study of 106 pregnancies post vaginal trachelectomy found a 20 and 3 percent rate of first and second trimester miscarriage, and 75 percent of patients who reached the third trimester delivered at term (&gt;37 weeks of gestation) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/24\">",
"     24",
"    </a>",
"    ]. Another series also reported successful obstetric outcomes post-trachelectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cerclage complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear if the cerclage itself may increase the risk of ascending intrauterine infection and thus increases the risk of preterm premature rupture of membranes (PPROM) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/22\">",
"     22",
"    </a>",
"    ]. Potential side effects of cerclage include chronic vaginal discharge and detection of Actinomyces on cervical cytology [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the cerclage has to be removed, another cerclage can be placed at the time of a subsequent pregnancy, ideally at 12 to 14 weeks of gestation. An abdominal cerclage may be required if the cervix is too short or scarred after the trachelectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=see_link\">",
"     \"Transvaginal cervical cerclage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32532?source=see_link\">",
"     \"Transabdominal cervical cerclage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pregnancy planning and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest patients wait at least six, and preferably 12 months, following VRT before attempting to conceive [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is limited evidence on which to base recommendations on the management of these pregnancies. Information from studies on preterm labor and PPROM in women whose primary diagnosis is cervical insufficiency has been extrapolated to this population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/53\">",
"     53",
"    </a>",
"    ]; there are no data from randomized trials directly addressing management of women after VRT. A variety of interventions have been proposed, including routine screening for genital tract infection, prophylactic antibiotics, bed rest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced physical activity, and routine administration of glucocorticoids to hasten fetal lung maturation in the event of a preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/49\">",
"     49",
"    </a>",
"    ]. Patients should be informed that pregnancies following VRT are associated with a higher risk of complications and, for this reason, a specialist in maternal fetal medicine should be involved in their care [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We and others do not advise patients to reduce physical activity during pregnancy unless there are signs of cervical shortening. Given the increased risk of second trimester pregnancy loss and preterm birth, we follow patients closely and suggest monitoring cervical length with serial ultrasound examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/22,23,58\">",
"     22,23,58",
"    </a>",
"    ] and administering antenatal glucocorticoids when indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link\">",
"     \"Cervical insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not administer prophylactic antibiotics to women with intact fetal membranes. Randomized trials in women at high risk of preterm birth have shown that broad spectrum antibiotic therapy administered to asymptomatic women does not prevent preterm labor or birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=see_link&amp;anchor=H26#H26\">",
"     \"Prevention of spontaneous preterm birth\", section on 'Antibiotics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If PPROM occurs, delivery is recommended if there is evidence of chorioamnionitis or the pregnancy is at least 32 to 34 weeks of gestation. In the absence of these findings, the cerclage is left in place and prophylactic antibiotics are administered during expectant management. Management of PPROM is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=see_link&amp;anchor=H15#H15\">",
"     \"Transvaginal cervical cerclage\", section on 'Management after PPROM'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Delivery route",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal delivery should be avoided because a lateral cervical tear in the short scarred cervix may extend into the nearby uterine vessels, resulting in catastrophic hemorrhage. For this reason, we suggest cesarean delivery, which we perform at 37 to 38 weeks of gestation. We usually perform a low transverse incision; others favor a low vertical incision in view of the potential risk of lateral extension into the uterine vessels, but this risk is very low [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/11,44\">",
"     11,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ABDOMINAL RADICAL TRACHELECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abdominal radical trachelectomy (ART) procedure, which is similar to the abdominal radical hysterectomy procedure, was developed by Smith et al in 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/59\">",
"     59",
"    </a>",
"    ]. The technique has been slightly modified from its original version [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/60\">",
"     60",
"    </a>",
"    ]. Use of the abdominal approach is increasing. There have been preliminary reports of robot-assisted laparoscopic radical trachelectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Briefly, a midline incision is usually performed. After completing the bilateral pelvic lymphadenectomy, the paravesical and pararectal spaces are developed. The round ligaments are divided and then the uterine vessels are divided at their origin from the hypogastric vessels. Care is taken to preserve intact the infundibulopelvic and tuboovarian ligaments, as they will constitute the main source of vascular supply to the uterus. The parametria and paracolpos, along with the uterine vessels, are mobilized with the trachelectomy specimen. A complete ureteral dissection through the parametrial tunnel is required as in a type III radical hysterectomy procedure. The posterior cul-de-sac is incised and the uterosacral ligaments are divided.",
"   </p>",
"   <p>",
"    The required length of vaginectomy is then resected circumferentially via an anterior colpotomy and the specimen is completely separated from the vagina distally. This may be facilitated by the use of a vaginal cylinder to help delineate the vagina. Proximally, the specimen is excised approximately 5 mm below the internal os and is sent for frozen section analysis. If margins are secure, a permanent cerclage is placed circumferentially at the level of the isthmus, although some authors do not place any cerclage at all. The uterine fundus, along with the preserved utero-ovarian ligaments, is inspected for signs of ischemia. Lastly, the lower uterine segment is reanastomosed to the vaginal apex with six to eight interrupted absorbable sutures.",
"   </p>",
"   <p>",
"    The main advantage of the abdominal approach is a shorter learning curve without the need to acquire skills in laparoscopic and vaginal surgery. Disadvantages include the need for a midline laparotomy incision, greater blood loss, longer hospital stay, and sacrifice of the uterine arteries bilaterally, which may cause endometrial atrophy and cervical",
"    <span class=\"nowrap\">",
"     stenosis/scarring,",
"    </span>",
"    as well as low birth weight in future pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/53\">",
"     53",
"    </a>",
"    ]. One group has described a delicate surgical technique to allow conservation of these arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few recurrences have been reported following ART. At least two recurrences among 91 patients were in patients with large lesions (3.8 and 5.0 cm), suggesting that strict selection criteria are important to avoid recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/63-66\">",
"     63-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resumption of normal menstrual patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/60\">",
"     60",
"    </a>",
"    ] and successful pregnancies have been described following ART, and the overall obstetrical outcome appears to be good [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/67\">",
"     67",
"    </a>",
"    ]. In one report, ART was performed in two young girls in whom the vaginal approach would have been technically impossible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/68\">",
"     68",
"    </a>",
"    ]. They felt the abdominal approach expanded the availability of radical trachelectomy to women with anatomical distortion and to those in whom vaginal access would not be possible. In addition, a small series in which ART was performed during pregnancy reported three of the five patients had a spontaneous miscarriage shortly after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a growing interest in the abdominal approach because of its technical similarity to the radical hysterectomy. Surgeons tend to be more familiar with this approach, since it does not require vaginal surgery skills. Moreover, with advances in minimally invasive surgical techniques, laparoscopic radical trachelectomy has been developed, and more recently, robot-assisted radical trachelectomy has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/28,61,70,71\">",
"     28,61,70,71",
"    </a>",
"    ]. The latter two approaches have the advantages of avoiding abdominal incisions, and they appear to have lower surgical morbidity. Long term oncologic and obstetrical outcome are awaited, but these newer surgical techniques appear very promising.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FUTURE ALTERNATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of fertility-preserving surgery has gained wide acceptance in the oncology community as a valid alternative for young women who wish to preserve their fertility potential. However, a significant proportion of women are denied access to the procedure because of the size of their lesion. Neoadjuvant chemotherapy (NACT) is emerging as a potential option in those women. Conversely, in women with very small lesions, the extensive nature of the radical trachelectomy may be excessive and more limited local surgery may be sufficient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical lesions &gt;2 cm are clearly associated with a higher risk of cancer recurrence following a VRT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. NACT is given to chemo-reduce the size of the lesion, making it possible for good responders to undergo fertility-sparing surgery after chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/72,74,75\">",
"     72,74,75",
"    </a>",
"    ]. We have used a NACT regimen consisting of a combination of taxol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (TIP) in three patients with excellent tumor response [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/76\">",
"     76",
"    </a>",
"    ]. Two had a complete pathological response and one had only residual dysplasia. There have been no recurrences so far. One patient had two uncomplicated cesarean deliveries at term within one year. Another patient is currently pregnant; the third patient (36 years of age) developed ovarian failure and has been unable to conceive.",
"   </p>",
"   <p>",
"    The concept of NACT is appealing and warrants further investigation. In the future, non-gonadotoxic and perhaps less aggressive chemotherapy regimen should be evaluated to reduce the impact on ovarian function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study reported use of NACT in seven patients with lesions measuring 3 to 4.5 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/77\">",
"     77",
"    </a>",
"    ]. At 22-month follow-up, there were no recurrences and one patient conceived a pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Ultraconservative fertility sparing surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the concept of fertility-preserving surgery evolves, it is clear that patients with very early invasive cervical cancer (IA2 and early IB1) probably do not benefit from a radical trachelectomy procedure since the chance of tumor spread to the parametrial tissue is very low [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/78\">",
"     78",
"    </a>",
"    ]. Moreover, studies have shown that 62 to 67 percent of patients do not have any residual cancer in the trachelectomy specimen if they had a diagnostic cone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/10,11,13\">",
"     10,11,13",
"    </a>",
"    ]. Therefore, a simple trachelectomy or a large cold knife cone involving the removal of most of the cervical tissue is probably sufficient for these patients. However, because of the potential risk of lymph node metastasis, a laparoscopic lymph node dissection or sentinel lymph node mapping has been suggested.",
"   </p>",
"   <p>",
"    This approach was evaluated in a study of a two-step outpatient treatment program involving 26 patients with stage 1A1-1B2 lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/79\">",
"     79",
"    </a>",
"    ]. Patients first underwent outpatient laparoscopic sentinel node mapping and frozen section followed by a complete pelvic lymph node dissection. One week later, a separate outpatient simple trachelectomy procedure was performed in node negative patients. Four patients had positive lymph nodes identified on frozen section (15 percent) and underwent a definitive radical hysterectomy. One patient developed a central recurrence successfully treated with chemoradiation. Fifteen pregnancies have occurred, with eight living children delivered at 24 weeks (1), 34 weeks (1), 36 weeks (1) and at term (5) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another group described their experience with conservative surgery in five young women with small volume stage IB1 tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/73\">",
"     73",
"    </a>",
"    ]. All patients had lesions less than 2 cm wide and superficial stromal infiltration less than 2 mm deep. The volume of tumor was less than 500 mm(3). A loop cone with or without laparoscopic pelvic node dissection was performed as definitive treatment. There was no residual disease or lymph node metastases in the final specimen, and no recurrences have been reported to date.",
"   </p>",
"   <p>",
"    The concept of an ultraconservative treatment approach warrants further investigation to evaluate its oncological safety in a larger group of patients. Strict selection criteria and detailed pathological evaluation of the cone specimen will be of paramount importance to avoid recurrences and deaths in these highly curable patients. The obstetrical impact of a large cone will also need to be studied, given that a meta-analysis demonstrated that conization alone is associated with a significant increase in preterm delivery rate and PPROM [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are ongoing studies to prospectively evaluate the safety of less radical surgery in small volume cervical cancer (ie, a simple cone or simple trachelectomy) for young women who wish to preserve fertility, versus simple hysterectomy in women who no longer wish to preserve fertility together with lymph node assessment. This less radical approach is an appealing alternative to further reduce the morbidity of more radical surgery, considering the very low risk of parametrial infiltration in this low-risk group of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/42/9898/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=see_link\">",
"       \"Patient information: Cervical cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=see_link\">",
"       \"Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link\">",
"       \"Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with cervical cancer who are candidates for fertility preservation include women of reproductive age with early stage disease (stage IA2 or IB1) who have no features of disease that is high risk for recurrence (ie, lesion size &gt;2 cm; lymph node metastases). Lymphovascular space invasion within the tumor is a risk factor for lymph node recurrence, but as a sole finding it is not a contraindication for trachelectomy. For women who meet these criteria and who wish to preserve their fertility, we suggest radical trachelectomy rather than radical hysterectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A magnetic resonance (MR) imaging of the pelvis is recommended prior to surgery, particularly in patients with a visible lesion. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preoperative assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to radical trachelectomy, a complete laparoscopic lymph node dissection is performed to exclude the presence of lymph node metastasis. If a visible lesion is present on clinical evaluation, the trachelectomy specimen is sent for frozen section to evaluate the status of the resection margins. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Procedure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Use of frozen section'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential side effects of radical trachelectomy include chronic vaginal discharge, irregular bleeding, deep dysmenorrhea, cerclage erosion, amenorrhea, and cervical stenosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Morbidity compared to hysterectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For similarly sized lesions, the overall rate of cervical cancer recurrence is similar after radical trachelectomy and radical hysterectomy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women who have undergone radical trachelectomy, hysterectomy after completion of childbearing is not routinely recommended. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Hysterectomy when childbearing is completed'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two-thirds of pregnancies following radical trachelectomy have ended in a live birth. About 40 percent of the pregnancies culminated with the birth of a healthy newborn at term. Rates of second trimester miscarriage and preterm birth were higher than in the general obstetrical population. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pregnancy outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaginal delivery should be avoided because a lateral cervical tear in the short scarred cervix may extend into the nearby uterine vessels, resulting in catastrophic hemorrhage. A cesarean delivery is performed at 37 to 38 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Delivery route'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the future, use of neoadjuvant chemotherapy followed by radical trachelectomy may prove to be an effective option in women with large lesions. Conversely, women with very small lesions may be effectively treated by limited local surgery. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Future alternatives'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/1\">",
"      Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24:2917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/2\">",
"      Carter J, Rowland K, Chi D, et al. Gynecologic cancer treatment and the impact of cancer-related infertility. Gynecol Oncol 2005; 97:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/3\">",
"      Corney RH, Crowther ME, Everett H, et al. Psychosexual dysfunction in women with gynaecological cancer following radical pelvic surgery. Br J Obstet Gynaecol 1993; 100:73.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.seer.cancer.gov/statfacts/html/cervix.html (Accessed on September 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/5\">",
"      Bisseling KC, Bekkers RL, Rome RM, Quinn MA. Treatment of microinvasive adenocarcinoma of the uterine cervix: a retrospective study and review of the literature. Gynecol Oncol 2007; 107:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/6\">",
"      Wright JD, NathavithArana R, Nathavithrana R, et al. Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access. Obstet Gynecol 2010; 115:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/7\">",
"      Dargent, D, Brun, JL, Roy, M. La trach&eacute;lectomie &eacute;largie (T.E.). Une alternative &agrave; l'hyst&eacute;rectomie radicale dans le traitement des cancers infiltrants d&eacute;velopp&eacute;s sur la face externe du col ut&eacute;rin. J Obstet Gynecol 1994; 2:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/8\">",
"      Roy M, Plante M. Pregnancies after radical vaginal trachelectomy for early-stage cervical cancer. Am J Obstet Gynecol 1998; 179:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/9\">",
"      Sonoda Y, Abu-Rustum NR, Gemignani ML, et al. A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible? Gynecol Oncol 2004; 95:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/10\">",
"      Marchiole P, Benchaib M, Buenerd A, et al. Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation): a comparative study with laparoscopic-assisted vaginal radical hysterectomy (LARVH). Gynecol Oncol 2007; 106:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/11\">",
"      Shepherd JH, Spencer C, Herod J, Ind TE. Radical vaginal trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer-cumulative pregnancy rate in a series of 123 women. BJOG 2006; 113:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/12\">",
"      Beiner ME, Covens A. Surgery insight: radical vaginal trachelectomy as a method of fertility preservation for cervical cancer. Nat Clin Pract Oncol 2007; 4:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/13\">",
"      Plante M, Renaud MC, Fran&ccedil;ois H, Roy M. Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature. Gynecol Oncol 2004; 94:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/14\">",
"      Sahdev A, Sohaib SA, Wenaden AE, et al. The performance of magnetic resonance imaging in early cervical carcinoma: a long-term experience. Int J Gynecol Cancer 2007; 17:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/15\">",
"      Peppercorn PD, Jeyarajah AR, Woolas R, et al. Role of MR imaging in the selection of patients with early cervical carcinoma for fertility-preserving surgery: initial experience. Radiology 1999; 212:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/16\">",
"      Hauspy J, Beiner M, Harley I, et al. Sentinel lymph nodes in early stage cervical cancer. Gynecol Oncol 2007; 105:285.",
"     </a>",
"    </li>",
"    <li>",
"     Plante M, Renaud MC, Roy M. Vaginal radical trachelectomy. In: Atlas of procedures in gynecologic oncology, Levine DA, Barakat RR, Hoskins WJ (Eds), Martin Dunitz, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/18\">",
"      Abu-Rustum NR, Sonoda Y, Black D, et al. Cystoscopic temporary ureteral catheterization during radical vaginal and abdominal trachelectomy. Gynecol Oncol 2006; 103:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/19\">",
"      Bernardini M, Barrett J, Seaward G, Covens A. Pregnancy outcomes in patients after radical trachelectomy. Am J Obstet Gynecol 2003; 189:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/20\">",
"      Saling E. [Early total occlusion of os uteri prevent habitual abortion and premature deliveries (author's transl)]. Z Geburtshilfe Perinatol 1981; 185:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/21\">",
"      Dargent D, Martin X, Sacchetoni A, Mathevet P. Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients. Cancer 2000; 88:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/22\">",
"      Jolley JA, Battista L, Wing DA. Management of pregnancy after radical trachelectomy: case reports and systematic review of the literature. Am J Perinatol 2007; 24:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/23\">",
"      Plante M, Renaud MC, Hoskins IA, Roy M. Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol 2005; 98:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/24\">",
"      Plante M, Gregoire J, Renaud MC, Roy M. The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecol Oncol 2011; 121:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/25\">",
"      Tanguay C, Plante M, Renaud MC, et al. Vaginal radical trachelectomy in the treatment of cervical cancer: the role of frozen section. Int J Gynecol Pathol 2004; 23:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/26\">",
"      Park KJ, Soslow RA, Sonoda Y, et al. Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system. Gynecol Oncol 2008; 110:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/27\">",
"      Sonoda Y, Chi DS, Carter J, et al. Initial experience with Dargent's operation: the radical vaginal trachelectomy. Gynecol Oncol 2008; 108:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/28\">",
"      Kim JH, Park JY, Kim DY, et al. Fertility-sparing laparoscopic radical trachelectomy for young women with early stage cervical cancer. BJOG 2010; 117:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/29\">",
"      Alexander-Sefre F, Chee N, Spencer C, et al. Surgical morbidity associated with radical trachelectomy and radical hysterectomy. Gynecol Oncol 2006; 101:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/30\">",
"      Boss EA, van Golde RJ, Beerendonk CC, Massuger LF. Pregnancy after radical trachelectomy: a real option? Gynecol Oncol 2005; 99:S152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/31\">",
"      Selo-Ojeme DO, Ind T, Shepherd JH. Isthmic stenosis following radical trachelectomy. J Obstet Gynaecol 2002; 22:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/32\">",
"      Aust T, Herod J, Macdonald R, Gazvani R. Infertility after fertility-preserving surgery for cervical carcinoma: the next challenge for reproductive medicine? Hum Fertil (Camb) 2007; 10:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/33\">",
"      Klemm P, Tozzi R, K&ouml;hler C, et al. Does radical trachelectomy influence uterine blood supply? Gynecol Oncol 2005; 96:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/34\">",
"      Aust TR, Herod JJ, Gazvani R. Placement of a Malecot catheter to enable embryo transfer after radical trachelectomy. Fertil Steril 2005; 83:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/35\">",
"      Lanowska M, Mangler M, Spek A, et al. Radical vaginal trachelectomy (RVT) combined with laparoscopic lymphadenectomy: prospective study of 225 patients with early-stage cervical cancer. Int J Gynecol Cancer 2011; 21:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/36\">",
"      Lanowska M, Morawietz L, Sikora A, et al. Prevalence of lymph nodes in the parametrium of radical vaginal trachelectomy (RVT) specimen. Gynecol Oncol 2011; 121:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/37\">",
"      Hertel H, K&ouml;hler C, Grund D, et al. Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer. Gynecol Oncol 2006; 103:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/38\">",
"      Beiner ME, Hauspy J, Rosen B, et al. Radical vaginal trachelectomy vs. radical hysterectomy for small early stage cervical cancer: a matched case-control study. Gynecol Oncol 2008; 110:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/39\">",
"      Burnett AF. Radical trachelectomy with laparoscopic lymphadenectomy: review of oncologic and obstetrical outcomes. Curr Opin Obstet Gynecol 2006; 18:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/40\">",
"      Covens A. Preserving fertility in early cervical cancer with radical trachlectomy. Contemp Ob Gyn 2003; 2:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/41\">",
"      Mathevet P, Laszlo de Kaszon E, Dargent D. [Fertility preservation in early cervical cancer]. Gynecol Obstet Fertil 2003; 31:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/42\">",
"      Marchiol&eacute; P, Bu&eacute;nerd A, Benchaib M, et al. Clinical significance of lympho vascular space involvement and lymph node micrometastases in early-stage cervical cancer: a retrospective case-control surgico-pathological study. Gynecol Oncol 2005; 97:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/43\">",
"      Chernofsky MR, Felix JC, Muderspach LI, et al. Influence of quantity of lymph vascular space invasion on time to recurrence in women with early-stage squamous cancer of the cervix. Gynecol Oncol 2006; 100:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/44\">",
"      Shepherd JH. Uterus-conserving surgery for invasive cervical cancer. Best Pract Res Clin Obstet Gynaecol 2005; 19:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/45\">",
"      Sahdev A, Jones J, Shepherd JH, Reznek RH. MR imaging appearances of the female pelvis after trachelectomy. Radiographics 2005; 25:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/46\">",
"      Singh N, Titmuss E, Chin Aleong J, et al. A review of post-trachelectomy isthmic and vaginal smear cytology. Cytopathology 2004; 15:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/47\">",
"      Carter J, Sonoda Y, Abu-Rustum NR. Reproductive concerns of women treated with radical trachelectomy for cervical cancer. Gynecol Oncol 2007; 105:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/48\">",
"      Kay TA, Renninson JN, Shepherd JH, Taylor MJ. Successful pregnancy following radical trachelectomy and in vitro fertilisation with ovum donation. BJOG 2006; 113:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/49\">",
"      Shepherd JH, Mould T, Oram DH. Radical trachelectomy in early stage carcinoma of the cervix: outcome as judged by recurrence and fertility rates. BJOG 2001; 108:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/50\">",
"      Noyes N, Abu-Rustum NR, Ramirez PT, Plante M. Options in the management of fertility-related issues after radical trachelectomy in patients with early cervical cancer. Gynecol Oncol 2009; 114:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/51\">",
"      Lavie O, Peer G, Sagi S, et al. The management of an early-missed abortion after radical trachelectomy--a case report and a review of the literature. Int J Gynecol Cancer 2006; 16:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/52\">",
"      Speiser D, Mangler M, K&ouml;hler C, et al. Fertility outcome after radical vaginal trachelectomy: a prospective study of 212 patients. Int J Gynecol Cancer 2011; 21:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/53\">",
"      Plante M, Roy M. Fertility-preserving options for cervical cancer. Oncology (Williston Park) 2006; 20:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/54\">",
"      Kolomainen DF, Herod JJ, Holland N, Shepherd JH. Actinomyces on a papanicolaou smear following a radical trachelectomy. BJOG 2003; 110:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/55\">",
"      Allahdin S, Lees DA, Busby-Earle RM, Querleu D. Persistent vaginal discharge after radical trachelectomy. J Obstet Gynaecol 2004; 24:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/56\">",
"      Lee KY, Jun HA, Roh JW, Song JE. Successful twin pregnancy after vaginal radical trachelectomy using transabdominal cervicoisthmic cerclage. Am J Obstet Gynecol 2007; 197:e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/57\">",
"      Alexopoulos E, Efkarpidis S, Fay TN, Williamson KM. Pregnancy following radical trachelectomy and pelvic lymphadenectomy for Stage I cervical adenocarcinoma. Acta Obstet Gynecol Scand 2002; 81:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/58\">",
"      Petignat P, Stan C, Megevand E, Dargent D. Pregnancy after trachelectomy: a high-risk condition of preterm delivery. Report of a case and review of the literature. Gynecol Oncol 2004; 94:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/59\">",
"      Smith JR, Boyle DC, Corless DJ, et al. Abdominal radical trachelectomy: a new surgical technique for the conservative management of cervical carcinoma. Br J Obstet Gynaecol 1997; 104:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/60\">",
"      Abu-Rustum NR, Sonoda Y, Black D, et al. Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. Gynecol Oncol 2006; 103:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/61\">",
"      Ramirez PT, Schmeler KM, Malpica A, Soliman PT. Safety and feasibility of robotic radical trachelectomy in patients with early-stage cervical cancer. Gynecol Oncol 2010; 116:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/62\">",
"      Wan XP, Yan Q, Xi XW, Cai B. Abdominal radical trachelectomy: two new surgical techniques for the conservation of uterine arteries. Int J Gynecol Cancer 2006; 16:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/63\">",
"      Del Priore G, Ungar L, Richard Smith J, Heller PB. Regarding \"First case of a centropelvic recurrence after radical trachelectomy: literature review and implications for the preoperative selection of patients,\" (92:1002-5) by Morice et al. Gynecol Oncol 2004; 95:414; author reply 414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/64\">",
"      Ungar L, Palfalvi L, Smith JR, et al. Update on and long-term follow-up of 91 abdominal radical trachelectomies. Gynecol Oncol 2006; 101:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/65\">",
"      Bader AA, Tamussino KF, Moinfar F, et al. Isolated recurrence at the residual uterine cervix after abdominal radical trachelectomy for early cervical cancer. Gynecol Oncol 2005; 99:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/66\">",
"      Cibula D, Slama J, Fischerova D. Update on abdominal radical trachelectomy. Gynecol Oncol 2008; 111:S111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/67\">",
"      Ung&aacute;r L, P&aacute;lfalvi L, Hogg R, et al. Abdominal radical trachelectomy: a fertility-preserving option for women with early cervical cancer. BJOG 2005; 112:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/68\">",
"      Abu-Rustum NR, Su W, Levine DA, et al. Pediatric radical abdominal trachelectomy for cervical clear cell carcinoma: a novel surgical approach. Gynecol Oncol 2005; 97:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/69\">",
"      Ung&aacute;r L, Smith JR, P&aacute;lfalvi L, Del Priore G. Abdominal radical trachelectomy during pregnancy to preserve pregnancy and fertility. Obstet Gynecol 2006; 108:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/70\">",
"      Li J, Li Z, Wang H, et al. Radical abdominal trachelectomy for cervical malignancies: surgical, oncological and fertility outcomes in 62 patients. Gynecol Oncol 2011; 121:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/71\">",
"      Hong DG, Lee YS, Park NY, et al. Robotic uterine artery preservation and nerve-sparing radical trachelectomy with bilateral pelvic lymphadenectomy in early-stage cervical cancer. Int J Gynecol Cancer 2011; 21:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/72\">",
"      Sakhel K, Khalil A, Kaspar H, et al. Placental site trophoblastic tumor in a patient with secondary infertility and radiological findings consistent with a leiomyoma: a case report. Int J Gynecol Cancer 2004; 14:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/73\">",
"      Naik R, Cross P, Nayar A, et al. Conservative surgical management of small-volume stage IB1 cervical cancer. BJOG 2007; 114:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/74\">",
"      Landoni F, Parma G, Peiretti M, et al. Chemo-conization in early cervical cancer. Gynecol Oncol 2007; 107:S125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/75\">",
"      Kobayashi Y, Akiyama F, Hasumi K. A case of successful pregnancy after treatment of invasive cervical cancer with systemic chemotherapy and conization. Gynecol Oncol 2006; 100:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/76\">",
"      Plante M, Lau S, Brydon L, et al. Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer: case report. Gynecol Oncol 2006; 101:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/77\">",
"      Marchiole P, Tigaud JD, Costantini S, et al. Neoadjuvant chemotherapy and vaginal radical trachelectomy for fertility-sparing treatment in women affected by cervical cancer (FIGO stage IB-IIA1). Gynecol Oncol 2011; 122:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/78\">",
"      Covens A, Rosen B, Murphy J, et al. How important is removal of the parametrium at surgery for carcinoma of the cervix? Gynecol Oncol 2002; 84:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/79\">",
"      Rob L, Charvat M, Robova H, et al. Less radical fertility-sparing surgery than radical trachelectomy in early cervical cancer. Int J Gynecol Cancer 2007; 17:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/80\">",
"      Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006; 367:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/81\">",
"      Klaritsch P, Reich O, Giuliani A, et al. Delivery outcome after cold-knife conization of the uterine cervix. Gynecol Oncol 2006; 103:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/42/9898/abstract/82\">",
"      Schmeler KM, Frumovitz M, Ramirez PT. Conservative management of early stage cervical cancer: is there a role for less radical surgery? Gynecol Oncol 2011; 120:321.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3200 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9898=[""].join("\n");
var outline_f9_42_9898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VAGINAL RADICAL TRACHELECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preoperative assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Use of frozen section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Morbidity compared to hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Oncologic issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk factors for recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Need for adjuvant treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hysterectomy when childbearing is completed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Reproductive issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Fertility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cerclage complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pregnancy planning and management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Delivery route",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ABDOMINAL RADICAL TRACHELECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FUTURE ALTERNATIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Ultraconservative fertility sparing surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3200\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3200|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/6/33902\" title=\"table 1\">",
"      Staging cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/49/25372\" title=\"table 2\">",
"      Oncologic outcome VRT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=related_link\">",
"      Cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=related_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=related_link\">",
"      Patient information: Cervical cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=related_link\">",
"      Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=related_link\">",
"      Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=related_link\">",
"      Prevention of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5498?source=related_link\">",
"      Small cell neuroendocrine carcinoma of the cervix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2841?source=related_link\">",
"      Spontaneous abortion: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32532?source=related_link\">",
"      Transabdominal cervical cerclage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=related_link\">",
"      Transvaginal cervical cerclage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=related_link\">",
"      Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_42_9899="Prevalence thrombophil defects";
var content_f9_42_9899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of thrombophilic defects in venous thrombosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence, percent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Activated protein C resistance",
"(factor V Leiden)",
"       </td>",
"       <td>",
"        12 to 40&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prothrombin G20210A gene mutation",
"       </td>",
"       <td>",
"        6 to 18&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deficiencies of Antithrombin,",
"protein C, protein S",
"       </td>",
"       <td>",
"        5 to 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiphospholipid antibody syndrome",
"       </td>",
"       <td>",
"        5 to 10",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Note: The lower percentage for each condition is for unselected patients; the higher percentage is for those with first events prior to age 50 or with a history of venous thrombosis in first-degree relatives.",
"     <br>",
"      &bull; Prevalence restricted to Caucasian populations.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9899=[""].join("\n");
var outline_f9_42_9899=null;
var title_f9_42_9900="Physiology in sleep";
var content_f9_42_9900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hemodynamic and ventilatory changes during normal sleep",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        NREM",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tonic REM",
"       </td>",
"       <td class=\"subtitle1\">",
"        Phasic REM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood pressure",
"       </td>",
"       <td>",
"        Decreases",
"       </td>",
"       <td>",
"        Decreases",
"       </td>",
"       <td>",
"        Increases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart rate",
"       </td>",
"       <td>",
"        Decreases",
"       </td>",
"       <td>",
"        Decreases",
"       </td>",
"       <td>",
"        Increases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vessel size",
"       </td>",
"       <td>",
"        Vasodilatation",
"       </td>",
"       <td>",
"        Vasodilatation",
"       </td>",
"       <td>",
"        Vasoconstriction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral blood flow",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Increases",
"       </td>",
"       <td>",
"        Further increases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory rate",
"       </td>",
"       <td>",
"        Decreases",
"       </td>",
"       <td>",
"        Decreases",
"       </td>",
"       <td>",
"        Increases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minute ventilation",
"       </td>",
"       <td>",
"        Decreases",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventilatory responses to hypercapnia",
"       </td>",
"       <td>",
"        Intact",
"       </td>",
"       <td>",
"        Intact",
"       </td>",
"       <td>",
"        Impaired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory muscle tone",
"       </td>",
"       <td>",
"        No change/small decrease",
"       </td>",
"       <td>",
"        Intercostals atonic, upper airway muscles hypotonic, diaphragm tonic",
"       </td>",
"       <td>",
"        Diaphragm transiently inhibited, other respiratory muscles atonic or hypotonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway smooth muscle",
"       </td>",
"       <td>",
"        Decreases",
"       </td>",
"       <td>",
"        Decreases",
"       </td>",
"       <td>",
"        Increases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arousal response",
"       </td>",
"       <td>",
"        Faster than in REM",
"       </td>",
"       <td>",
"        Slower than in NREM",
"       </td>",
"       <td>",
"        Slower than in NREM",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9900=[""].join("\n");
var outline_f9_42_9900=null;
var title_f9_42_9901="Rapid overview severe acute COPD exacerbation";
var content_f9_42_9901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid overview: Emergency management of severe acute COPD exacerbations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic obstructive pulmonary disease (COPD) exacerbations are most often precipitated by infection (viral or bacterial)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Differential diagnosis includes: Acute decompensated heart failure, pulmonary embolism (PE), pneumonia, pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical manifestations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardinal symptoms: Increase or change in character of dyspnea, cough, sputum production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess oxygen saturation with pulse oximetry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain arterial blood gas in severe exacerbations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain chest radiograph to assess for signs of pneumonia, acute heart failure, pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain complete blood count and measures of basic electrolytes and renal function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain electrocardiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pharmacotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxygen to target saturation of 90 to 94 percent and PaO2 of 60-70 mmHg; Venturi mask can be useful for titrating FiO2; high FiO2 usually not needed and can contribute to hypercapnia (high FiO2 requirement should prompt consideration of alternative diagnosis (eg, PE))",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhaled beta agonist (eg, albuterol 2.5 mg diluted to 3 mL via nebulizer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhaled anticholinergic agent (eg, ipratropium 500 micrograms via nebulizer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic corticosteroid (eg, methylprednisolone 60 mg IV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antibiotic therapy: Levofloxacin (750 mg IV) or alternative based on likely pathogens (including risk of pseudomonas infection) and local patterns of antibiotic resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Noninvasive Positive Pressure Ventilation (NPPV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indicated for moderate to severe exacerbations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use only if tracheal intubation not immediately necessary and no other contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contraindications to NPPV include: Severely impaired consciousness, inability to clear secretions or protect airway, high aspiration risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Initial settings for bilevel NPPV: 8 cm H2O inspiratory pressure (may increase up to 15 cm H2O if needed to aid ventilation); 3 cm H2O expiratory pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Monitoring and initial interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform continual monitoring of oxygen saturation, cardiac rhythm, and vital signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Place two peripheral IV catheters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tracheal intubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For patients with severe respiratory distress in whom NPPV is contraindicated or who fail to improve with NPPV and aggressive pharmacotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disposition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Criteria for hospitalization include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Patients with high-risk comorbidities (pneumonia, cardiac arrhythmia, heart failure, diabetes mellitus, renal failure, liver failure)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inadequate improvement of symptoms with initial therapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Marked increase in dyspnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inability to eat or sleep due to symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Worsening hypoxemia or hypercapnea",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9901=[""].join("\n");
var outline_f9_42_9901=null;
var title_f9_42_9902="TNM stage sinonasal sites";
var content_f9_42_9902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tumor node metastases (TNM) staging system for cancer of the nasal cavity and paranasal sinuses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"3\">",
"       Carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Maxillary sinus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor limited to maxillary sinus mucosa with no erosion or destruction of bone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, ethmoid sinuses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       T4a",
"      </td>",
"      <td colspan=\"3\">",
"       Moderately advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       T4b",
"      </td>",
"      <td colspan=\"3\">",
"       Very advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V",
"       <sub>",
"        2",
"       </sub>",
"       ), nasopharynx, or clivus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Nasal cavity and ethmoid sinus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor restricted to any one subsite, with or without bony invasion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor extends to invade the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       T4a",
"      </td>",
"      <td colspan=\"3\">",
"       Moderately advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       T4b",
"      </td>",
"      <td colspan=\"3\">",
"       Very advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than (V",
"       <sub>",
"        2",
"       </sub>",
"       ), nasopharynx, or clivus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       N2",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2c",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N3",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in a lymph node, more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Stage III",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Stage IVA",
"      </td>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IVB",
"      </td>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N3",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVC",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9902=[""].join("\n");
var outline_f9_42_9902=null;
var title_f9_42_9903="Herpes zoster rash B";
var content_f9_42_9903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes zoster",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAV4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDcinOQd3FW1mDHBrnYbwPgZq9FcquCTzXj2PcTN6KTHBHFWPM79RWNFdk+oFWYp1JyrVNikzVSUbgV4NWVfIOcVkLNgjv7irCTnAoGX1IGcninBgOaqLKvfNKsgHIPFA0Wt+fpS7+cAc1U81ecHmgSPjipLLZfB5GRTd43e1QozY+engqTx+NAFhD6GnZySKh47UoyRzSESABDn+GhiAMetJvAxuHFLnPQUCI3wBwOvelH04xSbj36GnA4HNBRGevtTRnt2NSAc5PNGec44oKEPP0pCNuc/hQeW9qe2O9AiPaNuKaVzn0qQDg01l496YXK0i4BJqvIuauSAAHPWq8nXpgUguVGA6/nVaRRjPrVqUDdx1qvMM4B4pAZ84wemap3CEr0rRlXg+lU5VwOec00SzHuUyMYzWZKp79K2rhMc461mzxkA9h2qkSzIcfMemRUZyVII/GrUqdWOSfaonT+EfWmQUJ1IOMfQ1TQCRc4I6g1rvHlM/pVIxgSMOg9KSYmjMu7dZYmRgDkV5xrWnmxunAHyMflP9K9VkiGDkfSue1/TkuoMMvI5zXRQq8krPY58RS543W5wulpmZ2HQDFaeKmttLeMFY1Aye7UlxC0Emx8bsZ4rtck2cUVZEWKMUtGKChuKMU/tSAYoA9J03xPGwA3frXR2mrxyAYcfnXhMU0kRyjGtmy1p4lBZzuz0rCVHsaQxHc9xg1AYG1sVfhv+x4PqK8hsfEuNoY5rorHX0kxljWEqbR1RqJnpUN6eMHircd2pODxXCW2rq2PmzWnb6mCcbqzcS+Y7D7QMdaek5bAXpXNx3gK5Bz+NWoL3jBbBqWi0zd3Z5+6fSpYpsdV4HesdLoMeccdwatRXe84zSKuafnZ6HinLJkfKKoiZT3GaeJQRjdj6UhpmjHJgc80GU/w81SSQjqcmpVfuTSHcvLKCvPX0pAWBPPHpVbeDzUobjmgCXGTyflpynA65FQqwORnjrTv93oaCh7Hjjr0pCecelIuOM9qeoBzxQguMwS2TTixHGO9GecGhTjOfShgKAe55NRseCM8U9mwMnnio3OAT6UARPnHJqvKM/jUzdQRkmonHU+nWkBFgc45AFVXIKcjknpVo8kharyjAIx0OKBFGTIz1qrLkZwM1dkXB+bk1VdScjr/AEpoTM+4T5R+VZs8eBjOa17gZB/Os5wMk1VyTLmTAxVZl+Y4BNaMsfOccCq0ifNgUAU3AHvVV0+YkdcYNXnUkcc+pqtKAPr3pCsVDGSnz9RmqFxFvVhj5SOta7jglR82OlUpojkgH5aExNHMmPy5SOKx9XOb8/7orob9TFJu25A7VzF7N594zgY4xj6V3UnfU8+rHlZDRTiKQ1uQFFL1opgZ65UnkU0HBp7LTD71Rzk0cu0jBxitG3vnjUHPXoQax6ejlehxScblKTR1tjqroASxYfWtm011hjBzXnsM5jPBOK1YLk+WGDhj3UdRWMqSOiFZnoltryHAJwfSta21ZZB/rCK8yju3zkrg+4q7BeHuSPpWLpHRGrc9Th1DIBLLV2LUORluPrXl9tqUiqMSDHbNa1rqxwAW+tZODRqpno0d6OCDjNWoroHBBrhoNSBxiTr2zWpb6gOBuI/HioasWpHYR3wBAY4q3Bcox6/SuXiu1bBBBNX7e8Q8E8+hqbFXOiDg8nrUivyA3XtWMtwSMg/gatwzhx8xx7UikzSBOcn9KlVic7apJIQME8dqmDEEc/KaVguWFJOSeveplbcBVNJCH2juM09GwSD2oGTlgG+tIck4HeowwYg9xQrYlPPHSgdyUj86ZIdp/nS7uTnpUbMpHB/GgER5zgg85qN89DUxIwQMcVBI3zDnGKTGRsBnjrUEnzA89DUrAFvSoZc/d4FAitIMcDrVaVffrV5kBJxxVSfH9aZJRmXqCOtUpY8HaelaUifL161UkB7YpoDMeMgt3x1qtKuAeK0nTrjjnmqk6k0CM9lyCeg74qqy5ORV+ZcLjpVdgMetICrgYwOvtUEy/K2Dj0q0Qc+gzUUij5vSgDB1CPcGyMnFcbqMPlT7hwDwfrXeXK5BOOhrl9ahzuwMk8110JWdjlrxurmJnPSimIeKkrrOQSlAooxQBXeOoXjrQZaiaPimYGey4pvNXGjqFo/aqTERJgnGcUp3KAVYg+lG0jsaTeUGAzAZ7UAXra7lQKzSuwHap1lLH5pnRe24Vmxyj7qxryfvNzVhT820OJADyw4A+lS0aRkaMcsqupBDYxgHvWnFd3Cn5lVQOQDjFZ0KOwyhRh2J5Y1YS2nnkJKl8Dp7VlJI2i2aUGpSD5jGCO+w81pWmtISPn5PZjXPpB5DFjbuoHQk4J/Cmuq+SZEdMg9GGGqHBM1U2jvrPV1+UbuT2HNbEGoqQDv3e2a8nS5mWNZATke39av2etyqR5jHHc+lZSpdjSNZHsFrfA4wfwNaUN0uck4NeZ2WskIGbOMffFblhrKNgOw/3h0rFxaN1K56FDcBlHO70qwJvmHOBXJWt7gg7to9uhrXjvV2gnFQ0UmbiSKWB7jipfMxJlj9Kx1uN7L2Aq2JflwWx6GgdzTRuCM45oVsngVRgmLqdvHPU1YV9qE96Bk7NuUgHnpRjB9hUa4yFz7mnl8gY6DtSHcHO0E96gfkH2604nJJb14FMYjoMdcYpANYqRkdu9QPg8jkdh61Pj6VAxJ6den4UAQSMVOc9aruQeo/OrEo3VAVAOR+tMRC65XBPPaq0q8Ht6VbkBJ9vQVDIPlPc0XEUXwCQOapy9Dx7gVfkHUdTVSUDp0PSgZnygsMe1VitXJe/rVaT06A9aQiq3QH3qFUPz5OcnP0q2QMDFQOAopoDMuwCDxXPakg259K6W5ABP6Vi6jHmMnH41tDRmc1dHESL5c7qfWnipdWjaOZX7HjNQoeK707q55zVnYdij8KWimMfikxTqSmc5GyAio2jqc9KSgZUeL0qKaMKnPNXsdaimTMbfSmIzVyG6cVaLDClgADyABgVXK5pzcKMZzn9KbQLQ6LQv3oIYEqvQA10scWIgsAaFuuSTyfrWJ4NgLQu+Mkviu3trOV1COcR91WuSq7SO6krxOYv0UpiVmLjrWLdQnJCc5716O2lQRDcIi6993P5Gsq+tLR42xCEYH0OamM7Fyhc4jypIeTn6Gp45W8seZGuD0z1Na1/p8mzccHrj0rHmt/KcLMpXB6r2rRSuYuLiTQsw3BHKRnrV2NbgJvhbcB781Rt5RE5QKHj7kjHHrW3ZxouGP+rJ5BqJuxrAv6Z4gktdsd2rFOgPpXVWWqRzKrQuD3x3rl30mGVQynnOOe4qRdJuY2/wBEO8DkEdPpWDUXsbJtHeW84I3Kd3861IbgYDKciuAsLy4t5PLuVeJhxnGQa6Syu8chgQ3XHas2rGikdSk5Azn8KsxyBtpbp2Fc9DKcAgt6ZBzWhBJsUYJb1z2qSzYWXDEngU9XbbzgA9aoLLwCePrVhJM8sDj6UATliSTgU04UDrn+dIrpjHIz60MecAZNACE8c81Exzx3B61KylfQHvTCRnB4x0z2oAiYYzkDHUmoWHJwM1O43DA5pjKB3BPQ0CKrjn+eO9QSA5PFWpB3x0qvLlcnr60AU5V6nFUZgBkn61fl+7VKQYHrQxopsOvHFV5VBGM1akwarSdOnApCK78VWkwRg8+9Tv0JJqGQZb1GKpCKdx8wOBzWVeqSnPPFa7/eNUbpcn61SZLOM1+P9yxA6c1jQtmun1hN0bqcjcCK5OE4bHccV6FJ3icFVWkXR0opFORThVkkmKTFOI4pD1pmA00Glo70ANxSFcqR606lHWgDJIoxzT3GGP1pPpVlHfeCYtunxtjqSf1r0O1jR4QxXnHWuE8KoY7CHbx8ozXYWUzAlR90elefUfvM76ekUaIUy/IEx7+tUdVtmCqAFJGT75qw0xRAyyY9OOKq3JeRAVcLjODjk+tZ3NLHO39qyqcquAckL2rJuBFNN5WGab09a6W9Q+RI0sgAx90ADNck7It1knDg9OtXFkNFa6gMM+x0KkcYNT2NyysSsb46ktyKuvmRDlQEHPA604Wy7UdGPlOfmA6A+9Ve61JSsbenzhdnnophZdu4DkVt2sKQ3SyRn9yRztfv9KwtKs1DNHcOTH95OePwratrORYY3i4G7lT2X1rnlobKzL97Zb9zRgNnjBHWqUcMkWGUFT7jOK6NYypjiBDqy7sg01IPMvDvzGGHTsTSuOxn2VwxHzgA+3Q1s2s25eBz6VDNZxxt8vUc4A6+9Ot1KSHJB49elA0zShyRk9fT0q3ECQOuPeqCS7XAOcH07VpQ/NtwSaVi7WQ/aew/CnCIqODn6UELG24g0BmYgjO3vRYY1gQ3OM1GwyTu+vNWcr/Cc4qIoG55oEV93J460xxngYFTvx9Kgk9O1SMrnAzweOTUEzAjHQ1PKSAQc5qvKc+57UwsU5+gxVSQg49qtydM54ziqcnPakMqy+p5qtJ1JPT2q2/TpVaTqSfSgllOQ8YqCRPlHWppDubgcioUUgsS2cn8qoRDIuc5zgVSucbT78VflJzg9qoXLfMVA6DOaaEzntVX5CfY1xGSJ3BxkGu51T7rCuEn+S7kGe9ehQ2ODE7ovRnipRzVaE5FWAeK0ZmiekNLSGmYiGkpaSgAoFFFAGa/Lt9aT+dLIMSMPelRdzAepqij0rwz8tvCp4+UfyrpoyA5OccDPt71zGlHy4kIIwAM1r+c7ANAu6TJ6ntXnz1Z6EdjSN5HuWN9oA53twKo31/E0eEbGDjd/h61SZd0m/erN1b0FZ90yKu+Vvp6mosWwvbs+UV3MSemKxSkhm3RqGfrz2qyJDO4KkhehOM1dijJZSAFUfqate6RuaGn26mD962XA6Adfap7e2O4+X/wIY4P4U+3gvAy7VMRblSTW3bxuxUtsWTvnuai4yvYRb5SpjPlnquOn0roIoGZFC7gvoeuKiXYgG1cyAcj0NXbeUjBfk54WoZUSxBbDChcBgPl4q0E3LtkGDkYNECq4ywwc/lVkIssOOSy8H3qC0RtatsDBsnPQ88U77FH2xk9atwqjRghSjLwQakWIAcnGadhmfLbFVzGCfoaktGlixkHB9qvrbj+EEj2ps8ZQDa/PoRTRcX9kmUhuvNSCIFCq8A9cVQaVww6Z9jU9rMWkKkn8KB+zaVx6wLCpCDGe5OTSPwBngfrVl1zgHPtUF4NkZ2jBI9aLErXcqykfgOarPhsYPvVO4a4LDGSo/KmwTMXwCTUG7pWV7k7845PXPFVZTyTjipLxnRPk4+tVEZnQFyMn0oRny6XI5BkHPbmq0g6HjBqxJ8oyT+NVGcAEkjmmKzIZMDJyTVOU8Y71afnrzVWYMVO0AntQiSoeScdfWoycAjjPapnXH1qvJ2xx70xETnJ5PSqF3licHHtV9sEZrOu3w1NCZzuoscPnsa4i7P+mPnrmu21MABgK4a6bddOfevRoHn4p6otQHpVsdKowHpVxTxWjMolo0hpaQ0jMQ0lKaSmhBRRSUDKFxxM1PtF8y6iX1YU264mNWdGTfqEXHTmm9rlx3PQNPT90p/KtW3iyGY8luoFZ9kMQ9s4rVjDKoaPriuB7netChf3QjRuI0b+70JH0rC5uGMjncD3rVuVVn+ZA3q2PyqHyUnmEcfEK8ZHf1pLQZSVnMZjiQHnitLR0L3KCQoSOSpPWq9+0UStHbfKOQWA7VsaNbrKAjhRlR8xHT/Iok9ARtx3CoAoUsB7c4q2kyJGXkiYAjAGKrvCsCgSSGNF/iXkH2FQxNNcON4CRDhVY/rWYy4su2NDGBubq/qPQVdgDhvNbIBI49KqWAWaWNnOUBwuK2/LLOpbGDSKJLWUqG3EcnpWlAFzlu9ZtsolGxxgg4z6VegOyTaxyB3x1pFpGjFHgZU/LUoySCynA9KpCcx4Kng8YPSprS580kMRmg0UHa5bXYWwMqffio7s7lPQ4qwCAuQAR6VDIVdCp/IUahBale2ODtcKQe9WgiRncgAz3rPjYQ5DcHsaWR2kG4AkexpnQ4NssPcESYLdOOBRcPmLK9SOpNQxmQHlAB+dZuoXbl2Tgr0680hqlzOyIZ7hkcqTuAOCKkjdDnHX+VV5YiqDy1y553E1XluDGWwQO2MVJpKHMtDRnxKhHY1TIWJQvT0zUaXLmXDAhcdaiupjuCgZOaRz+zd7EVzLiRlIO31FZwLSPsySq96tzP5ke0DDep7Ulum2PJHOe9BUvdiNZeAarSDk1bkGc9aryLgH271RzFKYDHHWqkgIHtV1xnrxiq0gJBApCKkhGAAaybw8HnOK0pflIrMvGwpFXHcmRz2qNhGPtXESn9+xHrXZau2UYDsK4yXmZj716NFaHm4l6lqHtVxSMVShq4p4rRkR2LppDQaQ1JAhpKU0meaYBRRRQBSux+8/CtHw5Huu2YjoMfnVC8+8p9q2/DCERb8Zy1TN2ia01eSOytOY8L96tA7xB99s9MA4qjanauRjPpUtxdFUCdzz9K4WdxQZvIkYyE4J4J6VWuZ9ifuyQzddvvReR+YVU/OT0BPSnW+llgrNIoUdA7cfU1Vu4DbS3LhGfcYgw3Z7mug08rE7FlL5ABUH8qoLKqW+WCBUHyqpyWPapdHYyMS6v5w+c5H5CpYG/HHGUJdVwowN56e9StDvQuTtiC5AIyTTXt/3MfmAKhYHaOPxq2cFEiUZd2+Y+1QNFqEMiwhFHbHsK24kDKVB59azoUyD6gfnV+JwE44IHIoGJHG6F8fMQeff3qeJHfBHOeopEb5l59qsW6Mk33uCMjNSjWLsOu7TzEyCQQM5qKBBFcjcSGNXeGRlJOMVFvAkUKCR64pm9KTehpxbFi5Y/WqZ3CbKSL9CKkeVlQAc5/Coi2WBGPz5oLpxsQzyNKz7dvy9cjg0iunR269weKsyxl4WKDmqkcA3KHBAzmkbpporyy7ZsIWOPTnNU7pQ0ufmye2K2zbozEBsZqpdoyDG0v6H0pMqM1fQqpGZIQULnbwM1Titcyt5oHHr3q7CZEDbzgdcVXx50xbedoB60iW2rla5zH8igAmq8Ebmcl+anlkVjgNkjgk9adCCzBgSB6GgiTcYleaDD7lOMc4pFG9c9MVckUHNVipXgAnNM5pSuiBx3qtMPkHSrUh68CqspBpGZUfPPSqknAwf0q1IM1Wk4HPSgRnXIG8HJwP1rLvCCDWtcDJ5rHvmBYqOoFXAUtjmNXI2tgdq5KUfvT9a6zVzhTXLXP8Arycda9KjseXiPiJYeKtr0qpD2q0tWyYl4000ppKkzA03vS0lMAoNFJQMr3g+Va6jw9Ftt4xjtXNXC7tgHUsBXZaOmI1HYVlWfu2Oigrs37SPK1PLbCRSCozSWQxV5F6jofU1yM7DI+wIZG4zj5QRxRdWkUbgEjYgHHqfTFayxrtG4k88Y71SuNounBBYKAQu3qaLgNntvLiEku3ONxAHAHtUOi5F2zPu2g5OevI4/pVmZZXG67ISNiDsHUgUliStyhVfnkYcH1GKAOg53KzDdt+Y7ux9Knsoi0zSMclQMj6npTI8BDEOdp5PqfT86uWg8s4PO5vzNSMuwMMtkYIp+c5xjr0qFgVl3Do3BqSNWwMc4PWiwFmJizgAbcHvV2HLsOAV6GqEB+7uHc81pwYyNuCPapKTJ1TkkfeIqsscsSMV+bmr8fAz1qcIrA5/Sg2hPlKyMDEDLkUNEhUFRkN3FRXPLlSpYVctIkeIDGMdqZvsriLtWPao9qjdHbIC064gkWRSi5A96mJbyewfHSgd7K6KUMI3jcDup8sALHaRmm75FOCPmNTFT5fONxFSE21qY9xBuOJGJqqkSqQWOT2HYVqPDK4wSKrm3VD8xJx+tIbnpa5Ua3jHzKo56mo32R8Zq3w2eMAVQmXMmT0680kZ77kbkKN2cConYlcinOScAYAJqOXHOO1MzkiCTkZ7VTc4NWZSByPwqpKc5z1oIK8xyarucgZ59KlZT2/OoZG2Ag9T0osBm3j/ALzbWRfBUdmxliK1LgjJYDkVk3/JYnqa1ihSZzGrNxjqcVzt4uJF47da3NRY7nPvWLek7krvp6HlVtWEParI6VVhqyOlWyI7F80lKaSpIEpKU000wCiiigBYxvniXrzmu00hTtH0rjdNy96fRRXbaYPkXFc9ZnZhlpc3bRSMcfhWjtz2x0zVSzHAzWko+XFc7OkYAqRsM5I9O1Z0GJrveewBOOa050HlOgAxjmn28SRyyFQAMDFILmPdo4mkZ/QqAecDg0qIY3t2wN6ktn0NJMfP1eRVJ8tSuT79ann5v4I1HGxmce1MRqwfKm8fdOGH8jVzONrfwnn8c1StseR5DHjPB9KsW7CVBHxvU5b6UhpM1U+Y4Pc1KBgnGcVFF8mOeD+lWFORzxSY0Oh54HrV2P5cEDjviqi8n1q1CCcZqWWi9EwOCDxVmNgW2g1StvkyCcirMaqr7hQi1YsvCj/U0tvCIfunrRGw7EZqVDzg4zTGpO1h8hGMY5rNlkEc5LNg9hWmRWXqTcYRFznvSehrR1dipdsWcPH82O4p0c7kfMOc9fSpTDyq7dq4zxVW4/dsV5wT2qWbXUlYma7RlODyKoQyGSfcWyPSm7yAFQE+vaoS6LyMjHJNIfs0k0i1MyopOQKz0lEpYY6HrUqgyFjk7T0FNEQQHYm0d6DBpRViCUH2HvVRyHXKkEdMjkVdlwMk84qmwEa4UbQD0poyKrgAYHQcYqtJxVh+B9aqyHB96BMgkOCRxz71m3XYkkAVfmAJJNZ12wyRniqSHEo3RyRjpWJfyEg4PIrXuwduFJxWLfYVSMVrAym9DnbwckHrWVqC/u1bNa10fmHqTiqepJm3HHau2J5tRXuZsNWl6VUhPSrSmtGRE0KQ0tIakgSkNLTTQAGkY4BozUczhEJNAF7QULNJIf4mrttNGFHrXJ6Im2CPA6nNddYLgDqa5Kr1O+grRN+0HArQQFsVn2mcgY4rUiHFYm24Mh2Fe+OtIsW5csx46ipzyp9cUoXn2PWkFjMsoQLpnxw+SfzxUdwQmsDoC0e3P4itKKMIAzdMHPtWZeKRMkpPIfH4YqrjjuTSMTcFYzjofpUtlIVnYnhuhFRRxlkXbjcVzT/meVXCnJHJoOhLodPEQy8Y9c1NGdy5BzWZFMEhAU54qa0mx8p780rEeye5qxAEccGrCLyM8VBF90EVYTn3FSQkTwsBzjmrSZJHINVkx24qdCQetCLuTrGN2cfMRjNTp8uOM1EhO3gZ/GpUbJGeKBkikjPHFQvCrybyPpU4A24prYUEZ4pDTtsRsoCHNYmoSbn2qSGHOcVtu2V6VUMCs28qM+tJq5pTkou7Mq2jZmy6nAHA9aSaEK4wgKnrWq6EdBzVW5IiTcw6UrD9o2ylsAJI6dqjmyeF4pZpiDlQcdqrSzMAPlyT19qRLi2RSKeTn6VVmyASec1aY/KN3r+VU55F5wRVEWZVm4H1qm/BPNOu5gueapPNzjrmgfs2Jcvszmslx5jMw5B/SrdzICu0/eqo2I0OD061SHJWRVuSApBz0zWHfHPf8K07ibdIR7VkXrcH6da1gjmmY03zTEgcVV1FcwNj0q5j5mqpfg+RIRXUtzjmtGzFiPNW16VSiPNW06VuzngzSNJS5pKgkSkNKaQnmgBKq3jZaOP+8easnPaqSjffr14P8qEB1mkINijHHFdRp5wwOKwdMTIXHYVvWYww65rjm9T0oKyN22FaUXIGDWba8r71oRE59KyNEWlAPB5qVhgAVCh/OpQeRSGKyDzAvZuTWfeQKQ3y8g5ArTIBZefoaqXKlGO7kN0+lMI7kNsAXBP4ipBGFkOz7pGSKopIyy7WBC561pojFhs6YGDTOhK2oRjeNwJAPUVKP4QASc9fSrBgO3K9cU5bZig56HPSkaRmjXsAfKAY9KuKuAMVUtUKRgcVbQce9JnNJ6sPNCsy4OByasQyrIoK1WdGbJHU1JZoyKQ46HgikXZNF9D+dTrgA8iq6evWplJ9eKLEkmcDAprN6jFJk0h5602gQd/eo3IDZx0pwGF9u+ajk444qSirPdKHIBy3pVG+uA8YGcZHSpbpMHeiAk9azbmRmfCjJ/iGOlSdEIrRoq+dlwQDjrSXE7FARgd6SRRs3EbcelQsp3KR0PPNBUrXEkY+UTzurNcsm4sckitIhsYJyepPYVSuIy7AEdaZmppGZdLlQSfrUEgCKGXqavzogZQfpiq13GGwBwKaFz33M6Vc7nPOOlULhtu71Jq/eOscRRSMisSd+SSauKJexWnYiTA61m3j7hirUsuVZs8niqE2CQK3ijlqLUrAE5OM1T1I7YuuOOa0VXC8YrK1MkRk/jWsdWc9TSJhp96radKpp96rUfSuhnDE1KTNOxSgCs7hYZg0AU/FBFIYwjAzVC2Obzd6Hn860GHykVUtIwZnPAYY/HmmgtqjudNXCqccfyrZhUZB5rI0t91pHg9hWzEoJGTya4pbnpw2NO0bBrSjIAyay7Y4rRj9e1SMuIw/GrCcmqsfY1YT2qSyYcHmo7iLzBjP0NPHOBmn9uaYjFuLaTzJHHIIwBWxpoY26Fhhscim7fmGeQTVyJQowOlBo5NxsTKBirEQ3VAmKsxDBFIhFhBwPap154qBSARUyHA7UhksYx3p9qGVm3tnPSo0JBxUyZHagaY+NWRmO7INTF/l3DJ9qYoyOT0pcYPOeKB3uSRtuAJ+U+9OZwBUZPH0ppOeCBQNIcX4OOTTGcYO7qaCx9KjcMfpSGMlweCazbi2yTs+XJ5PrWg/GB3PeoJW5wTSY1K2xnywKBk9qrFAHPAq5Pkg44qo4IAJyTmgHJkDDrnAzzVaUDJwKtS5xnAzVVqEQZ9xHukDMMYqpdMAvIyPatGcYzzWLftnIzhelUhrVmJdOzyv2FZtypwc962JEGMelZd1gNz0FaRZUp3MqQYHP4VXYZPJHAyasTHc59KjCHbz+NbLQ55asry8JxxWHqjZiaty6OFx+Vc/qhwh7jNa09zmrvQy4+tW0PFVI+tW4+nNbs4omv3pcU7H60YxWRQ0DNLiloxQA0jHas4OY7hsjqK0yKyZZM3cmeh4poT0Oz8OzFrVfrXSQH8xXJ6AwEK4GMnOK6i2JJHTFclRano0n7qNWJuFx3HWtC2bcmPSsmMkHI9K1LUBcc8kZrI2toXo+nWp4zxxVWM5IzVlSeOetIEWRwc9aeCO1RKT39KenYE89aYxwBLdKtRCoUBz2qYAjFIZLjaPU1Yj6Amq6sCTk9KlWRT34pAossjJANTJ71EgG0c4qZRgjBpBYmXpmpU5PHaoM84FSDLDGaBpE6s3BU0uSTyMVGqlec1Keg9aYDsd81C/7slyTg8cVKw7CmOAB/OlYpOwhyy0zBHelLYOOMU3Oc5piY3IHoTVaRgeeefWpn4PvUMmCfSkIqyEtxgYFQsgzVqQjkfrVaZjjjpSApzDqO1U5WxkDrVqZyoGOvoap3WNpyeKBlCebIPOcGsq7OSGYjr0rQumAU4wCax7k7mOCRTRVirO3OfXtWRdE4bJzk1ozsCeOfas6UEsSegrREMzZMjg9aSUHCkHinzDMq+9RTvxgH8q1RkyjeP+IFc/qTEp1xW1cnc+M1iap98AV0Uziru5Rj61bTpVWPrVpOlbM5om4KMYpcUu2sShoGaMc07GOtHvQMjcfKSOtZ11algHGS30rWAGeRmmEdR0zTTsJq5d0UlI0HpXUWbEgc1ymlNjg+ldNYsCBWFRanbSehu24GeRmr0XDA9xWdbN8orQjAJzWDN0y9GeADVhAQo6/jVeLnBParSk7ccdaRSJAGI68VLF15qCNiCw79qnTqKCidBz14qZQdwb0qKNhjpUrE4G045pDRG5JJI4yakULtAzgnvTnXdHxUXlsI/mHQ8UG0GmaVq5KeuKtjtnpVOwO8dOBV0Ad6TM56SJgBgEU5GHQmo8/LwaF5YHGRQSiynJpS2D0qINtz6VICMZP1oGBY44ozle1GeenBpMY4xSC4xlB60hOKfkZwRTHI9qAQw4HU5+tV5GJNSOeuDzVdztJJIyfWgBj+rGqkrrz2ovZiflj6mqDF9p3jmkWodWV7iUb+pOKp3UxzjILdfpVhlABYjvmsybmVmJ4FFi7IgmJdyKpSoF6nJ9BWhJwAR3qlMpB+UfUmmZN3M+VQDyOvp2rNv22DAHJ4rXmUYH51iXrfvST0ArSO5HmZ4zlj2AwKqStt3DP0qwzEBi3c1TdtzmuhGM2VJO7etYupnke9bk3LbR0rB1M/vcVtDc4q2xWiq0vSq0XarK9K1ZhE1LW8WTCykBuzetXSMniudHHIq/ZXpjOyTlP5VDj2BSNMClIpVwwBUgj1FKOpqCyP8ACl604jjmkwM0ALppxIR2zXR2LDAGa5qxOJW+tdDZHpWVQ6qT0OgtWGOa0oCM1kWp6elacOR9awOhGjEdyjnpVqM1RhJHHarKNyaRSLSnP1qdP1qshHap1bselIssIMmpl59ahTjpUyNQxliMY6/hU7gFcEVApyKmHGM81FxEtsiQgBasBxng1WU4Peng5IPegrfUsRnJ5qUYH1qFWIxkVKCScj8aAHDJ6045H4UdsgcGgjIx1oAAQR1yaUscYHWk28jPAozjJPSgLCnPUkVGWByB+tOfDdM/Woio9M4pDEIHrVSQ+YSHUgCrEpCqSc1XdzjNMPMpzBVOMc9jWbeE7uTx0xWnLyckVSniBOSBxQVGVjKuA5IC8ZqlduI8JtyScmtW6ZUGeq9qzLhGZtygnjjNBad9yGTHIzyKz5ZGLlVHFXfKfG4nBxyKoyME4B59aEZ2RVvXCoT6VgXOW+Zj9a1rzBDc1hzscFQc81tBEy2K9wQHK9+tVlXBye1PuDlxnt1+tAXjAxW2yOOTuyqU5Yk89a5rUm3XDV08/wAsZ9TXL3+PtDVtS3OWsRxVaWq0VWAeK2MYjmHFN6VYZPyqMqBUJisT2l20Jx95O4rXjkWVdyHIrnzUttO0L5Xp3HrQ43BOxu0Y7Go7e4SdMrwe49KlIxWZZBA224cH1resHziuez/pEn1FbOntjAzUTR0UmdNaHpjtWpEeBWPaHKCtOFuKwOpGnE3Iqyhzg1RhcrVmNyxqWUi5Gc9anXtVaOpxnGRSLRZDHIxUynuT0qshyQe9TJ1470mMtxmp1bPeqsZ55/Cp4+BUgTjLGpYypP8AOqwJBqZOCfU0DRaQj8qkByeDVZM44qdRjrmkMlAPYnFSBQBmo1J70oOcigB7H8RR14pqkDmgHPsaYCketRscUrntnmoyfzoERSgsODioMADDHmppHweeSKgcjnPWkMhkOQTis6VHORxirj8scDionIAzSuF2jNMWU+YdKgmUDgcVemYBMA1nyk57DFA73KVwcDaDzWFckiXHrWvdbgrc/SsS6cgEjk1SKjsUrw/ewayLnCde9ac4PljP1rLugdxwa2gYTkUtpd/pUxGF56U8Jt47mmSH5SDWl7nOUrw8da5O9bNy31rqbs/KSK5C+J+0se5ropHHWZPFU9ZsczL3q0lypHzcVrYyTNCKUMMGnsueRWejlTVuGYE81DiJMRlppBFWmQMMrUDLihMdhIXdHDISCK17a7WVcMdr9/esfpUsC7pPYcmiQI0IiXd39TWvYnBrNskygHrWjZDa2KwkddNHR2hyBWtbkcetYlo/TmteAjHfisTqWpfRuMHnNW4CF4HBqlHyB69asxseOlSNF6I89auIegqjD64wKtocN1pFonGAakU/PjFV1P41ICcA5pFFyNgW61MGwcE5qnE2eMYqzEM/h3qRFlCDUwHzY6ioI8ZqdTxxx70DRKPlNTo4OcVAnIGTUq49OaQyT0/Wnqcc+tQs2GHPWng4xRYB/G7rQQSOOKbnJOMZpcg5GelMBcgjJyMVFI3P8qk7Y71E7/lSERNz9agkHJzippD8oI/Sq7N17Uh3IZGGfaq0jZWp5SCDmqkp98CiwFWfnjPSs+blW556VclP3s1QlypJY8GkNFG6JNZlyo56cetacr8n1rMn5yTVIlszJuVJP/6qy3+Zicd60rt8Ar6is+TCjnvW0TGRC5wOarP1qeTiq7tWkTJmffNhSK5G6bzJCa6fUZNsTn2rlCcmuqktDjrPUQDFLmlzg0hwe1amJdpQxU8U3NLSAu21xg4NWmUOMrWQDg5FW7e424qJR7DTJGUg4xVm1XEMjevAoO2RMipo1xEi+pzUN6GkFqX7VMKOK0Ldec1Uh6DHpWjAvArCTOuCL1p71r2zHCnPHQ1kQ8c1p2zZFZM2RpqccirKYOOoqonK4qxD09qkovp0FWIz+dVozwM1PF8p4NBSLSdB71KijIJ4qBTxg1KhyPQUirlhRjpViI4HvVNGJ5/KrSMMYNIEyyhORU6gt34qBGHepkYLwKkdybOFHrTwGL9e1Rgg/eqUZ7dKYD8ZHWnKBt+tR4+Wnc49z0osMeCOgoLBQaYSc8Go2PzfMOaBEpfA4xUMhJA9qUuoPT8qgnZj/qyAfekArkkVWkP4805nOOT+IqJ2OKAGucZ/lVKRiSeMdqmc++aqynqaVgIJjyR2qhccqc96tzdKoXJOOKAuUpTjdxz61mXRwcetaFw+OtZNy/z/AFqkS2UJjliaqSkDJFWJ+Mn0qpIcDPrWqMpFeRsYqtKSBUpOWJNV5m4JPetUjGTMfWmAtm559K5s8NW1rsnG3pzWKSSea66a0OKo7sGUhiD24oqWUsq8EjLHpUZUk4Awe4qyC1S5opKQCilBwaSigC5aSksF9eK2Y16e1YunLuuAewFdBbqCOlYVNzeki1bLWpAvAqhCMVpQdK55HZFE6dAK0LY44qjFgNjvV2IVDLNKE/KM1YX5QD2qrD0Aq7GMqKkotQNgA5yDVtPWqEeQflBwKtRMcc8e1IotoRjmpkIPIquh454NSqcL70xosLipVbPAqurDvUiEAelIZZU47ipo3yTnOarRMCcZzUqnng0rDLiMCMHtU6kcdapRtgDOc1YD0ATl9vSlD5BJJqJXzngYpcr6UBck79aR8d6j3469f5Ux3HGG5pCHSOCvA6d6hYjrmmPKTkdqZuwvSiwCu49hUEp9OtDyfzqJz1560ARSEqPaqzscH0NTSHI+tVJHx1P0oAhmIAqlOfmqzMaozP1z0pE3KVyeevSsuc5J9KvXDZ6fnWdcHPHpVJCZTnOTiqc579hVuY4X3rPmatYoykQNzmqlwcCrT8Ke1UbtsKTWyMpHNay+6YCqCtg8gGrGoNuuWqtXXHY4ZO7JJG3qDjGCc0664x9TUKkjPoaezFkUHotMRoMobr19ahZSvX86nqJ3zwv50gGUuab06UoOTQBpaSMljW9arxWLpI+T8a3bb7ormqbnVS2Lsa1dg4IzVWLnircQ546Vzs6kWoxk8Vet1496pwDmtKAYXIFQyy1CvSrsY5qmmQQB1q5EcDmgZMnJqYHgVAvLe1TqMZ4oKJo85BqUHJ5qJOnH5U9cAjg0FIl5BHpVhOR61Cv0qRWAGOlAEynDA96nXBwaqg5xg4qRN2T6UAWgcVIkmRgj61ArYApwYDpzSAsbyOF70vmGq2/kYzQzkdulAFkvgdRk1GW71EJM9elIXwuBQAE5zn86ZnjrSM+aiYnPUUgB+tRM3FK7ZJFV2fnHSgBZGz+Heqs8g9AafJJjj86qyE+ozQIiduvOT71QuHGTzU87k5HSqE7elFhFSdicgDmqMnGSc1blbAPY1QuX61SJbKtw/PFUpGySRViVjmqkh6gVrEykQyHI5NZl6/B5q9KcA1kahLhGOegxW0Vqc83oc/Od0zn3pnbNITkmk9q6jkA0ufShutJQBfdix9qbRRSAKOtFFAGvpP8AqhW3bnmiiuae51Uti/Ccnir8S5oorBnUi7EOBjpWjbE496KKzLRcXoOlWIxkDNFFAyyo+UVKgyBmiigZMPapcgAcc0UUDQ4Nz0p4PeiigY/cD0qRSeoNFFAyQNT1IJ4oopAKCaCTnnqKKKBMaTjjjFRbjnGaKKBrYbuPpxUZbvziiigCNmJPJ/KoHaiikIrs3H+NVpXA5oooJKcztjpzVGYk8fnRRQIoytVCY7m5xgUUVcRMoTP3qrIepNFFbxMZFOdsDjtWBq0nykUUVrDc5aj0McdacBxRRXQYCNSUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vaibhav Parekh, MD, MBA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_42_9903=[""].join("\n");
var outline_f9_42_9903=null;
